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ABSTRACT
Abuse of buprenorphine has increased in Europe, North America and Asia. However, long-
term studies on persons abusing buprenorphine and their clinical characteristics are
lacking. Buprenorphine is used for the treatment of opioid dependence. Providing
unobserved opioid substitution treatment (OST) can offer advantages in terms of client
access  as  well  as  social  and occupational  rehabilitation but  involves  the  risk  of  diversion.
This thesis examined the characteristics of persons who sought treatment for
buprenorphine abuse. In addition, the thesis explored possibilities for improved
unobserved dosing in OST with electronic medicine dispensers (EMDs) and the provision
of OST from Finnish community pharmacies.
The thesis utilized a range of data collection methods. Epidemiological analyses were
conducted using data collected at the Helsinki Deaconess Institute (HDI) between January
31, 1997 and August 31, 2008 (studies I and II). Structured clinical interviews were
conducted with all clients seeking treatment (n=4,817). OST clients treated with
buprenorphine-naloxone (BNX) in  Kuopio received their  take-home BNX in  EMDs over  a
four month period in 2010-2011 (study III). Questionnaires and drug screen data from the
Kuopio University  Hospital  were  used to  investigate  the  impact  of  EMDs on diversion of
BNX. A cross-sectional postal survey was conducted of all community pharmacies
providing OST in Finland in August 2011 (study IV).
The  proportion  of  clients  seeking  treatment  for  buprenorphine  abuse  at  the  HDI
increased from 0% to 38% between 1997 and 2008. Most clients injected buprenorphine
(81%) and used buprenorphine on a daily basis (74%). Despite more intense abuse patterns,
buprenorphine clients had similar social, health and treatment-related characteristics to
amphetamine clients. EMDs improved the safe storage of take-home BNX but their ability
to prevent diversion was not demonstrated. About 10% of all BNX-treated clients in
Finland collected their medicines from community pharmacies. Finnish community
pharmacies  had  generally  positive  experiences  dispensing  BNX  and  only  26%  of
pharmacies had experienced problems, mainly in relation to timing or non-collection of
doses.
In conclusion, this study highlighted the increasing abuse of buprenorphine in Finland.
Buprenorphine clients had risky abuse patterns as evidenced by the high prevalence of
injecting and daily abuse. Different methods to provide unobserved BNX dosing can
produce variable outcomes and, therefore, their utility should be further examined.
National Library of Medicine Classification: QV 92, WB 330, WM 270, WM 284
Medical Subject Headings: Buprenorphine; Naloxone; Opiate Substitution Treatment; Substance-Related
Disorders; Epidemiology; Prescription Drug Misuse; Community Pharmacy Services; Pharmacies; Finland
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TIIVISTELMÄ
Buprenorfiinin väärinkäyttö on lisääntynyt Euroopassa, Pohjois-Amerikassa ja Aasiassa.
Tästä huolimatta buprenorfiinin väärinkäyttöä ja käyttäjien kliinisiä ominaisuuksia on
selvitetty puutteellisesti. Buprenorfiinia käytetään opioidiriippuvuuden hoidossa.
Opioidikorvaushoitolääkkeiden valvomattomaan ottoon liittyy huomattavia etuja, kuten
hoidon saatavuuden paraneminen ja potilaiden sosiaalisen sekä ammatillisen
kuntoutumisen edistyminen. Riski lääkkeiden välitykseen katukauppaan on kuitenkin
olemassa. Tämän väitöskirjatyön tavoitteena oli selvittää buprenorfiinin väärinkäytön takia
hoitoon hakeutuneiden henkilöiden ominaisuuksia. Lisäksi tutkimuksessa selvitettiin
mahdollisuuksia kehittää valvomatonta lääkkeenottoa elektronisten lääkehoidon-
seurantalaitteiden avulla sekä korvaushoidon toteuttamista suomalaisissa avoapteekeissa.
Osatutkimuksissa I ja II käytettiin Helsingin Diakonissalaitoksella 31.1.1997–31.8.2008
välillä kerättyä tietokantaa, joka sisältää kliinisten haastattelujen avulla kerättyä tietoa kai-
kista hoitoa hakeneista henkilöistä (n=4817). Osatutkimuksessa III buprenorfiini-naloksoni
–yhdistelmävalmistetta käyttäneet kuopiolaiset korvaushoitopotilaat saivat korvaushoito-
lääkkeensä kotiannokset seurantalaitteissa 4 kuukauden ajan. Laitteiden vaikutusta yhdis-
telmävalmisteen välitykseen tutkittiin kyselyiden avulla sekä tarkastelemalla Kuopion
yliopistollisessa sairaalassa otettuja huumeseulatuloksia. Osatutkimuksessa IV yhdistelmä-
valmistetta tilanneille suomalaisille avoapteekeille tehtiin kyselytutkimus elokuussa 2011.
Buprenorfiinin väärinkäytön takia hoitoon hakeutuneiden asiakkaiden osuus kasvoi 0
%:sta 38 %:iin vuosien 1997 ja 2008 välillä. Asiakkaat käyttivät buprenorfiinia pääasiassa
pistämällä (81 %) ja päivittäin (74 %). Vaikka buprenorfiinin käyttäjien väärinkäyttötavat
olivat intensiivisempiä amfetamiinin käyttäjiin verrattuna, sosiaalisten sekä terveyteen ja
hoitoon liittyvien ominaisuuksien välillä ei ollut eroja. Seurantalaitteet paransivat
yhdistelmävalmisteen kotiannostelun turvallisuutta, mutta niiden tehosta estää lääkkeen
välittämistä katukauppaan ei saatu näyttöä. Noin 10 % yhdistelmävalmistetta käyttävistä
suomalaisista korvaushoitopotilaista haki lääkkeensä apteekeista. Yhdistelmävalmisteen
toimittaminen avoapteekeissa oli sujunut hyvin, ja vain 26 % apteekeista oli kokenut
ongelmia, yleisimmin lääkkeenhaun ajoitukseen tai hakematta jääneisiin annoksiin liittyen.
Tämä tutkimus osoitti buprenorfiinin väärinkäytön yleistyneen Suomessa. Pistäminen ja
päivittäinen käyttö olivat yleisiä buprenorfiinin käyttäjillä. Valvomatonta korvaus-
hoitolääkkeiden ottoa kehittävien menetelmien vaikutukset ovat olleet vaihtelevia, joten
niiden käyttöön liittyviä tekijöitä tulisi tutkia.
Luokitus: QV 92, WB 330, WM 270, WM 284
Yleinen Suomalainen asiasanasto: buprenorfiini; naloksoni; opioidit; opiaatit; päihteet; korvaushoito;
väärinkäyttö; katukauppa; epidemiologia; apteekit; Suomi
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1 Introduction
Opioid abuse is a major public health problem worldwide (Degenhardt & Hall 2012). Abuse
refers to harmful psychoactive substance use causing damage to health (World Health
Organization 2012). The abuse of prescription opioids (PO) has been increasing in Europe,
North America and Asia (Degenhardt et al. 2008, Holmes 2012, Fischer et al. 2013b).
Buprenorphine is a semi-synthetic partial agonist at mu (µ) opioid receptors and it
produces opioid agonist-like effects (Martin et al. 1976, Cowan et al. 1977, Walsh et al.
1994). Early studies indicated that buprenorphine had low abuse potential (Martin et al.
1976, Cowan et al. 1977, Jasinski et al. 1978, Lewis 1985). However, buprenorphine abuse
has been reported since the 1980s (O'Connor et al. 1988), and more recently in Europe
(Casati et al. 2012), the United States of America (USA) (Johanson et al. 2012), Australia
(Aitken et al. 2008), and South Asia (Larance et al. 2011a). National reports have indicated
that buprenorphine abuse is especially common in Finland (Forsell et al. 2010, Varjonen et
al. 2012). A combination product containing buprenorphine and the opioid antagonist
naloxone was developed in order to deter the intravenous (IV) abuse of buprenorphine
(Mendelson & Jones 2003). However, the addition of naloxone has not been sufficient to
prevent buprenorphine abuse e.g., (Bruce et al. 2009, Duke et al. 2010). Most studies
examining the characteristics of buprenorphine users have been cross-sectional, had small
sample  sizes  or  had  short  follow-up  periods.  In  addition,  the  clinical  characteristics  of
buprenorphine users are not well-established. Characteristics such as older age, mental
health  disorders,  using  opioids  only  by  swallowing  or  sublingually,  and  no  prior  opioid
dependence treatment contacts may be associated with successful treatment outcomes
(Dreifuss et al. 2013).
Buprenorphine is marketed internationally as an opioid analgesic and for the treatment
of opioid dependence. Several studies have shown that buprenorphine is effective and safe
when used in opioid substitution treatment (OST) e.g., (Johnson et al. 1995b, Fudala et al.
2003, Mattick et al. 2008). Buprenorphine has enabled the provision of OST in primary
health care and office-based settings (Fiellin et al. 2008, Gunderson & Fiellin 2008). This can
increase the flexibility of OST in terms of client access and autonomy, especially if
unobserved dosing is allowed. Unobserved dosing refers to the daily administration of OST
medicines without direct supervision of treatment staff (Bell 2010). It can offer substantial
benefits, such as increased accessibility to OST, positive effect on social and occupational
rehabilitation and less stigma to OST patients (Bell et al. 2004, Anstice et al. 2009,
Gunderson et al. 2010). Community pharmacies can provide convenient and flexible dosing
sites for OST patients (Chaar et al. 2011). In many countries community pharmacies have a
major role in OST provision (Berbatis et al. 2005). According to Finnish legislation,
buprenorphine-naloxone combination product (BNX) may be dispensed by community
pharmacies since February 2008 (Ministry of Social Affairs and Health 2008). However, no
studies have examined the provision of OST in Finnish pharmacies. OST, especially
unobserved dosing, involves the risk of diversion (Bell 2010). Diversion refers to the supply
of  pharmaceuticals  to  the  illicit  drug market  or  to  persons  whom they were  not  intended
(Larance et al. 2011c). About 30% of OST patients reported having diverted their medicines
within the previous 6 months (Larance et al. 2011b). Various methods have been used and
suggested as ways to prevent or reduce diversion, such as training for health care
professionals, abuse-deterrent formulations, urine drug screens and regulatory controls
2(Fudala & Johnson 2006). The possibilities offered by technical devices have not been
examined thoroughly.
The purpose of this thesis was to examine both the abuse and therapeutic use of
buprenorphine. This thesis examined the characteristics of persons who sought treatment
for  buprenorphine  abuse.  In  addition,  the  thesis  explored  possibilities  for  improved
unobserved OST dosing with electronic medicine dispensers (EMDs) and the provision of
OST from Finnish community pharmacies.
32 Review of Literature
The focus of this literature review was buprenorphine abuse and diversion. The literature
searches were performed using PubMed, MEDLINE and Google Scholar. The searches were
performed using a combination of Medical Subject Headings (MeSH) and key words. These
included ‘buprenorphine’, ‘buprenorphine-naloxone’, ‘abuse’, ‘misuse’, ’substance-related
disorders’, ‘opioid’, ‘dependence’, ‘addiction’, ‘diversion’, ‘prescription opioid’, ‘treatment’,
‘opioid substitution treatment’, ‘efficacy’, ‘supervision’, and ‘community pharmacy’.
Reference lists of included articles were searched for articles not identified in the database
search. Publications in languages other than English or Finnish were excluded. The review
focused on human studies. Preclinical studies were excluded with the exception of early
animal studies examining the basic pharmacology of buprenorphine. The relevant
publications were included in the respective chapters concerning buprenorphine in general
(see 2.1) and the use of buprenorphine in OST (see 2.3.2; 2.3.3). Studies concentrating solely
on the cost-effectiveness of OST were excluded. Studies examining the epidemiology of
buprenorphine abuse in Chapter 2.2.3.1 have been presented in chronological order.
2.1 BUPRENORPHINE
2.1.1 Pharmacology
Buprenorphine was developed in 1966 at the research laboratory of Reckitt & Coleman in
England (Campbell & Lovell 2012). Buprenorphine is a semi-synthetic opiate derivative
made from thebaine which is a natural alkaloid in opium (Davids & Gastpar 2004).
Buprenorphine is a partial mu (µ) opioid receptor agonist with lower intrinsic activity
compared to full agonists (Martin et al. 1976, Cowan et al. 1977, Lewis 1985). Therefore, it
does not activate receptors as completely as a full agonist (Martin et al. 1976).
Buprenorphine produces an action with rapid onset and long duration (Cowan et al. 1977,
Walsh et al. 1994). Depending on the route of administration, the onset of buprenorphine
effects occurred in 6-90 minutes and effects persisted up to 72 hours (Umbricht et al. 2004).
Buprenorphine shows high affinity for and slow dissociation from receptors which explain
the long duration of action and difficulty to displace it from receptors (Lewis 1985, Walsh &
Eissenberg 2003). Buprenorphine has a bell-shaped dose response curve which means that
as the dose increases the effect increases to a maximum and then starts to decrease, despite
the dose still increasing (Johnson et al. 2003).
Buprenorphine’s desired effects are thought to be mediated mainly by its mu receptor
agonism (Takemori et al. 1986, Tzschentke 2002, Walsh & Eissenberg 2003, Johnson et al.
2003). It has a high affinity for kappa (?) opioid receptors with antagonist effects (Su 1985,
Leander 1987, Leander 1988). At delta (?) opioid receptors, buprenorphine acts as an
antagonist with high affinity and low efficacy (Negus et al. 2002) and it may block epsilon
??) opioid receptors at small doses (Mizoguchi et al. 2003). Buprenorphine also activates
opioid receptor-like (ORL-1) receptors which are considered as the fourth group of opioid
receptor family (Lutfy & Cowan 2004). It has been speculated that the bell-shaped dose
response curve may stem from buprenorphine’s differing effects at mu and kappa receptors
(Johnson et al. 2003). Cowan and colleagues (1977) suggested that mu effects are
predominant at low doses whereas kappa effects offset them at higher doses.
4There is a ceiling on buprenorphine’s effects at high doses (Martin et al. 1976, Walsh et
al. 1994). Walsh and colleagues (1994) examined the effects of sublingual buprenorphine in
non-dependent opioid users (n=4). For all measures (physiologic, subjective and
behavioural), there was a ceiling dose and larger doses did not produce greater effects. For
most euphoria-sensitive measures, the ceiling dose was between 8 and 16 mg and the 32 mg
dose produced lower scores usually. However, the presence of ceiling effect depends on the
intensity of stimulus and the endpoint chosen, e.g., it applies to respiratory depression but
not to analgesia (Pergolizzi et al. 2010). Pergolizzi and colleagues speculated that use of the
term ‘partial agonist’ is only appropriate when describing buprenorphine’s functions which
are dependent upon the conditions under which the drug is used, and it is not
buprenorphine’s characteristic per se. Mechanisms behind the ceiling effect are not totally
clear. Harris and colleagues reported that less than dose-proportional increase in
concentrations may contribute to the ceiling effect, indicating pharmacokinetic mechanisms
behind it (Harris et al. 2004). However, another study claimed that pharmacokinetic
adaptations do not explain the ceiling – at least at the dose range 2-16 mg intravenously
(IV) – and suggested that pharmacodynamic adaptations are more likely to explain this
phenomenon (Huestis et al. 2013). It has been speculated that buprenorphine’s effects on
ORL-1 receptors may contribute to buprenorphine’s ceiling effect as well as its bell-shaped
dose response curve (Lutfy & Cowan 2004).
The bioavailability of oral buprenorphine is very low due to extensive first-pass
metabolism in the gastrointestinal tract and liver (Chiang & Hawks 2003, Elkader & Sproule
2005). The bioavailability of sublingual buprenorphine has been estimated to be between
28-51% (Kuhlman et al. 1996, Mendelson et al. 1997b, Harris et al. 2000). In non-dependent
opioid users, a decrease in bioavailability was seen with increasing sublingual
buprenorphine doses (Harris et al. 2004). Elkader and Sproule (2005) reviewed clinical
pharmacokinetics studies examining buprenorphine and summarized that maximum
plasma concentration was reached in approximately one hour after sublingual
administration (range 0.7-3.5 h). The rapid sublingual absorption is followed by an
accumulation in various organs and a delayed systemic absorption. Buprenorphine is
highly lipophilic with a large volume of distribution and an ability to cross the blood-brain
barrier. Buprenorphine is extensively metabolized by N-dealkylation to norbuprenorphine,
which is the primary metabolite, and conjugated with glucuronic acid (Cone et al. 1984).
CYP3A4 is the major cytochrome P450 enzyme mediating this reaction (Iribarne et al. 1997,
Kobayashi et al. 1998). Norbuprenorphine is an active metabolite although its effects are
weaker than those of buprenorphine (Cone et al. 1984, Elkader & Sproule 2005).
Buprenorphine undergoes enterohepatic circulation which may prolong its effects (Cone et
al. 1984). Buprenorphine has a long elimination half-life, but significant variation in values
exists (Elkader & Sproule 2005). In the studies reviewed by Elkader and Sproule, the mean
elimination half-life ranged between 2 and 44 hours. Differences may be related to assay
sensitivities as well as different routes of administration (IV, intramuscular IM, sublingual).
Kuhlman and colleagues (1996) reported that elimination half-life is longer for the
sublingual route compared to IV administration. Buprenorphine is mainly eliminated in
faeces while the excretion in urine plays only minor role (Cone et al. 1984).
2.1.2 Effects in humans
Buprenorphine produces opioid agonist-like effects in humans (Jasinski et al. 1978,
Mendelson & Mello 1992, Pickworth et al. 1993). It causes decreased respiratory rate,
miosis, increased heart rate, varying changes in systolic and diastolic blood pressure,
analgesia, sedation, and nausea in some individuals. Some studies have reported that study
participants experienced euphoria after IV administration (Pickworth et al. 1993), while
5others have reported only ‘general feeling of contentment’ and not getting ‘high’ after
subcutaneous administration (Mendelson & Mello 1992). Buprenorphine may cause
constipation, a common side-effect of opioid use (Lange et al. 1990). Constipation has been
reported by 1-5% of patients receiving buprenorphine for the treatment of pain (Kress 2009)
and by 33-47% of buprenorphine-treated OST patients (Ray et al. 2004, Magnelli et al. 2010).
Tolerance develops to the sedative and analgesic effects of buprenorphine (Martin et al.
1976, Cowan et al. 1977). Tolerance means “a decrease in response to a drug dose that
occurs with continued use” (World Health Organization 2012). Both physiological as well
as psychosocial factors may contribute to the development of tolerance. Cessation of
regular buprenorphine consumption leads to a mild-to-moderate opioid-type withdrawal
syndrome which usually starts slowly and peaks at about 5 days after the last
buprenorphine dose (Fudala et al. 1990, San et al. 1992).
Buprenorphine’s effects depend on the person to whom it is administered and his/her
recent history of opioid use and the level of tolerance and possible dependence (Walsh &
Eissenberg 2003). Zacny and colleagues examined subjective, psychomotor and
physiological effects of IV buprenorphine in healthy volunteers (n=16) (Zacny et al. 1997).
Buprenorphine induced miosis, decreased respiratory rate, impaired psychomotor
performance  and  increased  the  ratings  of  ‘nodding’,  ‘skin  itchiness’,  ‘turning  of  the
stomach’, ‘dizziness’, ‘nauseousness’ and ‘sleepiness’. Buprenorphine did not increase
‘drug liking’ ratings. Morphine produced less severe subjective and psychomotor-
impairing effects than buprenorphine. Saarialho-Kere and colleagues reported similarly
that buprenorphine (sublingual administration) depressed respiration, impaired different
measures of performance and produced drowsiness and mentally slow/muzzy feelings in
healthy volunteering study participants (n=12) (Saarialho-Kere et al. 1987). In opioid
experienced study participants not dependent on opioids, buprenorphine produced similar
physiological effects (pupil constriction, depressed respiration, changes in blood pressure)
but also typical opioid agonist effects, such as positive mood and increased ‘drug liking’
ratings, however, these effects were not dose-related (Jasinski et al. 1978, Weinhold et al.
1992, Pickworth et al. 1993, Walsh et al. 1994, Walsh et al. 1995b, Umbricht et al. 2004).
Umbricht and colleagues (2004) compared the effects of sublingual and IV buprenorphine
and found out that effects were generally similar but after IV administration the onset and
peak effects occurred earlier and the duration of effects was shorter. Drug users may prefer
IV administration, due to rapid onset of effects. On the other hand, adverse effects, such as
nausea and vomiting, may decrease the abuse potential by injecting.
Buprenorphine effects in opioid-dependent persons depend on the level of dependence,
opioid used, dose and time since last opioid dose (Walsh & Eissenberg 2003). In untreated
heroin-dependent opioid users (n=8), IV buprenorphine produced non-significant
physiological effects and increased opioid agonist measures (e.g., ‘drug liking’) (Mendelson
et al. 1996). Strain and colleagues reported similar results with regard to physiological
effects (Strain et al. 1992). They examined the effects of IM buprenorphine on opioid-
dependent methadone maintained study participants (n=6). Buprenorphine produced
minimal physiological effects and neither agonist nor antagonist-like effects. Strain and
colleagues  conducted a  further  study with a  similar  study design but  shorter  time period
between methadone and buprenorphine doses (2 hours vs. 20 hours) (Strain et al. 1995).
They reported that buprenorphine produced non-dose-related antagonist-like effects.
Walsh and colleagues demonstrated that sublingual buprenorphine precipitated opioid
withdrawal symptoms 40 hours after methadone dosing (30mg or 60 mg/day) in
methadone-maintained opioid-dependent study participants (especially in those
maintained on higher dose) (Walsh et al. 1995a). Therefore, it has been hypothesized that
buprenorphine-precipitated withdrawal follows a U-shaped time-action curve (Walsh &
6Eissenberg 2003). However, in addition the opioid used before buprenorphine
administration and its dose seem to affect the withdrawal symptoms caused by
buprenorphine. Schuh and colleagues demonstrated that IM buprenorphine produced
opioid agonist-like effects in morphine-maintained (15 and 30 mg/day) opioid-dependent
study  participants  (n=6)  but  these  effects  were  diminished  as  morphine-doses  were
increased up to 120 mg per day (Schuh et al. 1996). Authors speculated that this was
probably due to the development of cross-tolerance to acute opioid effects. However,
withdrawal syndrome was not precipitated by buprenorphine which may have been
explained  by  a  relatively  low  level  of  dependence  of  the  study  participants.   Fudala  and
colleagues reported contrasting results from their study in which opioid-dependent
morphine-maintained (15 mg/day) study participants (n=10) were given IV buprenorphine
without any statistically significant effects (Fudala et al. 1998).
2.1.3 Use as an opioid analgesic
Initially, buprenorphine was developed as an analgesic (Campbell & Lovell 2012). Its
analgesic properties were demonstrated in the first studies examining its effects (Cowan et
al. 1977, Jasinski et al. 1978). Animal studies indicated that it is 25-40 times more potent as
an analgesic than morphine (Cowan et al. 1977). Buprenorphine’s analgesic effects come
from its agonist effects at mu opioid receptors (Johnson et al. 2005). Buprenorphine shows a
relatively  slow  onset  and  offset  of  the  antinociceptive  action  which  are  more  likely  to  be
caused by biophase distribution than slow receptor association-dissociation kinetics
(Yassen et al. 2006). Nevertheless, buprenorphine has been used successfully in the
management of acute pain (Johnson et al. 2005). According to the World Health
Organization (WHO) three-step ladder for the treatment of cancer pain in adults,
buprenorphine  is  included  in  to  step  III  opioids  which  are  regarded  as  strong  opioids
(Wolff et al. 2012, World Health Organization 2013). Buprenorphine is used for the
treatment of moderate to severe pain (Johnson et al. 2005). An International Expert Panel
has  recommended  that  buprenorphine  should  be  the  first-line  opioid  analgesic  in  elderly
people, if they have impaired hepatic and renal function because these impairments have
no effect on buprenorphine’s half-life (Pergolizzi et al. 2008). There are different
buprenorphine formulations including products administered by parenteral, transdermal
and sublingual routes (Johnson et al. 2005). Typical sublingual dose ranges between 0.2-0.4
mg and parental dose between 0.3-0.6 mg every six hours. The 72-hour buprenorphine
patch, which is the most commonly used transdermal buprenorphine formulation, releases
buprenorphine 35, 52.2 or 70 µg/hour.
Several studies have proven buprenorphine’s efficacy in the treatment of acute pain
(Downing et al. 1977, Harcus et al. 1980, Tigerstedt & Tammisto 1980, Gundersen et al.
1986, Carl et al. 1987). A more recent study compared the analgesic effects of sublingual
buprenorphine  (0.4  mg)  and  IV  morphine  (5  mg)  for  acute  pain  management  in  a
randomized controlled trial (Jalili et al. 2012). Pain scores and the frequency of adverse
effects  were  similar  in  both  groups.  Sublingual  buprenorphine  was  easier  and  quicker  to
administer compared to morphine. The slow onset of analgesia (approximately one hour
after a sublingual administration) should be taken into account when using buprenorphine
for acute pain (Hoskin & Hanks 1991). However, Carl and colleagues (1987) reported that
the sublingual absorption of buprenorphine was rapid and there were no differences in
pain intensity between patients receiving IM or sublingual buprenorphine.
The long duration of action and the possibility to use non-parental routes of
administration make buprenorphine a good treatment option for chronic pain (Hoskin &
Hanks 1991). In one of the first studies examining buprenorphine’s effects in the treatment
of chronic pain, sublingual buprenorphine was given to 141 patients with moderate cancer
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most commonly reported reason was side-effects such as drowsiness. The remaining 47
patients used buprenorphine on average for 12 weeks with good analgesic results. Zenz
and colleagues administered epidural buprenorphine or morphine to 139 patients with
severe cancer pain and reported that 87% of patients had remarkable pain relief (Zenz et al.
1985). Sublingual buprenorphine was administered to 51 elderly patients with chronic
moderate pain and statistically significant improvements in pain scores were achieved
within 48 hours (Nasar et al. 1986). No unwanted side-effects were reported by 71% of
patients. At least in the early studies examining buprenorphine’s effectiveness in pain
treatment, constipation has been a rare side-effect (0-2% of patients) (Robbie 1979, Nasar et
al. 1986). However, doses have been lower compared to studies, which examined
buprenorphine’s effects in opioid-experienced persons e.g., (Mello et al. 1982, Lange et al.
1990, Umbricht et al. 2004).
More recently, research has concentrated on transdermal buprenorphine. A randomized,
double-blind, controlled multicentre study of patients with severe chronic pain found that
35 and 52.2 µg/hour products of transdermal buprenorphine were more efficient in pain
management than placebo (response rates 37% and 48% vs. 16%, p<0.05) (Sittl et al. 2003).
Another study reported that 70 µg/hour transdermal buprenorphine was more efficient
than placebo in the treatment of severe chronic cancer pain in a randomized double-blind
trial (n=289) (p=0.0003) (Poulain et al. 2008). Wolff and colleagues conducted a systematic
literature review comparing transdermal buprenorphine to transdermal fentanyl and oral
morphine (Wolff et al. 2012). Compared to fentanyl, there were no differences in pain
measures but buprenorphine caused significantly less nausea and a lower number of
treatment discontinuations due to adverse effects. Compared to morphine, buprenorphine
caused significantly better pain control and less constipation as well as fewer cases of
treatment discontinuations.
2.2 ABUSE
2.2.1 Definitions of opioid dependence and abuse
Opioid dependence is a complex health condition with social, psychological and biological
determinants and consequences (World Health Organization 2004). It develops after
regular  opioid  use  and  is  a  chronic  disease  with  relapse  and  remission  phases  (World
Health Organization 2004, World Health Organization 2009). There are no universally
accepted definitions for opioid dependence or abuse. Internationally, two main systems of
classification for diagnostic criteria of substance use disorders are used: The International
Classification of Diseases (ICD-10) (World Health Organization 1993, American Psychiatric
Association 2000) and the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
(World Health Organization 1993, American Psychiatric Association 2000). ICD-10 is
published by the WHO and it is the official diagnostic classification in Finland. DSM-IV is
preferred within the mental health sector and the USA as well as in international addiction
research (Larance et al. 2011c). The diagnostic criteria for opioid use disorders according to
these  systems  are  presented  in  Table  1.  The  new  version  of  DSM  criteria,  DSM-V  (5th
edition) was released in May 2013 with some changes in criteria and terminology for
substance-related and addictive disorders (American Psychiatric Association 2013).
There has been controversy surrounding the terms addiction and dependence for
decades (O'Brien 2011). Both ICD-10 and DSM-IV used the term dependence even though it
has  been  denoted  to  refer  only  to  physical  dependence  which  is  body’s  normal
physiological response (Larance et al. 2011c). However, in the latest version of the DSM (5th
edition), dependence has been replaced with a term ‘substance use disorder’ in order to
8avoid confusion and possible under-treatment of pain due to fear of addiction (O'Brien
2011). In addition, the abuse/dependence dichotomy has been removed and replaced with a
single disorder which is measured on a scale from mild to severe (American Psychiatric
Association 2013). American Society of Addiction Medicine uses the term addiction and
defines it as: “a primary, chronic, neurobiological disease, with genetic, psychosocial, and
environmental factors influencing its development and manifestations” (American Society
of Addiction Medicine 2001). Addiction is characterized by impaired control over use,
compulsiveness,  continued  use  despite  harm  and  craving.  According  to  the  WHO,
dependence syndrome is a phenomenon characterized by: “a strong desire to take the drug,
impaired control over its use, persistent use despite harmful consequences, a higher
priority given to drug use than to other activities and obligations, increased tolerance, and a
physical withdrawal reaction when drug use is discontinued” (World Health Organization
2012). In this thesis, the term dependence according to the WHO definition has been used
when referring to this disorder.
Similarly, various definitions have been used when referring to drug abuse, such as illicit
use, misuse, non-medical use, unsanctioned use, extramedical use, harmful use and
hazardous use, with some of them being used interchangeably (Larance et al. 2011c).  For
example, illicit use may be confusing when referring to PO abuse due to their legal status.
Larance and colleagues recommended to use either hazardous use, which refers to, “a
pattern of substance use that increases the risks of harmful consequences for the user,
regardless of a diagnosis of dependence”, or extramedical use which refers to, “use of a
medication outside a doctor’s prescription, not excluding the possibility that the user may
have medically driven reasons for using the drug” (Larance et al. 2011c). Cicero and
colleagues defined abuse as a substance use with the intention to get high, use in
combination with other drugs to get high, or use as a substitute for other drugs of abuse
(Cicero et al. 2007a). In a study by Katz and colleagues, the term abuse was used
interchangeably with nonmedical use, with the latter being defined as, “use of prescription-
type drugs not prescribed for the respondent by a physician or used only for the experience
or feeling they caused” (Katz et al. 2007). The WHO defined abuse as a pattern of harmful
psychoactive substance use causing damage to health (World Health Organization 2012). In
this  thesis,  the  terms  harmful  use  and  drug  abuse  are  considered  synonymous  with  each
other, and the term abuse has been used throughout the text.
9Table 1. The diagnostic criteria for opioid use disorders according to the International
Classification of Diseases (ICD-10) and the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) (World Health Organization 1993, American Psychiatric Association 2000)
ICD-10 Diagnostic criteria
Harmful use Clear evidence that the substance use was responsible for physical or psychological
harm. The nature of the harm should be clearly identifiable.
The pattern of use has persisted for at least one month or has occurred repeatedly
within a 12 month period. The disorder does not meet the criteria for any other mental
or behavioural disorder.
Dependence Three or more of the following manifestations should have occurred together for at
least one month or if persisting for periods of less than one month then they have
occurred together repeatedly within a 12 month period.
(1) A strong desire or sense of compulsion to take the substance.
(2) Impaired capacity to control substance-taking behaviour in terms of onset,
termination or level of use.
(3) A physiological withdrawal state when substance use is reduced or ceased, as
evidenced by the characteristic withdrawal syndrome.
(4) Evidence of tolerance to the effects of the substance.
(5) Preoccupation with substance use (important alternative pleasures or interests
being given up or reduced; or a great deal of time being spent in activities necessary to
obtain/take the substance, or recover from its effects).
(6) Persisting with substance use despite clear evidence of harmful consequences.
DSM-IV
Abuse A maladaptive pattern of substance use leading to clinical signs of impairment or
distress, as manifested by one (or more) of the following occurring within a 12-month
period, and the symptoms have never met the criteria for substance dependence for
this class of substance.
(1) Recurrent substance use resulting in a failure to fulfil major role obligations at work,
school, or home.
(2) Recurrent substance use in situations in which it is physically hazardous (e.g.
driving).
(3) Recurrent substance related legal problems.
(4) Continued substance use despite having persistent/ recurrent social/ interpersonal
problems caused/ exacerbated by the effects of the substance.
Dependence A maladaptive pattern of substance use leading to clinical signs of impairment or
distress, as manifested by 3 or more of the following occurring at any time in the same
12 month period.
(1) Tolerance defined by either the need for markedly increased amounts of substance
or a markedly diminished effect with continued use.
(2) Withdrawal, as evidenced by either the characteristic withdrawal syndrome; or the
same (or closely related) substance is taken to relieve or avoid withdrawal symptoms.
(3) The substance is often taken in larger amounts or over a longer period than was
intended.
(4) Persistent desire or unsuccessful efforts to cut down or control substance use.
(5) A great deal of time is spent in activities necessary to obtain the substance or
recover from its effects.
(6) Important social, occupational or recreational activities are given up or reduced.
(7) Substance use is continued despite of having a persistent/recurrent physical or
psychological problems.
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2.2.2 Abuse potential of buprenorphine
In general, drugs with abuse potential have reinforcing properties and cause harm to the
individual and the society (Lewis 1985). Abuse liability can be defined as a likelihood of a
psychoactive drug to sustain patterns of nonmedical self-administration with undesirable
consequences (Johnson et al. 2005). The pharmacokinetic properties of a drug generally
determine its abuse liability (Schaeffer 2012). Large brain concentration within a short time
correlates with the feeling of euphoria. However, formulations without these properties
may  be  tampered  with  the  drug  delivery  system  in  order  to  make  them  better  suited  for
abuse. In addition, extrinsic factors contribute to the abuse potential, e.g., media attention,
peer preferences, cost and availability (Romach et al. 2013). Early studies indicated that
buprenorphine did not produce physical dependence and it had low reinforcing efficacy
(Martin et al. 1976, Cowan et al. 1977, Jasinski et al. 1978, Lewis 1985). Jasinki and
colleagues reported that buprenorphine produced minimal abstinence symptoms and that
withdrawal was easily managed. Due to these features as well as partial agonism and slow
onset of action, it was assumed that the abuse potential of buprenorphine was low.
However, more recent studies have indicated that situation is not that straightforward.
There is evidence of a statistically significant correlation between therapeutic exposure to
buprenorphine (measured by filled prescriptions) and the magnitude of its abuse (Cicero et
al. 2007b). Authors speculated that the value of a drug for non-therapeutic purposes may
determine the level of diversion and, therefore, the rate of abuse can be viewed as an
indicator of abuse liability. However, there are specific abuse liability studies which are
mainly based on animal or human laboratory testing (Balster & Bigelow 2003). In human
abuse liability testing, the drug effects have usually been compared to a known substance,
and the most common assessments are subjective ratings of ‘liking’ of the drug effect
supplemented with physiological and behavioural assessments.
Intravenous administration of buprenorphine increased the positive responses of ‘feeling
the drug’ and increased the scores of drug-liking, good effects and euphoria in non-
dependent opioid users (n=6) (Pickworth et al. 1993). Other studies examining the effects of
sublingual and IM buprenorphine in non-dependent opioid users have reported similar
results (Weinhold et al. 1992, Strain et al. 2000, Duke et al. 2010). The results of Duke and
colleagues indicated that intramuscularly administered buprenorphine may have greater
abuse potential compared to sublingual administration. Buprenorphine (IV and IM
administration) also served as a reinforcer among recently detoxified heroin users (Bedi et
al. 1998, Comer & Collins 2002). In opioid-dependent volunteers maintained on sublingual
buprenorphine (n=8), IM buprenorphine produced agonist-like effects, especially the
highest dose (16 mg) (Strain et al. 1997). Intravenous buprenorphine (8 mg) produced
similar increased ‘drug liking’ and ‘high’ ratings compared to heroin among opioid-
dependent heroin users maintained on sublingual buprenorphine (Comer et al. 2010).
Eissenberg and colleagues conducted antagonist challenges in opioid-dependent persons
maintained on sublingual buprenorphine and measured the effects by subject and observer
ratings as well as physiological measures (Eissenberg et al. 1996). The authors concluded
that buprenorphine can produce physical dependence in humans. For methadone-
maintained opioid users, buprenorphine seems to have lower abuse potential because IM
administration produced mild antagonist-like effects (Strain et al. 1995). Another study
compared the abuse liability of different POs in morphine-maintained heroin-dependent
volunteers (n=8) (Comer et al. 2008). Despite statistically significant increases in the ratings
of ‘drug liking’ and ‘good drug effect’ from IV buprenorphine, it was not self-administered
by  study  participants  and  it  precipitated  mild  withdrawal  symptoms.  As  a  conclusion,
buprenorphine seems to have abuse potential, especially in non-dependent opioid users.
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Nevertheless, relying solely on subjective ‘drug liking’ ratings when measuring abuse
potential, may be insufficient.
2.2.3 Epidemiology of buprenorphine abuse
2.2.3.1 International studies
The first reports of buprenorphine abuse emerged in the early 1980s in New Zealand,
Australia and the United Kingdom (UK) (Harper 1983, Quigley et al. 1984, Strang 1985,
Rainey 1986). At this time, buprenorphine was marketed as a low-dose product for the
treatment of pain (Temgesic®). Low-dose buprenorphine refers to buprenorphine products
used for pain treatment and high-dose buprenorphine to products used for the treatment of
opioid dependence. In 1986, Robertson and Bucknall highlighted the extensive abuse of
buprenorphine in Edinburgh and advised doctors to be aware of the dangers of prescribing
it (Robertson & Bucknall 1986). Another study reported a marked increase in the number of
buprenorphine users presenting for substance abuse treatment in Ireland between 1986 and
1987 (O'Connor et al. 1988). During the same time period, a 9% increase in the proportion of
new clients using buprenorphine was detected in an outpatient clinic in Glasgow, Scotland
(Sakol et al. 1989). The first report about the dependence potential of buprenorphine was
published by Gray and colleagues (Gray et al. 1989). More than half (58%) of the new clients
referred to their Glasgow clinic during a 6-month period reported that buprenorphine was
their preferred drug. Low-dose buprenorphine was the most frequently abused drug
among IV drug users in Glasgow between 1989 and 1990 (Lavelle et al. 1991). Due to these
reports, restrictions on prescribing of buprenorphine were introduced in Glasgow in
September 1989 but this led only to a moderate drop (20%) in incidence of abuse cases
which started to rise again after few months (Stewart 1991). Reports from India (Nizamie &
Sharma 1990, Chowdhury & Chowdhury 1990, Singh et al. 1992) and Spain (San et al. 1993)
also indicated increasing abuse of buprenorphine. In 1989, the WHO Expert Committee on
Drug Dependence recommended the inclusion of buprenorphine in Schedule III of the
Convention on Psychotropic Substances 1971 (World Health Organization 1989). Schedule
III substances are under international control (International Narcotics Control Board 2010).
In addition to buprenorphine, for example pentazocine and flunitrazepam are included in
the  list.  The  first  report  of  abuse  of  buprenorphine  by  snorting  was  published  in  1991
(Strang 1991). In New-Zealand, low-dose buprenorphine was withdrawn due to abuse in
1991 and replaced by a buprenorphine-naloxone combination product (0.2 mg
buprenorphine + 0.17 mg naloxone) (Robinson et al. 1993). The proportion of clinic patients
self-reporting buprenorphine abuse in New Zealand dropped from 81% in 1990 to 57% in
1991-1992 indicating lower but still existent IV abuse potential of the combination product.
French general practitioners (GPs) have been able to prescribe high-dose buprenorphine
to patients for the treatment of opioid dependence since 1996 (Thirion et al. 2002). Since
then  the  abuse  of  buprenorphine  has  been  widely  documented  in  France.  Obadia  and
colleagues reported that 24% of their injecting drug user (IDU) sample injected only
buprenorphine and 34% injected it occasionally in parallel with other drugs (Obadia et al.
2001). Another French study reported similar results, with 27% of their IDU sample using
only buprenorphine and 37% being poly-drug users (Moatti et al. 2001). Valenciano and
colleagues reported even higher proportions as 45% of needle exchange program (NEP)
clients (n=1,004) were categorized as main buprenorphine users and 73% had used
buprenorphine in the last month (Valenciano et al. 2001). Falsified prescriptions to obtain
buprenorphine from community pharmacies have been detected in France (Baumevieille et
al. 1997). Around the same time, buprenorphine abuse has also been reported in Nepal
(Shrestha et al. 1998) and India (Kumar et al. 2000). A rapid assessment conducted in
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Madras, India revealed that 42% of IDUs interviewed (total n=100) used buprenorphine as
their primary drug of abuse in 1998 (Kumar et al. 2000). Another Indian study reported that
buprenorphine abuse increased rapidly until 1994 and then started to gradually decrease
(Sharma & Mattoo 1999).
More recently, buprenorphine abuse has been documented all over the world, such as in
Australia, in the USA and in many European and Asian countries (Yokell et al. 2011). The
main studies examining buprenorphine abuse published within the last 10 years have been
summarized in Table 2. In Australia, high-dose buprenorphine products have been
available since 2000 (Jenkinson et al. 2005). In a survey conducted in 2002, 57% of IDUs
(total n=156) reported life-time use of buprenorphine and 37% reported life-time injecting of
buprenorphine  (Jenkinson  et  al.  2005).  Aitken  and  colleagues  conducted  a  similar  survey
with IDUs in Melbourne in 2005-2006 (n=316) and reported that 32% (n=101) had injected
buprenorphine during the previous 3 months and 10% (n=33) were primary buprenorphine
users  (Aitken  et  al.  2008).  Buprenorphine  injecting  has  also  been  reported  in  Malaysia
(Bruce et al. 2008) and Nepal (Aich et al. 2010). Among Indian IDUs, buprenorphine was
the second most commonly injected drug in 2005-2006 (Solomon et al. 2010). Buprenorphine
abuse has caused large-scale public health problems in Singapore (Chua & Lee 2006,
Winslow et al. 2006) and in the south Caucasus state of Georgia (Parfitt 2006). In 2005, 39%
of patients treated in Georgian detoxification units were seeking treatment due to
buprenorphine abuse (Parfitt 2006). In 2007, buprenorphine was the most commonly
abused IV drug among IDUs (n=381) using NEP services in Georgia (96% reporting lifetime
injecting and 75% reporting last-month injecting) (Otiashvili et al. 2010). Despite the high
prevalence of abuse, only 13% of respondents reported buprenorphine as their favorite
drug. There were at least 3,800 buprenorphine users in Singapore in 2006 (Lee 2006). As a
countermeasure for large-scale abuse, Singaporean authorities tightened buprenorphine
controls, prohibited buprenorphine from being dispensed as take-home doses and forbade
GPs to start any new patients on buprenorphine.
A systematic literature review examining the abuse of medicines in the countries of
European Union (EU) indicated that buprenorphine was one of the most abused medicines
in this area (Casati et al. 2012). However, there were regional differences across the EU
region. In Sweden, 89% of heroin users and 24% of amphetamine users visiting a NEP had
used buprenorphine during the last year in 2004 (Hakansson et al. 2007). Intravenous abuse
was reported by 43% altogether. According to a recent qualitative study, buprenorphine
abuse was not generally perceived as a widespread problem among Swedish adolescents
(Richert & Johnson 2013). A Norwegian multi-indicator model which utilized data from
seizures, treatment units, pharmacy sales, helplines, key informants and media monitoring
indicated increasing illicit use of buprenorphine between 2002 and 2006 (Mounteney &
Haugland 2009). France was the first country to introduce a generic buprenorphine product
in April 2006 (Nordmann et al. 2012). In 2008, 32% of clients entering drug addiction
treatment centres were consuming generic buprenorphine (Nordmann et al. 2012). The
studies mentioned above refer to the abuse of high-dose buprenorphine. The abuse of low-
dose buprenorphine has been reported in the South Asia region (Larance et al. 2011a). Data
about opioid abuse and injecting from this region are not complete but buprenorphine
abuse has been reported in Bangladesh, India, Nepal and Pakistan. In Bangladesh and
Nepal, buprenorphine has been reported to be the most favored drug among IDUs (Larance
et al. 2011a).
The USA research has predominately highlighted the abuse of oxycodone and
hydrocodone (Cicero et al. 2005) while the abuse of buprenorphine has remained low
(Cicero & Inciardi 2005, Cicero et al. 2007c, Hughes et al. 2007). According to poison centre
data collected between 2002 and 2003, hydrocodone and oxycodone had the highest abuse
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rates in the USA (3.75 and 1.81 per 100,000 population, respectively) (Hughes et al. 2007). A
study utilizing poison centre and prescription database information in 2003-2005 reported a
low abuse rate of buprenorphine (Smith et al. 2007). The average quarterly abuse ratio per
1,000 prescriptions dispensed was 0.08 for the single-ingredient buprenorphine (BUP) and
0.16 for the BNX. In 2005, only 1% of PO users enrolled in OST reported recent abuse of
buprenorphine (Rosenblum et al. 2007). Among a sample of street drug users in New York
City (n=586) in 2004 to 2006, buprenorphine products were the least used POs (0.2% of the
sample) (Davis & Johnson 2008).
However, according to more recent data from drug screens and interviews conducted in
parole and probation units, buprenorphine abuse increased in the USA between 2005 and
2010 (Wish et al. 2012). A post-marketing surveillance study using data from the
Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System
Programs reported similar findings (Dasgupta et al. 2010). Nevertheless, the rates of
methadone abuse and diversion were significantly higher than those for buprenorphine.
From 2005 to 2009, the different measures of diversion and abuse of buprenorphine (user
and physician surveys, exposures to buprenorphine reported to Poison Control Centres,
seizures, emergency department visits) all steadily increased (Johanson et al. 2012). In 2007,
Stimmel speculated that buprenorphine abuse would increase in the USA as a consequence
of the growing number of people for whom buprenorphine is prescribed (Stimmel 2007).
The USA Food and Drug Administration (FDA) approved buprenorphine (both BUP and
BNX) for the treatment of opioid dependence in 2002, later than in many European
countries or Australia.
Buprenorphine abuse by OST patients has been widely reported. Approximately half of
404 buprenorphine-maintained OST patients in France reported ever injecting
buprenorphine (Vidal-Trecan et al. 2003). Factors associated with buprenorphine injecting
were IV use of some other substance (OR 13.18, 95% CI 5.36-32.42), cannabis use (OR 2.34,
95% CI 1.51-3.63), having another source of income than salary (OR 1.58, 95% CI 1.02-2.45)
and heroin use (OR 0.23, 95% CI 0.09-0.61). Another French study reported that 36% of
buprenorphine-treated OST patients (n=142) injected buprenorphine during the previous
month which was a considerably higher proportion than methadone patients injecting
methadone (less than 1%, p< 0.01) (Guichard et al. 2003). Factors associated with injecting
among buprenorphine patients were unstable housing (odds ratio OR 4.3, 95% confidence
interval CI 1.6-11.5) and high buprenorphine dosage (OR 6.2, 95% CI 2.0-19.7). Roux and
colleagues found out that 32% of buprenorphine-treated OST patients (n=111) reported
buprenorphine injecting after treatment initiation (Roux et al. 2008a). Patients who reported
inadequate buprenorphine dose (OR 2.7, 95% CI 1.1-7.0) or an experience of suicide
ideation or suicide attempt (OR 2.6, 95% CI 1.2-5.7) had a significantly increased risk of
injecting. In the same study population, 30% of patients reported intranasal use of
buprenorphine after the initiation of OST (Roux et al. 2008b). Authors speculated that this
behaviour may be a response to dissatisfaction with treatment. Besides France, other
countries have also reported buprenorphine abuse among OST patients. In Italy, 23% of
OST patients (total n=307) had injected buprenorphine and injecting was more common
among those treated with buprenorphine compared to methadone-treated patients (35% vs.
18%, p<0.001) (Moratti et al. 2010). Approximately one quarter (27%) of buprenorphine-
treated OST patients had ever injected buprenorphine in 2005 (Winstock & Lea 2010). In
Australia, current OST was significantly associated with buprenorphine injection among
IDUs (OR 10.7, 95% CI 4.5-25.9) (Aitken et al. 2008). Contrary to these results, a recent
German study reported that injecting OST medicines (buprenorphine or methadone) was
more common among study participants currently in OST compared to users who abused
buprenorphine/methadone but were not in OST (p<0.001) (Schmidt et al. 2013). Life-time
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prevalence of buprenorphine/methadone abuse was 61.8% among OST patients and 70.3%
among other study participants. In 2008, among 440 Australian OST patients, 18% reported
having  ever  inhaled  (smoked  or  snorted)  buprenorphine  (Horyniak  et  al.  2011).  Other
studies  have  also  reported  intranasal  use  of  buprenorphine  (i.e.  snorting,  inhaling  and
sniffing) (Roux et al. 2008b, Daniulaityte et al. 2012).
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2.2.3.2 Finnish studies
Until the 1990s, drug abuse was generally small-scale in Finland (Hakkarainen & Tigerstedt
2005).  The  availability  and  abuse  of  drugs,  including  cannabis,  stimulants  and  heroin,
started increasing from the early 1990s. The number of ‘problem drug users’ in Finland was
estimated to be 11,500-16,400 in 1998 (Partanen et al. 2000). ‘Problem drug users’ refer to
amphetamine and opioid users who have experienced social and/or health harms due to
their drug abuse and, therefore, have been in contact with some authorities. In 2005, the
number had increased to 14,500-19,000 persons, of whom about 80% were estimated to be
amphetamine users and the remainder used opioids (Partanen et al. 2007). About half (50-
60%) of  problem drug users  lived in  Southern Finland and more than half  of  them in  the
Helsinki metropolitan area.
The first reports of buprenorphine abuse in Finland date back to the late 1990s (Partanen
et al. 2004). Partanen and colleagues interviewed 494 NEP clients in the three largest cities
of Finland between 2000 and 2002 (Partanen et al. 2004). Fifty-nine percent had injected
buprenorphine in the previous month and 78% reported life-time injecting. Thirty-three
percent of respondents injected buprenorphine on a daily basis and daily/extensive abuse
was  more  common  among  young  users  (less  than  25  years  old).  About  one-third  had
injected both buprenorphine and amphetamine, and one in seven had injected
buprenorphine, amphetamine and heroin concurrently in the previous month. Some
respondents (6%) had started injecting drugs with buprenorphine. In the early 2000s,
buprenorphine-trafficking from France was relatively common among Finnish drug users
(Tacke 2002). After the Schengen regulations, this kind of ‘medication tourism’ has been
less popular (Varjonen et al. 2012). Currently, it is believed that most illicit buprenorphine
is smuggled into Finland but there are also leakages from legal OST programs (Skretting &
Rosenqvist 2010). In 2005, buprenorphine was the most frequently used IV drug for 73% of
IDUs using NEP services (n=131) in the Helsinki area (Alho et al. 2007). Another study
examined NEP clients in the Helsinki metropolitan area annually between 2005 and 2010
(excluding 2009) and reported that buprenorphine was the most frequently used IV drug
during the study period (68-78% of clients) (Simojoki & Alho 2013). Aalto and colleagues
interviewed 30 consecutive clients entering to OST in Kotka between 2004 and 2005 and
found that 97% (n=29) used buprenorphine as the primary opioid of abuse (Aalto et al.
2007). All, except two participants, used buprenorphine intravenously. Even though 97% of
clients reported life-time use of heroin, 30% (n=9) had started opioid abuse with another
opioid than heroin. Buprenorphine abuse was the main reason for treatment seeking in 33%
of all clients with substance use disorders in Finland in 2009 (Forsell et al. 2010) and in 35%
in 2011 (Varjonen et al. 2012). In 2011, those seeking treatment for buprenorphine abuse
were mainly injecting it (86%) and almost half (44%) used buprenorphine on a daily basis
(Forsell 2012). Clients seeking treatment for buprenorphine abuse represented 82% of all
clients seeking treatment for opioid abuse. In 2009, Tammi and colleagues conducted a
structured interview study among 100 drug users from the Helsinki metropolitan area
(Tammi et al. 2011). Sixty percent of participants had used buprenorphine in the previous
month and 39% reported using BNX. Injecting was the most commonly mentioned route of
self-administration (93% and 72%, respectively). Almost 50% of buprenorphine users used
it on a daily basis. Illicit drug market was the most commonly mentioned source of both
BUP and BNX. Malin and colleagues conducted a qualitative interview study among 12
buprenorphine users (Malin et al. 2006). Even though study participants used
buprenorphine mainly intravenously, they considered their abuse as self-medication and
thought that buprenorphine enabled their functioning in everyday life. Poly-drug abuse
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was common among study participants, especially the abuse of benzodiazepines (BZDs),
amphetamine and alcohol. Frequent poly-drug abuse has been highlighted in other Finnish
studies as well (Partanen et al. 2004, Tammi et al. 2011, Forsell 2012).
The magnitude of buprenorphine abuse can be indirectly estimated via poisoning data.
Buprenorphine  was  the  most  frequent  cause  of  fatal  poisonings  among  drug  users  in
Finland in 2007 (25% of all intoxications) (Simonsen et al. 2011). These abuse patterns in
Finland were different from other Nordic countries, but buprenorphine intoxications have
increased  in  Sweden  and  Norway  as  well.  The  number  of  buprenorphine  findings  in
forensic post-mortem investigations has increased from less than 10 cases in 2000 to 156
cases in 2010 (Varjonen et al. 2012). However, the detection of buprenorphine from post-
mortem samples does not mean that buprenorphine has necessarily caused the death. In
2010, buprenorphine was the underlying cause of death in 46 cases. Fatal buprenorphine
poisonings were usually associated with concurrent use of BZDs and alcohol (82% and 58%
of buprenorphine poisonings in Finland from 2000 to 2008, respectively) (Häkkinen et al.
2012).
2.2.4 Abuse of the buprenorphine-naloxone combination product
A combination product of buprenorphine and naloxone in a 4:1 ratio (Suboxone®) was
developed to prevent diversion and reduce the abuse potential of buprenorphine (Johnson
et al. 2003). Naloxone is an opioid antagonist which has poor sublingual bioavailability and,
therefore, the combination product produces only buprenorphine effects when taken
sublingually (Mendelson & Jones 2003). However, when injected by an opioid-dependent
person naloxone can precipitate withdrawal symptoms and reduce the re-enforcing effects
of buprenorphine.  The 4:1 ratio of buprenorphine and naloxone has been demonstrated to
be better than the 8:1 ratio in reducing abuse and better than the 2:1 ratio in producing
shorter-term withdrawal symptoms. Stoller and colleagues reported that IM
buprenorphine-naloxone precipitated withdrawal symptoms in heroin-dependent
individuals (n=10) (Stoller et al. 2001). Other studies have reported similarly that
subcutaneously  or  intravenously  given  BNX  produced  antagonist-like  effects  in  opioid-
dependent individuals including both methadone/morphine-maintained individuals and
those not in maintenance treatment  (Bigelow et al. 1987, Preston et al. 1988, Mendelson et
al. 1996, Mendelson et al. 1997a, Fudala et al. 1998). Similar results have been reported in
non-dependent opioid users (IM administration) indicating low abuse potential (Weinhold
et al. 1992). However, controversial results have also been published. Buprenorphine and
buprenorphine-naloxone produced similar opioid agonist-like effects in non-dependent
opioid users when taken sublingually (n=7) (Strain et al. 2000) or intramuscularly (n=8)
(Duke et al. 2010). In opioid-dependent individuals maintained with buprenorphine (n=9),
BUP and BNX produced similar modest agonist-like effects (sublingual and IV
administration) (Harris et al. 2000). Comer and Collins demonstrated that IV
buprenorphine produced higher positive subjective ratings compared to the combination
product in recently detoxified heroin users (n=6), however, both products served as
reinforcers and were self-administered by study participants (Comer & Collins 2002).
Buprenorphine-maintained heroin users (n=12) self-administered buprenorphine-naloxone
intravenously less frequently than buprenorphine or heroin (p<0.0005) and reported lower
subjective ratings for ‘drug-liking’ and ‘desire to take again’ (p=0.0001) (Comer et al. 2010).
These studies indicate that the BNX has a lower IV abuse potential than BUP. The
reinforcing  effect  of  the  combination  product  seems  to  depend  on  an  individual’s  opioid
tolerance.  It  may  be  abused  by  less-frequent  opioid  users  and  by  detoxified  or
buprenorphine-maintained opioid users. Regular buprenorphine users can probably use it
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without marked withdrawal symptoms and even heroin users are not totally deterred from
injecting BNX (Mammen & Bell 2009).
Several studies have examined the abuse potential of BNX under real-life conditions
(Alho et al. 2007, Degenhardt et al. 2009, Bruce et al. 2009, Vicknasingam et al. 2010, Larance
et al. 2011b, Smirnov & Kemp 2012). In general, they have reported lower abuse potential
compared to BUP but the addition of naloxone has not been able to completely prevent IV
abuse  of  buprenorphine.  Alho  and  colleagues  reported  that  68%  of  IDUs  using  NEP
services in the Helsinki area in 2005 had tried IV use of BNX and 80% described it as ‘a bad
experience’ (Alho et al. 2007). Respondents were also willing to pay more for an 8 mg BUP
tablet compared to an 8 mg BNX tablet (p < 0.0001). Similarly, Degenhardt and colleagues
found that combination product was injected less frequently and less commonly than BUP
among both regular IDUs (9% and 23% during the previous 6 months, respectively) and
OST patients (10% and 30% during the previous 6 months, respectively) (Degenhardt et al.
2009). Differences were especially notable when the availability of both products was taken
into account. Larance and colleagues examined current OST patients in Australia and found
that significantly fewer BNX patients reported recently injecting their medicine compared
to BUP patients (13% vs. 28%) (Larance et al. 2011b). Similarly removing supervised doses
(i.e. secreting medicine out of the dosing site instead of ingesting) was less common among
BNX patients compared to BUP patients (22% vs. 35%). Thirty-eight percent of BNX
patients reported ‘not liking’ the drug effect compared to 18% of BUP patients. These
findings are in agreement with the level of injecting among regular IDUs (adjusted for the
volume of sales) which indicated a lower level of BNX injecting compared to BUP in 2008-
2009. Despite these differences, the street price of BNX and BUP was similar ($35 for an 8
mg tablet in 2008, $28-30 in 2009). Smirnov and Kemp reported consistent results from the
Brisbane area in Australia, indicating lower rates of abuse of the combination product
compared to BUP and methadone (Smirnov & Kemp 2012). In addition to Australia
(Larance et al. 2011b), BNX diversion has been recently reported from the USA as well
(Johanson et al. 2012). In the USA, the abuse rate of BNX was slightly higher compared to
BUP between 2003 and 2005 (0.16 and 0.08 abuse cases per 1000 prescriptions dispensed,
respectively) (Smith et al. 2007). This difference probably reflects the more frequent
therapeutic use of BNX than BUP in the USA.
In Malaysia, BNX was introduced in December 2006, and since this time physicians have
only been able to prescribe the combination product for the treatment of opioid dependence
(Bruce et al. 2009). However, this action did not reduce the IV abuse of buprenorphine or
related risk behaviours and resulted in an increase in the mean daily dose of buprenorphine
among IDUs (n=41). Nevertheless, the combination product was not as desirable as BUP
among buprenorphine IDUs (Vicknasingam et al. 2010). In addition, daily buprenorphine
injecting was more common before the introduction of the combination product than after
among  regular  IDUs  (daily  BUP  injecting  63%,  daily  BNX  injecting  34%).  In  focus  group
discussions, participants explained that they divided BNX tablets into small portions or
combined them with heroin or BZDs in order to minimize naloxone effects and enhance
positive effects. Buprenorphine-naloxone may also be used intranasally (Horyniak et al.
2011). Compared to sublingual administration, intranasal BNX had greater bioavailability
and a faster onset of effects (Middleton et al. 2011). The bioavailability of naloxone was
relatively high, 24-30% after intranasal administration compared to 10% after sublingual
administration (Harris et al. 2000), and this may deter the likelihood of intranasal abuse by
some users.
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2.2.5 Characteristics of buprenorphine users
Basu and colleagues conducted one of the first studies examining the characteristics of
buprenorphine users. They described the characteristics of 94 clients seeking treatment for
buprenorphine dependence in India between 1987 and 1993 (Basu et al. 2000). All clients
were men, on average 26 years old, 45% were married and one-third unemployed. All had
used another substance, most commonly alcohol (100%) or heroin/other opioids (75%)
before switching to buprenorphine. Polydrug abuse was common as 90% of participants
used  some  other  substance  concomitantly  to  buprenorphine.  Further  studies  have  now
investigated the characteristics of buprenorphine users in Singapore, Malaysia, and the
USA. People abusing buprenorphine were mostly males (90-98%) (Winslow et al. 2006,
Vicknasingam et al. 2010), 53-76% were employed (Winslow et al. 2006, Cicero et al. 2007c,
Vicknasingam et al. 2010, Lofwall & Havens 2012), and 20-25% were married (Winslow et
al. 2006, Lofwall & Havens 2012). Homelessness has been reported to be associated with
buprenorphine injecting among French IDUs (Blanchon et al. 2003). A French OPPIDUM
survey examined the changes in the profile of buprenorphine users (sample included also
OST patients) between 2006 and 2008 (Nordmann et al. 2012). The mean age of users had
increased (p=0.007), the proportion of users with an occupation had increased (p<0.0005),
and the daily buprenorphine dose (p=0.02) as well as the proportion of IV users (p=0.002)
had decreased.  The frequency of daily buprenorphine abuse varies according to the study
population (ranging from 9.6% to 100%) (Kumar et al. 2000, Vicknasingam et al. 2010,
Lofwall  &  Havens  2012).  The  most  commonly  mentioned  sources  of  buprenorphine  have
been medical prescribers (57%) (Cicero et al. 2007c), friends (32-81%), and dealers (59%)
(Larance et al. 2011b, Lofwall & Havens 2012). In the USA study by Bazazi and colleagues,
76% of participants (n=100) reported obtaining BNX illicitly from the street and that it was
easy or very easy to get access to BNX (Bazazi et al. 2011). According to a recent study,
availability of illicit buprenorphine from the Internet seems to be relatively poor and prices
high (Bachhuber & Cunningham 2013).
Compared to other PO users, buprenorphine users were more commonly white (OR 3.19,
p<0.01), younger (31 vs. 35 years old, p<0.01), more highly educated (OR 1.72, p<0.01) and
more commonly employed (OR 1.63, p<0.01) (Cicero et al. 2007c). Another US study
reported similar results among young (18-23 years old) PO users (Daniulaityte et al. 2012).
Factors associated with buprenorphine abuse were white ethnicity (OR 19.7, 95% CI 2.5-
159.0), intranasal use of POs (OR 3.8, 95% CI 1.5-9.3), symptoms of opioid dependence (OR
3.5, 1.1-10.7), and a greater number of illicit POs used during lifetime (OR 1.4, 95% CI 1.1-
1.8). The qualitative interviews with a representative sub-sample of study participants
indicated that buprenorphine users were usually more experienced users and they used
buprenorphine mainly orally or by intranasal route while injecting was relatively
uncommon. Similarly, other studies have reported that the most common routes of
administration have been sublingual or per oral (87-100%) (Cicero et al. 2007c, Schuman-
Olivier et al. 2010). However, a high frequency of buprenorphine abuse via injecting has
been reported in many studies (Jenkinson et al. 2005, Alho et al. 2007, Aitken et al. 2008,
Aich et al. 2010), as described in Chapter 2.2.3.1. Syringe/needle sharing was significantly
associated with buprenorphine injecting among Australian IDUs (4.9 vs. 2.1 times/previous
3 months) (Aitken et al. 2008). In contrast to these findings, an Indian study reported that
buprenorphine  users  were  less  likely  to  share  injecting  equipment  compared  to  other  IV
users (Solomon et al 2010). Buprenorphine injecting can cause various complications, such
as soft tissue infections, peripheral ischemia of limbs (Loo et al. 2005, Winslow et al. 2006,
Ho et al. 2009, Partanen et al. 2009) and even endocarditis (Chong et al. 2009).
Concurrent abuse of BZDs is common among buprenorphine users (46-89% of users)
(Basu et al. 2000, Ahmed & Ara 2001, Winslow et al. 2006, Nielsen et al. 2007b, Otiashvili et
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al. 2010, Vicknasingam et al. 2010, Lofwall & Havens 2012). Forty-six percent of
buprenorphine-treated OST patients (total n=170) used BZDs during the previous month
(Lavie et al. 2009). Thirty-one percent met the DSM-IV criteria for BZD abuse or
dependence. A US study reported similar findings, showing that 47-56% of patients
receiving buprenorphine filled prescriptions for BZDs (Mark et al. 2013). High levels of
psychological disorders such as depression and anxiety may explain the BZD use among
opioid users (Lintzeris & Nielsen 2010). Opioid users may also use these anxiolytics in
order to relieve abuse-related symptoms or to increase the euphoric effects of opioids
(Sharma & Mattoo 1999, Bruce et al. 2008, Lintzeris & Nielsen 2010). Concurrent BZD use is
alarming because it increases the risk of fatal buprenorphine poisoning (Häkkinen et al.
2012). Buprenorphine users with concurrent BZD abuse have been shown to be more
commonly IV users (p=0.001), share syringes (p=0.02) and be seropositive for hepatitis C
(p=0.04) (Ng et al. 2007). Schuman-Olivier and colleagues found no differences in OST
retention or illicit opioid use between buprenorphine-treated OST patients with or without
BZD use (Schuman-Olivier et al. 2013). Patients with BZD prescriptions had more
emergency department visits during OST compared to patients without BZD prescriptions
(p<0.001) regardless of history of BZD abuse. In addition to BZDs, other concurrent
substance abuse has been reported among buprenorphine users. Current heroin abuse was
common (62-64%) among IDUs using buprenorphine in Malaysia (Vicknasingam et al.
2010). Lofwall and Havens reported that 64-86% of buprenorphine users had used another
opioid in the previous 30 days; marijuana use was reported by 64% and cocaine use by 27%
(Lofwall & Havens 2012).
Self-treatment has been defined as “any attempt to provide an appropriate therapeutic
strategy for oneself in the absence of professional advice or consent” (Schuman-Olivier et
al. 2010). Self-treatment of opioid withdrawal symptoms and/or dependence is the most
common reason users give for their buprenorphine abuse (48-92% of users) (Alho et al.
2007, Hakansson et al. 2007, Otiashvili et al. 2010, Schuman-Olivier et al. 2010, Moratti et al.
2010, Larance et al. 2011b, Bazazi et al. 2011). The same applies to the abuse of BNX
(Vicknasingam et al. 2010, Bazazi et al. 2011). However, other reasons which do not support
the self-treatment hypothesis have been reported as well. Among 120 buprenorphine users
in Singapore, 33% initiated buprenorphine abuse out of curiosity and 33% switched to
buprenorphine injecting to get an extra ‘high’ (Winslow et al. 2006). Using buprenorphine
to ‘get high’ or experience pleasure has been reported by 42% of Malaysian IDUs
(Vicknasingam et al. 2010), 32% of US IDUs, 69% of non-IDUs (Bazazi et al. 2011), and 70%
of US PO users (Lofwall & Havens 2012). The cheaper price of buprenorphine compared to
heroin has also been mentioned as a reason for buprenorphine abuse (Ahmed & Ara 2001,
Aitken et al. 2008). Otiashvili and colleagues (2010) reported that 27% of young
buprenorphine users (10-24 years old) reported buprenorphine as the first drug of getting
addicted to. In the study by Winslow et al. (2006), 53% of buprenorphine users had started
IV-drug  use  with  buprenorphine.  A  Finnish  study  reported  that  44%  of  NEP  clients  had
started IV drug use with buprenorphine in 2010 (Simojoki & Alho 2013). Another
explanation for buprenorphine use may be the self-treatment of depression which was
reported by 30% of participants (both illicit and licit buprenorphine users) in the study by
Schuman-Olivier et al. (2010). There is evidence from small open-label clinical studies and
surveys that buprenorphine may alleviate depressive symptoms (Kosten et al. 1990,
Schuman-Olivier et al. 2010, McCann 2008). Anti-depressive effects may tentatively be
attributable to buprenorphine’s kappa receptor antagonism (Gerra et al. 2006).
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2.2.6 Prescription opioid abuse in general
Prescription drug abuse has grown worldwide (Kuehn 2007). In the USA, the abuse of
prescription drugs is more prevalent than the abuse of any illicit drug, except cannabis
(International Narcotics Control Board 2013). Abuse of POs has become a significant
problem in the USA, South Asia, some parts of Europe and to lesser extent in Canada,
Australia and New Zealand (Degenhardt et al. 2008). At the same time, the abuse of heroin
has decreased (Fischer et al. 2006, Fischer & Rehm 2007, Holmes 2012). The most commonly
used prescription or pharmaceutical opioids include buprenorphine, methadone, codeine,
morphine, dextropropoxyphene, oxycodone, fentanyl, pethidine (meperidine),
hydrocodone, propoxyphene, and hydromorphone (Degenhardt et al. 2008). The
populations abusing POs can be very different across countries. In some countries, e.g.,
India and Australia, POs are abused by IDUs whereas in the USA, PO abuse is relatively
common  among  the  general  population.  The  abuse  of  POs  can  be  highly  prevalent  in
subsamples of the general population, e.g., aboriginal populations in Canada where more
than 50% of adults abuse POs (Webster 2013).
In the USA, PO abuse has increased markedly during the last decade and has become a
significant public health problem (Compton & Volkow 2006a, Compton & Volkow 2006b,
McCarthy 2007, Mendelson et al. 2008, Office of Applied Studies 2010, Fischer et al. 2013b).
In 2008, 14% of the general population in the USA self-reported life-time illicit use of POs
(Substance Abuse and Mental Health Services Administration 2009). Treatment admissions
to substance abuse treatment services due to PO abuse increased from 2% in 2000 to 9% of
all admissions in 2010 (Substance Abuse and Mental Health Services Administration 2012).
Among 5,663 opioid dependent persons enrolling in OST in the USA, POs were abused by
67% and 38% indicated that a PO was their primary drug of abuse (Rosenblum et al. 2007).
Among street drug users in New York City (i.e. drug users recruited in public settings), PO
abuse was also  common and methadone was the  most  commonly abused PO (72% of  the
sample) (Davis & Johnson 2008). In Canada, the number of PO-related admissions to
addiction treatment services rose by 60% in 2004-2009 and the prevalence of problematic
PO use for the five-year study period was 12.3% (Fischer et al. 2010). In the general
population within Canada, the prevalence of past year PO abuse was 15.5% in students and
5.9% in adults (Fischer et al. 2013a). In the UK, there was a growing trend in the number of
PO related deaths in 2001-2011 (Giraudon et al. 2013). The abuse and injection of POs has
also increased in the South Asia region while the use of heroin has declined (Larance et al.
2011a). India is thought to account for extensive diversion of POs in this area but there is a
paucity of empirical data across the South Asia region (Larance et al. 2011a). In India, the
abuse of natural opioids, such as opium and poppy husk, has decreased with a concomitant
increase in the abuse of POs such as buprenorphine, codeine and dextropropoxyphene
between 1978 and 2008 (p<0.001) (Basu et al. 2012).
There is a significant correlation between the therapeutic use of POs and the magnitude
of their abuse (Cicero et al. 2007b, Unick et al. 2013). It has been suggested that increased
availability along with greater social acceptability and a perception that licit drugs are safe
contribute to the rise of PO abuse (McCarthy 2007). A relationship between opioid
prescribing and opioid overdoses has also been reported (Bohnert et al. 2011). A growing
abuse problem has led to several negative consequences. Overdose deaths involving opioid
analgesics have increased throughout 1997-2007 in the USA (Paulozzi et al. 2011). Between
1999 and 2002, the number of opioid analgesic poisonings increased by 91% (Paulozzi et al.
2006). Between 1999 and 2009, the PO-related overdose death rate increased almost fourfold
and POs accounted for the highest relative increase in death rates (Calcaterra et al. 2013). In
New York City, PO related overdose deaths showed an increasing trend from 1990 to 2006
(p<0.01) with an almost sevenfold increase in death rate (from 0.39 to 2.7 per 100.000
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persons) (Cerda et al. 2013). Hospitalizations for poisonings by POs, sedatives and
tranquilizers increased by 65% in the USA from 1999 to 2006 (Coben et al. 2010). Women
seem to be especially susceptible to PO abuse (Green et al. 2009, Tkacz et al. 2012) and
abuse-related hospitalizations (Coben et al. 2010, Unick et al. 2013). However, contrasting
results have also been reported. In the USA general population (n=55,023), women were
less likely to abuse POs than men in 2003 (past-year prevalence 4.5% vs. 5.2%, p=0.0098)
(Tetrault et al. 2008).
Spiller and colleagues reported four-year trends from different US states and showed
that there was a consistent, increasing trend between poverty and unemployment rates and
PO abuse rate (Spiller et al. 2009). Various studies have examined the characteristics of PO
users (sociodemographics, social and health factors, substance abuse behaviour, treatment-
related factors) (Brands et al. 2004, Sigmon 2006, Rosenblum et al. 2007, Moore et al. 2007,
Subramaniam & Stitzer 2009, Green et al. 2009, Fischer et al. 2010, Katz et al. 2013). Fischer
and colleagues examined PO-related treatment admissions in Ontario, Canada between
2004 and 2009 (n=61,509) and found that approximately 60% of PO users were younger than
34 years old, 29% were married, 27% were employed, about half received income from
social assistance or insurance programs and less than half (47%) self-referred to treatment
(Fischer et al. 2010). Concurrent substance abuse was common (75%). Similarly, other
studies have reported that concurrent substance abuse is common among PO users
(Subramaniam & Stitzer 2009, Green et al. 2009). Injecting the primary drug of abuse was
relatively uncommon (11-33%) in PO users (Rosenblum et al. 2007, Office of Applied
Studies 2010, Cicero et al. 2011b). In the study by Fischer et al. (2010), 24% of PO users had
injected drugs  in  the  past  year.  The most  commonly mentioned source  of  POs has  been a
dealer (50-86%) (Rosenblum et al. 2007, Cicero et al. 2008, Cicero et al. 2011b). Other
commonly mentioned sources have been friends/relatives (68%) and physicians (63%)
(Cicero et al. 2008). Reasons for abuse of POs include easy access, legal status, greater social
acceptability compared to illicit drugs, high purity and predictable dose and, therefore,
increased safety (Cicero et al. 2007a). POs may also be used to self-treat pain or
dependence, to seek euphoria or to substitute for illicit substances when their availability is
poor (Degenhardt et al. 2008). The high prevalence of psychiatric disorders among PO users
has been documented in many studies (Cicero et al. 2008, Wu et al. 2010, Wu et al. 2011a,
Fischer et al. 2012). In the general population reporting PO abuse, a pooled prevalence of
any mental health symptoms was 32% (95% CI 24-40) (Fischer et al. 2012). The lifetime
prevalence of any DSM-IV mood disorder or personality disorder was 48% and 40%,
respectively (Wu et al. 2011a). Both comorbid mental and physical disorders can increase
the risk of PO abuse and dependence (Katz et al. 2013).
Several studies have compared the characteristics of heroin and PO users (Sigmon 2006,
Rosenblum et al. 2007, Moore et al. 2007, Fischer et al. 2008, Nielsen et al. 2011, Wu et al.
2011a, Wu et al. 2011b, Tkacz et al. 2012). Compared to heroin users, PO users have been
reported to be younger (Sigmon 2006, Moore et al. 2007, Rosenblum et al. 2007, Fischer et al.
2008, Wu et al. 2011b), more commonly white (Sigmon 2006, Moore et al. 2007, Rosenblum
et al. 2007, Fischer et al. 2008, Tkacz et al. 2012), and more commonly have pain problems
and less experience with substance abuse treatment (Sigmon 2006, Moore et al. 2007,
Rosenblum et al. 2007). Daily use has been reported to be more common among heroin
users (71%) compared to PO users (61%) (Office of Applied Studies 2010). Heroin users
were more likely to report lifetime/recent IV drug use (range 61–92%) compared to PO
users (range 0–67%) (Brands et al. 2004, Sigmon 2006, Rosenblum et al. 2007, Fischer et al.
2008, Office of Applied Studies 2010). Tkacz and colleagues reported that PO users were
more likely to be married (34% vs. 16%) and had more years of education (13.1 vs. 12.3
years) compared to street users of heroin (current or life-time) (Tkacz et al. 2012). PO users
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have also been reported to earn more income, have fewer years of opioid use, and be less
likely to have Hepatitis C antibodies (p<0.05) (Moore et al. 2007). PO users had improved
treatment response in terms of retention (21.0 vs. 14.2 weeks), opioid-negative urine
samples (56.3% vs. 39.8%) and completing the treatment (59% vs. 30%) compared to heroin
users. Certain socio-demographic and clinical characteristics may be associated with a
successful treatment outcome among PO users (Dreifuss et al. 2013). Dreifuss and
colleagues examined PO dependent patients treated with BNX (n=360) and reported that
age (OR 1.3, 95% CI 1.0-1.6), lifetime major depression (OR 1.8, 95% CI 1.2-2.9), route of use
other than oral or sublingual (OR 0.5, 95% CI 0.3-1.0), and prior opioid dependence
treatment contacts (OR 0.6, 95% CI 0.4-1.0) were significantly associated with successful
treatment outcome (Dreifuss et al. 2013).
However,  among  PO  users  there  are  distinct  groups  differing  from  each  other  in  key
variables such as age, gender, ethnicity, education, concurrent substance abuse, duration of
abuse, familial substance abuse, psychiatric disorders, treatment history, and in risk for
adverse events (Martins et al. 2009, Green et al. 2011, Wu et al. 2010). An example of distinct
user groups was reported in an Australian study which compared the characteristics of
heroin and PO users (Nielsen et al. 2011). Clients seeking treatment for heroin or PO abuse
were relatively similar in demographics as well as health and injecting-related factors.
Nevertheless, there was a distinct group of PO users who did not inject, initiated opioid use
as a treatment for pain and had poor physical and mental health status.
2.3 THE USE OF BUPRENORPHINE IN OPIOID SUBSTITUTION
TREATMENT
2.3.1 Definition of opioid substitution treatment
According to the WHO, OST is defined as “the administration of thoroughly evaluated
opioid agonists, by accredited professionals, in the framework of recognized medical
practice, to people with opioid dependence, for achieving defined treatment aims” (World
Health Organization 2009). In general, the aims are to reduce the illicit use of opioids and
mortality  and  morbidity  related  to  it,  reduce  criminal  behaviour,  reduce  injecting  and
associated risk behaviour, improve physical and psychological health and social
functioning, and enable employment and/or education and, hence, reintegration into the
society (World Health Organization 2004, World Health Organization 2009). Aiming to
achieve a drug-free state is the ultimate goal of OST but it is not feasible for everyone
(World Health Organization 2004). Therefore, it is not considered as one of the primary
goals of OST. Opioid agonists methadone and buprenorphine are the most commonly used
medicines in OST (World Health Organization 2009). Dole and Nyswander demonstrated
the use of methadone in the treatment of heroin dependence in the 1960s (Dole &
Nyswander 1965). They concluded that methadone was able to reduce narcotic hunger and
block the euphoric effects of heroin leading to marked improvements in patients’
functioning and social abilities. According to a review of the history of buprenorphine
development, buprenorphine was developed in 1966 and its potential in the treatment of
opioid dependence was discovered soon after (Campbell & Lovell 2012). However, the use
of buprenorphine as an OST medicine started officially in the 1990s.
Gerra and colleagues pointed out that methadone and buprenorphine should not be
considered as substitutes for the euphoric effects of heroin but instead medicines which can
control addictive behaviour in individuals with opioid dependence (Gerra et al. 2009).
Authors speculated that the term ‘substitution’ oversimplifies their actions and contributes
to the misunderstanding of this treatment approach. The WHO utilizes the term
‘maintenance treatment’ when referring to the treatment of drug dependence by a
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substitute drug whose action is based on cross-dependence or cross-tolerance (World
Health Organization 2012). In Finland, opioid agonist treatment was originally divided into
‘substitution treatment’ which aimed at rehabilitation and abstinence and ‘maintenance
treatment’ which aimed mostly towards harm reduction (Hermanson 2008). These
categories were removed when the new Decree of the Ministry of Social Affairs and Health
on the detoxification and substitution treatment of opioid addicts with certain medicinal
products (33/2008) came into effect in February 2008. Decree 33/2008 defines substitution
treatment as: “treatment of an opioid addict by using medicinal products containing
buprenorphine or methadone in which the objective is either, rehabilitation and a lifestyle
free of illegal drugs, or harm reduction and improved quality of life of the patient”
(Ministry of Social Affairs and Health 2008). As this is currently the official definition used
in Finland, this thesis uses this definition and the term ‘opioid substitution treatment’ when
referring to this treatment.
2.3.2 Efficacy and safety of buprenorphine
2.3.2.1 Single-ingredient buprenorphine
It was suggested as early as in the 1970s that buprenorphine may be a potential drug in the
treatment of opioid dependence due to its long duration of action, low potential for
producing physical dependence and low toxicity (Jasinski et al. 1978). It has been shown
that buprenorphine can suppress the self-administration of other opioid agonists and block
their effects (Martin et al. 1976, Jasinski et al. 1978, Bickel et al. 1988, Mello et al. 1982).
Currently it is known that buprenorphine can produce dependence as well (Eissenberg et
al. 1996) but most early research into the potential use of buprenorphine in OST programs
is still valid.
The majority of prominent studies examining the effects of buprenorphine in the
treatment of opioid dependence were published in the 1990s (Johnson et al. 1989, Fudala et
al. 1990, Lange et al. 1990, Johnson et al. 1992, Johnson et al. 1995b, Ling et al. 1998, Johnson
et al. 2000). They led to the conclusion that buprenorphine is a safe and effective medicine
in the treatment of opioid dependence. Johnson and colleagues reported that
buprenorphine-treated patients were more likely to remain on their initial dose and less
likely to request dose changes compared to placebo (Johnson et al. 1995b). Ling and
colleagues conducted a multicentre randomized clinical trial evaluating the safety and
efficacy of sublingual buprenorphine (1-16 mg/day) in the treatment of heroin dependence
(Ling et al. 1998). The authors concluded that buprenorphine was effective in retaining
patients in treatment, decreasing the number of opioid-positive urine samples and reducing
heroin  craving  as  well  as  ratings  for  the  severity  of  drug  problems  when  given  in  an
adequate dose (8 mg statistically more efficient than 1 mg/day). Buprenorphine treatment
has also been shown to improve patients’ clinical status, social adjustment and quality of
life (Maremmani et al. 2007). Mattick and colleagues reported that buprenorphine
improved patients’ self-reported HIV-risk behaviour and physical as well as psychological
health and also reduced criminal activity (Mattick et al. 2003). A large multicentre clinical
trial comparing buprenorphine (alone and in combination with naloxone) to placebo in the
treatment of heroin dependence had to be terminated early because active treatment had
markedly better efficacy than placebo in terms of opiate craving, patients’ overall status and
opioid-negative urine samples (Fudala et al. 2003). Similarly, the study by Schottenfeld and
colleagues was terminated earlier than planned because the outcomes of buprenorphine
treatment were superior compared to placebo and naltrexone, an opioid antagonist which
can be used for the treatment of opioid dependence (Schottenfeld et al. 2008). Most
commonly mentioned side-effects related to buprenorphine treatment include sedation,
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constipation, decreased libido, headache, withdrawal symptoms, pain, and insomnia (Mello
et al. 1982, Lange et al. 1990, Fudala et al. 2003). Ling and colleagues reported that most
adverse effects seen in their clinical trial were typical side effects of opioid treatment (Ling
et al. 1998).
Kakko and colleagues compared OST with buprenorphine to placebo in heroin users
(n=40) and reported 1-year treatment retention in the buprenorphine group to be 75%
compared with 0% in the placebo group (p=0.0001) (Kakko et al. 2003). Other studies have
reported generally lower retention rates which have varied between 38-62% (Johnson et al.
1992, Strain et al. 1994, Ling et al. 1998, Fischer et al. 1999, Johnson et al. 2000, Pani et al.
2000, Petitjean et al. 2001, Ahmadi 2002, Mattick et al. 2003, Cozzolino et al. 2006, Soyka et
al. 2008, Leonardi et al. 2008, Haddad et al. 2013). Various factors, such as buprenorphine
dose, length of study, inclusion criteria and other treatment given (e.g. psychosocial
support) may have a substantial impact on retention. Maremmani and colleagues reported
12-month treatment retention of 78% but they did not include the first 3 months of
treatment  which can be  a  critical  period for  retention (Maremmani  et  al.  2007).  A Finnish
study (n=30) examined the effectiveness of buprenorphine-based OST in buprenorphine
users and reported a 3-month retention of 100% (Aalto et al. 2011). At 12 months the
retention rate was 83%. Contrary to previous studies, study participants were dependent on
buprenorphine, not heroin as in most other studies. Studies comparing the effects of
different buprenorphine doses have usually indicated that larger doses produce better
treatment outcomes in heroin-dependent patients (Ling et al. 1998, Ahmadi 2002, Ahmadi
2003).
Compared to methadone, studies have shown that buprenorphine is equally effective
(Strain et al. 1994, Strain et al. 1996, Johnson et al. 2000, Ahmadi 2003, Vigezzi et al. 2006,
Maremmani et al. 2007, Soyka et al. 2008) or that methadone is more effective than
buprenorphine in retaining patients in treatment (Kosten et al. 1993, Ling et al. 1996, Fischer
et al. 1999, Pani et al. 2000, Petitjean et al. 2001, Mattick et al. 2003). Outcome measures
other than retention (e.g., opioid-positive urine samples, self-reported drug abuse, heroin
craving) have usually shown similar results between buprenorphine and methadone
treated patients (Pani et al. 2000, Petitjean et al. 2001, Mattick et al. 2003). Fischer and
colleagues reported lower retention (p<0.05) but otherwise better treatment outcomes
(lower level of illicit opioid use, p=0.04) in the buprenorphine group compared to the
methadone group (Fischer et al. 1999). It has been speculated that high attrition rates (44-
53%) in buprenorphine-treated patients may reflect inadequate dosing (Pani et al. 2000,
Petitjean et al. 2001). Lower induction doses of buprenorphine have been associated with
higher relapse rates (51% with 2 mg of buprenorphine vs. 21% with 10 mg dose) (Leonardi
et al. 2008). Soyka and colleagues conducted a randomised clinical study with a flexible
dosing regimen and found no differences in outcomes between methadone and
buprenorphine-treated patients (retention rates 55% vs. 48%, p=0.42) (Soyka et al. 2008).
Other possible reasons for lower retention in buprenorphine treatment include too slow
induction and patients being able to terminate buprenorphine treatment more easily on
their own compared to methadone due to milder withdrawal symptoms (Jones 2004).
Lower retention in buprenorphine treatment may be explained by differences in the effects
of buprenorphine and methadone, i.e., buprenorphine is a less reinforcing drug and
supresses withdrawal symptoms less completely compared to methadone (Bell 2012). A
systematic literature review examined the effects of buprenorphine in comparison to
placebo and methadone and concluded that buprenorphine was significantly more effective
in retaining patients in treatment compared to placebo but less effective than methadone
when administered at adequate doses (Mattick et al. 2008). Nevertheless, buprenorphine
may be more suitable in some settings due to its safety and the possibility of alternate-day
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administration (see 2.3.3). Buprenorphine is not very likely to cause overdoses due to the
ceiling effect on respiratory depression (Dahan 2006).
2.3.2.2 Buprenorphine-naloxone combination product
The buprenorphine-naloxone combination product has been reported to be equally
effective and safe compared to BUP (Harris et al. 2000, Fudala et al. 2003). A large,
multicentre  study  found  that  both  BUP  and  BNX  decreased  opioid  craving  (Fudala  et  al.
2003). The rates of adverse effects were similar and no differences in the proportions of
opioid-negative urine samples were detected between BNX and BUP-treated patients (18%
vs. 21%). Buprenorphine-naloxone reduced the reinforcing and subjective effects of heroin
(BNX doses 8/2 and 32/8 mg per day) and was well-tolerated among heroin-dependent
individuals (n=7) (Comer et al. 2005). A US study reported 2-year retention of 38% in office-
based BNX treatment (Fiellin et al. 2008). No serious adverse events directly related to BNX
were reported during the follow-up period over 2-5 years. A nationwide prospective
surveillance  study  in  Germany  reported  high  effectiveness  and  safety  of  BNX  in  routine
care (Apelt et al. 2013). The 12-month treatment retention was 57% and rates for serious and
non-serious adverse events were low (1.2% and 17.5%, respectively). Other studies have
similarly shown that BNX is a suitable treatment option in the primary health care setting
(Finch et al. 2007, Mintzer et al. 2007). Naloxone can produce dose-dependent sympathetic
activation with increases in heart rate, blood pressure and respiratory rate, which may be
unpleasant but are not dangerous (Mendelson & Jones 2003). Because buprenorphine’s half-
life is markedly longer than naloxone’s half-life (32 h vs. 1 h) and naloxone is poorly
absorbed when taken sublingually, buprenorphine effects dominate when the combination
product is taken sublingually (Chiang & Hawks 2003). However, there is evidence that
sublingual naloxone may precipitate withdrawal in heroin users and methadone-
maintained OST patients, at least in large doses (up to 8 mg, which is equivalent to 32 mg of
BNX) (Preston et al. 1990).
Compared to methadone, BNX produced similar treatment outcomes in terms of opioid-
negative urine samples, retention, concurrent drug abuse, medication compliance and
overall functioning (Kamien et al. 2008). An Italian 1-year follow-up study (n=3,812)
reported that retention in methadone vs. buprenorphine-naloxone treatment was similar
(p=0.369) but a higher percentage of BNX-treated patients was married, had higher
educational levels and lower rates of illicit drug abuse (p<0.001) (Curcio et al. 2011).
However, selection bias may have affected the results because it is possible that more stable
patients were selected to receive BNX. Buprenorphine-naloxone and methadone were
highly and equally effective in retaining patients in the treatment (retention rate 62-68%)
and reducing heroin abuse in a naturalistic study conducted in the UK (McKeganey et al.
2013). Methadone and stepped treatment using both BNX and methadone were equally
efficient in a 6-month follow-up study (overall retention 78%) but only 46% of patients in
the stepped care group remained on BNX while others were switched to methadone (Kakko
et al. 2007). In stepped treatment patients started taking BNX with flexible doses but they
could be transferred to methadone if necessary. BNX has been linked to better cognitive
functioning compared to methadone, at least in the early phase of OST (Rapeli et al. 2007).
However, it should be taken into consideration that in the study by Rapeli and colleagues,
most study participants reported buprenorphine as their primary opioid of abuse whereas
in other studies participants have been mainly heroin users, if not otherwise stated.
Originally, OST was developed for the treatment of heroin dependence but more
recently its efficacy in the treatment of PO dependence, including buprenorphine, has been
demonstrated (Ahmadi et al. 2003, Moore et al. 2007, Aalto et al. 2011). Findings from a
large randomized controlled trial suggest BNX treatment can assist PO users to reduce their
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opioid abuse (Weiss et al. 2011). However, when tapering off buprenorphine-naloxone, the
rate of unsuccessful outcomes was shown to be high (exceeding 90%).
Switch  from  BUP  to  BNX  has  been  shown  to  be  well-tolerated  and  adverse  effects,
including withdrawal symptoms, were mild and relatively rare in the observational study
conducted in Italy (n=77) (Magnelli et al. 2010). The average buprenorphine dose increased
from 7.3 mg/day to 12.7 mg/day. Other studies have reported similarly positive outcomes
related to the switch from BUP to the combination product (Bell et al. 2004, Stimolo et al.
2010, Montesano et al. 2010, Daulouede et al. 2010). However, dose adjustments may be
needed and both dose increases (Bell et al. 2004, Magnelli et al. 2010) as well as reductions
(Simojoki et al. 2008) have been reported. Amato reported that the switch was associated
with no problems in 50% of patients and that most patients (78%) did not experience any
withdrawal symptoms related to the combination product (Amato 2010). In the study by
Simojoki and colleagues, 50% of patients experienced adverse effects during the 4-week
follow-up period after the medication switch (Simojoki et al. 2008). However, during the 4-
month follow-up, only 27% reported adverse effects. A French trial examined medication
preferences among OST patients and reported that 54% of patients who switched to BNX
from BUP preferred BNX and 71% wished to continue treatment with it (Daulouede et al.
2010). Other studies have reported similarly high patient satisfaction with BNX treatment in
the office-based setting (Barry et al. 2007, Fiellin et al. 2008).
2.3.3 Clinical use of buprenorphine and OST practices
OST practices and delivery models vary from country to country due to different social,
political and professional determinants (Farrell et al. 2000, Fischer et al. 2002, Carrieri et al.
2006, Skretting & Rosenqvist 2010). In some jurisdictions, GPs and community pharmacies
have major roles whereas others rely mainly on specialized substance abuse treatment
units. In some countries, such as Russia, opioid agonist-based treatments are prohibited
(Carrieri et al. 2006). OST practices may change over time, e.g., in Nordic countries official
OST guidelines have become less strict in the recent years (Skretting & Rosenqvist 2010).
The WHO has given minimal as well as best practice recommendations for the provision of
OST in different settings (World Health Organization 2009). Due to its complex nature,
opioid dependence usually requires long-term treatment (World Health Organization
2004). Certain single treatment modalities are not effective for everyone and therefore,
different  treatment  options  should be  available.  The efficacy and safety  of  buprenorphine
(both BUP and BNX) have been demonstrated and it has been shown to have great
relevance for clinical practice (Soyka et al. 2011). Buprenorphine established its position as
OST medicine rapidly since its launch to the market in the late 1990s and early 2000s
(Jenkinson et al. 2005, de Wet et al. 2005). For example, in England the number of
buprenorphine prescriptions increased from 13% in 2001 to 23% of the total number of
opioid prescriptions for OST or opioid withdrawal treatment in 2003 (de Wet et al. 2005). In
the USA, the number of buprenorphine prescriptions increased from 48,000 prescriptions in
2003 (the year when buprenorphine products were launched to the USA market) to
1,911,000 prescriptions in 2007 (Mark et al. 2009). In 2005, BUP (Subutex®) had been
approved for the treatment of opioid dependence in 44 countries worldwide (Carrieri et al.
2006). In March 2005, buprenorphine was added to the WHO list of essential medicines (14th
Model  List  of  Essential  Medicines  LEM) (Herget  2005).  Nevertheless,  the  majority  of  OST
patients in Europe received methadone (60%), although variation between countries exists
(range between 19.3% of OST patients in Austria and 75.4% of OST patients in the UK)
(Dale-Perera et al. 2012).
Besides specialised substance abuse treatment units, buprenorphine is efficient and safe
in primary health care and office-based settings (Fiellin et al. 2002, Lintzeris et al. 2004,
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Carrieri et al. 2006, Fatseas & Auriacombe 2007, Fiellin et al. 2008, Gunderson & Fiellin
2008, Hersh et al. 2011, Kraus et al. 2011, Haddad et al. 2013). This enables new types of
clients to enrol into treatment and improves the flexibility of treatment. However, office-
based treatment is not suitable for all opioid users (Bell 2012). Opioid users with complex
problems require more structured treatment and possibly a more reinforcing medicine
(methadone). The longest experience of office-based buprenorphine treatment comes from
France where all GPs have been able to prescribe buprenorphine without any special
education since 1996 (Fatseas & Auriacombe 2007). In France, the introduction of
buprenorphine  led  to  an  increase  in  the  number  of  OST  patients  (from  14  to  69%)  and  a
decrease in the number of IDUs (from 55 to 22%) between 1995 and 1997 (Thirion et al.
2001). At the same time, the number of overdose deaths declined by 79% (Auriacombe et al.
2001). A review summarizing the French experience with office-based buprenorphine
treatment since its introduction until the early 2000s concluded that there are more societal
and individual-level benefits than problems related to it (Auriacombe et al. 2004). In
Sweden, the drug policy was liberalized in 2005 (Romelsjö et al. 2010). As a consequence,
the sales of OST medicines and number of patients increased more than three-fold and
opioid-related mortality and the number of hospitalizations reduced 20-30% between 2000
and 2006. However, buprenorphine/methadone related mortality increased from 9 cases in
1998 to 49 cases in 2006.
In Finland, OST programs with methadone and BUP were officially started in 1997
(Hakkarainen & Tigerstedt 2005). The buprenorphine-naloxone combination product was
first marketed in 2006. Since December 2007, it has been the only licit high-dose
buprenorphine product since BUP was withdrawn from the market due to widespread
abuse. In 2010, 60% of Finnish OST patients (estimated n=2000) were treated with BNX and
the rest were in methadone treatment (Varjonen et al. 2012). Single-ingredient
buprenorphine is used only for OST in pregnant women by special permission from the
Finnish Medicines Agency. OST services are regulated by the Decree of the Ministry of
Social Affairs and Health on the detoxification and substitution treatment of opioid addicts
with certain medicinal products (33/2008) (Ministry of Social Affairs and Health 2008). OST
can be started in a person with opioid dependence (F11.2x according to ICD-10), if
detoxification treatment has not been successful. Treatment begins with the assessment of
the treatment needs which can be done in either an outpatient or inpatient setting
(Varjonen et al. 2012). According to the Decree 33/2008, treatment can be initiated and
provided at a municipal health care centre, substance abuse treatment unit or prison health
care unit. Usually more demanding patients are treated in specialised health care and
others in the primary health care units (Varjonen et al. 2012). Often assessments and
treatment initiations are done in specialised health care units even though Decree 33/2008
recommends that only the ‘more demanding cases’ should be treated there. Because OST is
long-lasting, treatment should be provided close to patient’s place of residence. OST should
be  based  on  an  individual  treatment  plan  which  specifies  the  pharmacotherapy,  other
medical and psychosocial treatment as well as rehabilitation and treatment follow-up
(Ministry of Social Affairs and Health 2008). Unobserved doses to a maximum of 8 daily
doses (for special reasons up to 15 daily doses) can be given to patients showing good
treatment compliance.
Buprenorphine-based OST is started with an individually-tailored dose (most commonly
4 mg) which depends on the level of tolerance, the half-life and amount of opioids used and
the time since the most recent use (Johnson et al. 2003, World Health Organization 2009). It
has been recommended that patients should be in moderate withdrawal state before the
first buprenorphine dose is given (Kraus et al. 2011). The stabilization phase concentrates
on finding the optimal dose. Generally most patients can be stabilized on a dose of 8-24
34
mg/day which is usually an adequate maintenance dose as well (World Health
Organization 2009, Kraus et al. 2011). The dose may need to be increased if illicit opioid
abuse continues (World Health Organization 2009). A survey was conducted among French
GPs in 2002, and it revealed that untrained GPs were especially prone to prescribing doses
of buprenorphine that were commonly ineffective (too low) (Feroni et al. 2005a). Authors
highlighted the need for clear guidelines and improved training for GPs. Buprenorphine is
also suitable for alternate-day or thrice-weekly dosing with similar retention compared to
daily dosing regimen (Johnson et al. 1995a, Schottenfeld et al. 2000, Mattick et al. 2003,
Marsch et al. 2005). Less-than-daily dosing has been associated with better compliance and
retention in buprenorphine treatment compared to daily dosing (Leonardi et al. 2008).
Amass and colleagues demonstrated the acceptability and efficacy of alternate-day dosing
of BNX as well (Amass et al. 2000). There is no information about the optimal duration of
OST but it can be long-term, even life-long (Kraus et al. 2011). Dose reductions should be
done gradually in order to prevent withdrawal and illicit use, and assure retention
(Johnson et al. 2003). Possible dose reduction schedules include equal reduction, such as 2
mg, or 50% dose reductions every 4-7 days or slower. Buprenorphine can also been safely
used in the treatment of certain subpopulations such as people with concurrent psychiatric
disorders, adolescents, older people, and people with HIV and liver disease although
further research is needed (Kraus et al. 2011). For pregnant women, buprenorphine without
naloxone is a safe and effective treatment option (Kraus et al. 2011, Jones et al. 2012).
Pharmacological treatment should be combined with psychosocial interventions, such as
cognitive and behavioural therapy and contingency management, or at least patients
should be offered the possibility to receive psychosocial treatment as well (World Health
Organization 2009, Soyka et al. 2011, Kraus et al. 2011). According to Finnish legislation,
psychosocial treatment is an essential part of OST (Ministry of Social Affairs and Health
2008). In international studies, the proportion of patients given/willing to receive
psychosocial support ranges between 24-100% (Leonardi et al. 2008, Amato 2010, Dale-
Perera et al. 2012, Haddad et al. 2013). Psychosocial support can improve the treatment
outcomes in terms of less craving and better retention (Leonardi et al. 2008, Haddad et al.
2013). However, no difference in treatment outcomes were detected between standard
medical  management  and  standard  treatment  plus  opioid  dependence  counseling  among
outpatient PO users treated with BNX (n=653) (Weiss et al. 2011). A systematic Cochrane
review reported that extra psychosocial interventions did not offer benefits compared to
standard treatment in terms of retention (risk ratio RR 1.03, 95% CI 0.98-1.07), opioid
abstinence during the treatment (RR 1.12, 95% CI 0.92-1.37) or any other outcome measures
used in the review (Amato et al. 2011). These results may be explained by the fact that
standard treatments already offer routinely counseling in addition to pharmacotherapy.
2.3.3.1 Unobserved dosing
Unobserved dosing in relation to OST refers to the daily administration of OST medicines
without direct supervision by treatment staff (Bell et al. 2004). It does not mean that
patients’ treatment is not supervised or monitored otherwise. A pilot study on
unsupervised BNX treatment showed that the combination product was well tolerated, 6-
month retention was high (88%) and unobserved dosing did not attenuate patients’ stability
(Bell et al. 2004). However, strict inclusion criteria were applied including at least part-time
employment and, therefore, only a small proportion of patients was eligible for the study.
According to a large European study which examined OST practices in 10 countries, 41.9%
of OST patients were under daily supervision (range 15.0-77.9%) (Dale-Perera et al. 2012).
Methadone-treated patients were more commonly supervised daily (48.2%) compared to
BUP or BNX-treated patients (42.4% and 22.8%, respectively).
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Unobserved dosing can offer substantial advantages compared to observed dosing such
as increased accessibility to OST (Bell et al. 2004, Gunderson et al. 2010), positive effect on
social and occupational rehabilitation, and less stigma related to OST (Bell et al. 2004,
Anstice et al. 2009). Daily visits to treatment centres can be problematic, especially for
persons living in rural, remote areas where travel distances to treatment centres are long
(Farrell et al. 2000, Webster 2013). Some patients want to isolate themselves from their
previous  ‘drug  using  life’  and,  therefore,  find  it  difficult  to  meet  other  OST  patients  or
former peers at the addiction clinics (Treloar et al. 2007, Anstice et al. 2009). Studies
comparing observed and unobserved dosing have found no differences in treatment-
retention or substance abuse (Fiellin et al. 2006, Bell et al. 2007, Moore et al. 2012). Holland
and colleagues found out that retention was better among those not supervised (89%)
compared to daily supervision (75%) even though all patients collected their medications
daily from community pharmacies (Holland et al. 2012). Bell and colleagues conducted a
cost-effectiveness analysis in conjunction with their clinical trial (Bell et al. 2007). Authors
concluded that as there were no differences in outcomes, simply the cost of treatment
matters, and unsupervised treatment was less costly compared to supervised treatment. In
the study by Barry and colleagues, patients who received weekly dispensing had a higher
mean overall satisfaction score on a 5-point scale compared to those receiving thrice weekly
dispensing (mean difference 4.9, p=0.03) (Barry et al. 2007). Other studies have not shown
statistically significant differences in treatment satisfaction (Holland et al. 2012, Moore et al.
2012) or quality of life scores (Bell et al. 2007) between unobserved and observed dosing
conditions. OST patients valued take-home allowances because of enhanced personal
freedom and flexibility, as well as convenience in terms of less travelling and better
employment opportunities (Stone & Fletcher 2003, Treloar et al. 2007, Madden et al. 2008).
Patients thought that unobserved dosing gave them the sense of being normal and ‘trusted’
and increased their treatment compliance. In general, OST patients considered the
possibility of unobserved dosing as an essential part of OST.
For long, direct observation of OST medication dosing has been the principal feature of
OST programs (Farrell et al. 1994, Bell et al. 2007). This was done in order to prevent the
abuse (e.g., injecting) or diversion of medicines. In France, the lack of supervision has been
associated with more illicit drug use and psychotropic drug use compared to a strict
treatment protocol among buprenorphine clients (Barrau et al. 2001). In order to reduce the
risk  of  diversion,  the  UK  national  guidelines  directed  GPs  to  utilize  arrangements  for
instalment dispensing and supervision of consumption in the late 1990s (Strang et al. 2007).
Between 1995 and 2005, the mean number of dispensings per week increased from 3.3 to
4.7, and the proportion of buprenorphine prescriptions dispensed supervised increased
from  0%  to  26%.  Diversion  by  selling  may  be  tempting  for  OST  patients  as  a  way  to  get
more income. For example, Finnish street buprenorphine users were willing to pay on
average €28 (±4) for one 8 mg buprenorphine tablet (Alho et al. 2007). On the other hand,
some OST patients do not want to receive take-home allowances presumably due to a fear
that medicines could be stolen or that they would be put under pressure to share their
medicines  with  or  sell  to  other  users  (Stone & Fletcher  2003).  Several  studies  have shown
the association between methadone take-home doses and diversion (Darke et al. 1996,
Lintzeris et al. 1999, Darke et al. 2002, Ritter & Di Natale 2005, Duffy & Baldwin 2012).
Ritter and Di Natale found a clear association between methadone injecting and less strict
jurisdictional methadone take-away policies between different Australian states (Ritter &
Di Natale 2005). However, authors stated that besides take-away policies, many other
things influence injecting, such as drug preference and availability as well as treatment
access. In addition, all the above mentioned studies concerned methadone, not
buprenorphine. Winstock and colleagues examined the prevalence of self-reported
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diversion among OST clients receiving their medicines from community pharmacies and
found out recent diversion was more than 10 times higher among buprenorphine clients
compared to methadone clients (Winstock et al. 2008). Authors speculated that this may be
due to relative ease of diverting a tablet compared to liquid, difficulties in supervising the
consumption of a sublingual tablet as well as less strict take-away policies concerning
buprenorphine compared to methadone. However, another Australian study reported that
entitlement to take-away doses did not predict injecting of BUP (OR 0.9, 95% CI 0.8-1.1) or
BNX (OR 1.1, 95% CI 1.0-1.2) among OST patients (Degenhardt et al. 2009).
Bell and colleagues reported that withdrawal of unobserved dosing as a punishment due
to violations against treatment guidelines can lead to significant drop-out from treatment
(6-month retention 22%) (Bell et al. 2008). French experience reveals that daily supervised
dosing  for  6  months  compared  to  2  weeks  at  the  beginning  of  buprenorphine-based  OST
may result in better retention (80% vs. 46 %) and lower proportion of opiate-positive urine
samples (14% vs. 18%) (Fatseas & Auriacombe 2007). Therefore, the manner in which take-
away doses are introduced to patients may have a substantial impact on treatment
outcomes. According to the Australasian clinical guidelines, appropriate patient selection,
transparent treatment guidelines and clinical monitoring are the key issues for successful
unobserved OST dosing (Winstock & Bell 2006). Take-away doses are only suitable for
patients in a stable clinical situation which includes social, personal and physical
functioning, as well as stability of psychosocial conditions, medicines and substance abuse
behaviour. Providing take-away doses to unstable patients is detrimental in terms of
patients’ treatment outcomes, and it can increase diversion and negative public opinion on
OST services. However, relapses are common among drug-dependent individuals and,
therefore,  in  case  of  instability,  supervised  dosing  should  be  reintroduced.  Involving
patients in all treatment-related decisions may reduce challenging clinical situations and
improve patients’ treatment compliance. Clinical guidelines defining the risk management
measures needed for prescribing take-away doses can be used to harmonize treatment
practices between different treatment providers (Bell 2010). They may also be efficient in
reducing diversion.
In recent years, there has been a trend towards less restrictive treatment policies. In
Finland, the decree regulating OST services was amended in February 2008 to become less
restrictive in order to improve access to OST, shorten waiting times and enable patients to
live as normal as possible (Hermanson 2008). Swedish drug policy was liberalized in 2005
and as a result, the use of take-away doses increased (Romelsjö et al. 2010). In addition, less
strict national guidelines resulted in an increase of OST and reductions in opioid-related
mortality and inpatient care while retention in treatment was unchanged. The decline in
mortality and inpatient care was especially pronounced in Stockholm County which had
the least restricted treatment policy. In the USA, the federal opioid treatment program
regulations were amended in the beginning of 2013 (Substance Abuse and Mental Health
Services Administration & Department of Health and Human Services 2012). This allows
programs to dispense buprenorphine more flexibly, since take-home doses of
buprenorphine can be dispensed to patients without temporal restrictions on treatment
duration. Authorities acknowledged the possibility of additional risk of diversion but
concluded that benefits of increased flexibility and access to treatment outweigh possible
risks.
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2.3.4 Diversion
2.3.4.1 Definition and frequency of diversion
There are various definitions of diversion. Carrieri and colleagues applied a broad
definition for buprenorphine diversion involving diversion to the black market, non-
adherence to physicians’ recommendations about the dose or the concurrent use of other
substances, and the use of buprenorphine by injection or snorting (Carrieri et al. 2006).
Dasgupta and colleagues defined diversion as “wilful illegal removal of a controlled
substance from the distribution chain or storage of the patient for whom it was prescribed,
for the purpose of distribution or sale, including acts by the patient” (Dasgupta et al. 2010).
Similar definitions have been used in other studies (Inciardi et al. 2007, Degenhardt et al.
2008, Larance et al. 2011b, Larance et al. 2011d). Stockpiling medicines for later use has also
been regarded as diversion (Bell 2010). Larance and colleagues reviewed different
definitions used for diversion in the scientific literature (Larance et al. 2011c). They
concluded that defining diversion as ‘not taking medicines as directed’ or ‘not complying
with all OST constraints’ is problematic because these definitions would not be exactly the
same everywhere due to variations in treatment guidelines. In addition, these definitions
do not separate situations where patients are noncompliant voluntarily (e.g., lack of
commitment, desire to divert) or due to service constraints. Authors recommended that
diversion should be defined as: “unsanctioned supply of regulated pharmaceuticals from
legal sources to the illicit drug market, or to a user for whom the drugs were not intended”
(Larance et al. 2011c). This definition has been used in this thesis.
Diversion can also occur during supervised dosing and it has been defined as “a client
removing  or  attempting  to  remove  a  supervised  methadone  or  buprenorphine  dose  from
the dosing site before the dose has been fully absorbed by the client” (Winstock et al.
2009b). Winstock and colleagues examined diversion methods and motivations at OST
clinics in Australia and found out that there seemed to be a misunderstanding between
clinicians and patients to what constitutes diversion (Winstock et al. 2009a). Authors
highlighted the need of consistent definition of diversion of supervised OST medicines and
recommended the term ‘non-adherence’ with dosing instructions to be used when referring
to diversion of supervised doses.
Winstock and colleagues examined 71 episodes of diversion during supervised dosing at
OST clinics in Sydney, Australia (Winstock et al. 2009a). Removal of buprenorphine from
the  mouth  (n=35)  and  secretion  of  buprenorphine  in  the  mouth  (n=32)  were  the  most
common methods of diversion. In almost half of the episodes (45%), patients denied the
diversion. The most commonly mentioned motivations for diversion were stockpiling for
later use (n=15) and discarding buprenorphine (n=11). Diversion as a form of ‘spit backs’
has  been  reported  in  another  Australian  study  as  well  (Aitken  et  al.  2008).  The  risk  of
microbiological contamination is especially high for this kind of diversion. In another
Australian study, 18% of buprenorphine-treated OST patients (n=98) reported ever
diverting their supervised buprenorphine dose and 15% reported doing it during the
previous 12 months (Winstock & Lea 2010). Diversion of supervised doses was more
common among buprenorphine patients compared to methadone patients. In an Australian
pharmacy survey, 46% of community pharmacies with buprenorphine clients reported
incidents of attempted diversion of supervised buprenorphine (Winstock et al. 2009b).
Diversion has always been a part of OST (Bell 2010). Historical overview of OST and
diversion indicates that opioid diversion occurs in proportion to the unobserved dosing of
opioids and in inverse proportion to the availability of heroin. Diversion is associated with
severe adverse consequences including fatal overdoses, increased prevalence of
dependence, injection-related harms like infectious diseases and vascular and soft tissue
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damage as well as negative public attitude towards OST (Degenhardt et al. 2008).
According to a large European study, 24.0% of OST patients reported ever having diverted
their OST medicines (range 15.6-39.1% of patients in different countries) (Dale-Perera et al.
2012). In the USA, all survey respondents who were aware of BNX (n=49) diverted it and
61% obtained the drug from an individual with legal prescription for it (Monte et al. 2009).
Twenty-eight percent of Australian OST patients (n=440) reported having diverted their
medicines during the previous 6 months (Larance et al. 2011b). There were no differences
between patients receiving methadone, BUP or BNX. Contrary to these findings, Winstock
and colleagues found that buprenorphine patients reported diverting their medicines
significantly more often during the previous 12 months compared to methadone patients
(23.8% vs. 2.2%) (Winstock et al. 2008). In legislation with buprenorphine by prescription,
buprenorphine diversion has been shown to be associated with social vulnerability and
prescriptions from multiple GPs (Carrieri et al. 2006).
Prescribers found it difficult to assess abuse and diversion among OST patients (Larance
et al. 2011d). About half (54%) were confident in assessing the risk of injection and even less
(37%) the risk of diversion. Prescribers perceived that diversion and IV-use were relatively
uncommon among buprenorphine patients (2-20% and 5% of patients, respectively). The
most  commonly  mentioned  sources  of  information  about  diversion  were  patients’  self-
report (51%) and pharmacist reports (49%). In the USA, physicians were more sceptical
since 46% of physicians believed that BNX is diverted and sold on the street and 53%
thought that the source of illegal BNX is OST patients (Johanson et al. 2012).
Doctor-shopping  can  be  regarded  as  a  subtype  of  diversion  and  it  means  that  OST
patients turn to several prescribers in order to get more buprenorphine than the prescribed
dose  (Feroni  et  al.  2005b).  This  is  possible  in  countries  such  as  France  where  GPs  can
prescribe buprenorphine and patients collect their medicines from community pharmacies.
A French study revealed that OST patients had on average 3.1 prescribers over the last 12
months in 2001 (Feroni et al. 2005b). However, consultations of several prescribers were
mostly successive rather than concomitant. Pradel and colleagues reported that the majority
of buprenorphine-treated OST patients (75%) had no overlapping prescriptions from
different physicians indicating no doctor-shopping behaviour (Pradel et al. 2009). It has
been estimated that about 13% of reimbursed buprenorphine prescriptions were obtained
by doctor-shopping in France in 2006 (Pauly et al. 2011). Nevertheless, high-dose
buprenorphine was most likely to be obtained through doctor-shopping and the second
most likely to be obtained by forged prescriptions compared to other opioid analgesics,
BZDs and methadone in France over 2006-2008 (Pauly et al. 2012).
2.3.4.2 Methods to prevent diversion
Besides supervision, various approaches have been suggested and used as ways to reduce
opioid diversion (Fudala & Johnson 2006, Katz et al. 2007, Bell 2010). These include both
general wide-ranging actions, such as educational programs for physicians, abuse-deterrent
formulations, prescription monitoring programs, supply chain interventions, and
restrictions on use, as well as patient-orientated approaches, such as careful screening and
monitoring of patients, urine drug screens, patient education, and the assessment and
treatment of comorbid conditions (Katz et al. 2007). Restrictions on use can refer to
tightening of regulatory controls or prescribing guidelines or restricting the use to
supervised settings (Fudala & Johnson 2006). Practical, traditional methods include tablet
counts, patient diaries and interviews, random drug testing and contracts between patients
and physicians (Fishman et al. 2000). According to a US survey, most pharmacies (74%)
were willing to conduct buprenorphine pill counts and five pharmacies were already
performing pill counts (Lofwall et al. 2010). In relation to buprenorphine, a widely used
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method to minimize diversion is ‘off-label’ crushing of buprenorphine tablets (Muhleisen et
al. 2003, Winstock et al. 2009b, Simojoki et al. 2010). According to Simojoki and colleagues,
there were no differences in serum buprenorphine or norbuprenorphine levels or in clinical
effects between crushed and whole tablets (Simojoki et al. 2010). A Finnish research group
recently developed a new analysis method for BNX in urine (Heikman et al. 2013). Authors
suggest that it may be possible to differentiate sublingual therapeutic use of BNX from its
parental use when analysing naloxone residual concentration and naloxone/buprenorphine
ratio in urine. In the future, this method could be used in detection of noncompliance
among BNX-treated OST patients. Non-compliance could serve as an indicator for intention
to diversion. In methadone treatment, dilution of methadone liquid is an easy way to
discourage injecting and indirectly also diversion (Bell 2010). Winstock and Lea highlighted
better supervision, standardized administration procedures and education as ways to
reduce buprenorphine diversion (Winstock & Lea 2010). The need of personnel and time
resources, as well as patient acceptability should be taken into account when planning new
attempts to prevent diversion.
Abuse-deterrent formulations (ADFs) are drug formulations developed to prevent the
tampering and abuse of drugs (Schaeffer 2012). Schaeffer (2012) divided ADFs into four
categories: physical or mechanical barrier, aversion or the addition of a noxious component,
agonist-antagonist combinations, and pro-drugs. Mechanical or physical barriers refer to
solid physical barriers which cover the tablets (e.g., extended release oxycodone) and to
viscous or semisolid gel formulations (e.g., controlled release oxycodone). These usually
prevent the release of active substances if tablets are crushed, chewed or attempting an
extraction (Katz et al. 2007, Schaeffer 2012). Manufacturers have added aversive
components and antagonists to products in order to make their abuse less rewarding
(Schaeffer 2012). The buprenorphine-naloxone combination product is an example of an
agonist-antagonist combination. Naloxone has also been combined with pentazocine,
tilidine, oxycodone and methadone (Fudala & Johnson 2006, Katz et al. 2007, Schaeffer
2012). An example of a product, which utilizes aversive components, is an immediate
release oxycodone which is formulated with several possibly aversive or irritating
components creating e.g., a burning sensation if snorted (Romach et al. 2013). Pro-drugs are
biologically inactive before being metabolized to the active form in the body (e.g.,
lisdexamphetamine for attention deficit/hyperactivity disorder). ADFs have been shown to
deter drug abuse; however, there are also reports of disadvantages, such as increased risk
of adverse effects for compliant patients and problems to swallow the tablets (Romach et al.
2013). Other drug formulations, such as transdermal or injectable sustained-release
formulations can also possibly decrease the abuse liability and diversion (Fudala & Johnson
2006). Buprenorphine films and implants have been developed as countermeasures against
abuse and diversion (Ling et al. 2010, Soyka 2012, Lintzeris et al. 2013). Whether these
formulations reduce the risk of diversion needs further studies.
More sophisticated methods include the use of radio frequency identification (RFID)
technology (Fudala & Johnson 2006). RFID technology can be used to track medicines in the
supply chain or individual dosage units given to end users. Similar technology has been
used in electronic adherence monitoring devices which usually contain microprocessors to
record the openings of devices in real time (Fishman et al. 2000). The most commonly
known  device  is  MEMS  (Medication  Event  Monitoring  System)  by  Aprex  Corp.  These
kinds of devices provide information about container openings but not about ingestion or
other possible routes of administration or the number of tablets (dose) taken. There are few
publications about the use of electronic monitoring devices as part of OST but they have
used devices in collecting reliable adherence data and have not aimed towards preventing
diversion or abuse (Arnsten et al. 2001, Fiellin et al. 2006, Sorensen et al. 2007). A small
40
Finnish study (n=12) found that electronic monitoring devices were well-accepted among
OST patients, they increased treatment compliance and three patients reported that devices
had prevented them from diverting BNX (Tacke et al. 2009).
Possible strategies to prevent diversion in countries where buprenorphine prescribing is
possible  include  increased  patient  monitoring,  shorter  duration  of  prescriptions  and
enhanced  training  of  GPs  (Carrieri  et  al.  2006).  Training  as  a  means  to  prevent  diversion
was examined in the study by Lofwall and colleagues (Lofwall et al. 2011). They
demonstrated that physicians’ knowledge about buprenorphine pharmacology and OST
legislation was poor but improved markedly during an educational intervention. Authors
speculated that improved OST practices may result in decreased risk of diversion but this
was not examined in the study per se. There is evidence that a prescription monitoring
program implemented in the French region of the Bouches-du-Rhône in 2004 was able to
decrease doctor-shopping quantity and ratio, which were used as indicators to measure the
impact of program (Pradel et al. 2009). French authorities have successfully used doctor-
shopping indicator and clustering method in the surveillance of buprenorphine abuse and
diversion in the population level (Pauly et al. 2011). In the USA, monitoring programs
utilizing data from poison centres and emergency departments have been successfully used
as indicators for PO abuse (Hughes et al. 2007). However, their ability to serve as an
indicator of diversion is unclear. The company marketing buprenorphine products (Reckitt
Benckiser Pharmaceuticals Inc.) has a risk management program which aims to monitor
and  prevent  the  diversion  of  buprenorphine  in  the  USA  (McCormick  et  al.  2009).  The
program includes monitoring the distribution of buprenorphine products, educational
activities and different surveillance methods. Risk management aims to minimize harms
associated with the use of opioids while maintaining the requisite access to treatment at the
same time (Katz et al. 2007). A sample of US physicians who had prescribed buprenorphine
was asked what steps they had taken to reduce the abuse and diversion (Yang et al. 2013).
Respondents reported taking a mean of 4.4 steps from a pre-specified 12-steps list. Most
commonly mentioned steps were limiting 30-day prescriptions to compliant patients (72%),
prescribing the lowest effective dose (61%) and requiring regular drug screening (59%).
Actions which required coordination with other staff or units, e.g., counseling, were
underutilized. In addition, authors highlighted that methods included in the list have not
been scientifically proven to reduce diversion.
The most common reason for taking diverted buprenorphine or methadone was self-
treatment of withdrawal symptoms or opioid dependence due to not being able or willing
to get into treatment (Gwin Mitchell et al. 2009). In the study by Lofwall and Havens,
inability to access buprenorphine treatment was a predictor of diverted buprenorphine use
(OR 7.3, 95% CI 2.1-25.8) (Lofwall & Havens 2012). In a qualitative study done in New York
City,  NEP clients  felt  that  the  lack of  access  to  buprenorphine treatment  was a  reason for
buprenorphine diversion from treatment programs (Sohler et al. 2013).  To address the
barriers  to  OST  entry  (e.g.,  lowering  the  threshold  of  treatment,  shortening  the  waiting
time, reducing the costs of treatment) may serve as a way to prevent diversion (Gwin
Mitchell et al. 2009, Lofwall & Havens 2012).
The battle against diversion is ongoing and there are no easy answers. Approaches
which are too controlling or restrictive will compromise the acceptance of treatment and in
the opposite situation, the harms of diversion will be predominant (Bell 2010). The
prevalence of drug abuse as a medical condition in society is likely to remain relatively
constant (Romach et al. 2013). When restricting the availability or abuse potential of one
substance, it will be replaced by another substance with lower cost and better availability
(Cicero et al. 2012, Unick et al. 2013). This has been the case in the USA, where abuse-
deterrent formulation of oxycodone reduced the abuse of oxycodone and, as a consequence,
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heroin abuse has increased (Cicero et al. 2012). Therefore, as long as opioids are used, there
will be diversion, especially when dosing is not directly supervised (Bell 2010). The key is
to find the balance between benefits and harms in consensus with all parties involved.
2.3.5 The role of community pharmacies in OST provision
Community  pharmacies  have  been  involved  in  methadone  dispensing  to  OST  clients  in
Denmark in the late 1960s (Farrell et al. 2000). Since the late 1960s, there have also been
small community pharmacy-based methadone programs in the USA and Australia
(Bowden et al. 1976, Berbatis et al. 2005). Bowden and colleagues described a one-year
follow-up of 96 clients who received their methadone from community pharmacies in San
Antonio, US between 1970 and 1971 (Bowden et al. 1976). The authors concluded that
treatment outcomes were similar compared to traditional programs, 1-year retention was
70% and methadone security was not a problem. More recently, pharmacies are involved in
OST provision in Canada (Buxton et al. 2010), the USA (Gunderson & Fiellin 2008), New
Zealand (Walters et al. 2012), Australia (Lawrinson et al. 2008, Chaar et al. 2011) and many
European countries such as Belgium, Germany, the UK, Ireland, Spain, France, and Austria
(Farrell et al. 2000). Services provided by pharmacies include dispensing, supervising
consumption, counseling, monitoring treatment, identifying problems and reporting them
to physicians (Farrell et al. 2000). However, there are differences in the role of community
pharmacies in provision of these services between countries (Berbatis et al. 2005). In some
countries, such as the USA, pharmacies concentrate purely on dispensing whereas
pharmacies have more clinical duties in some other countries, such as France, the UK and
Australia (Berbatis et al. 2005, Gunderson & Fiellin 2008). Pharmacy-based OST provision
offers many advantages such as reduced costs and work load in treatment units, increased
capacity for new clients, convenient location with flexible dosing and reduced stigma
(Chaar et al. 2011).
The main pharmacy surveys examining community pharmacy-based OST services which
were published within the last 10 years have been described in Table 3. Most of these
studies were conducted in the UK and Australia. Experience from these countries suggests
that the number of clients per pharmacy was usually relatively low (<10) (Nielsen et al.
2007a, Sheridan et al. 2007, Lawrinson et al. 2008), however, some pharmacies have larger
OST programs, e.g., the mean number of OST clients per pharmacy was 24-26 in Victoria,
Australia (Nielsen et al. 2007a, Winstock et al. 2010). The number of pharmacies providing
OST and the number of clients using these services have been on the increase (Sheridan et
al. 2007, Matheson et al. 2007). In England, the proportion of community pharmacies
dispensing OST medicines had increased from 51% to 62% between 1995 and 2005
(p<0.0001) (Sheridan et al. 2007). The mean number of clients per pharmacy had increased
from 5.9 in 1995 to 9.2 in 2005 (p<0.0001). In Scotland, the proportion of pharmacies
dispensing OST medicines had increased from 59% in 1995 to 83% in 2006 (Matheson et al.
2007). In Switzerland and Australia, almost 70% of OST clients were treated in community
pharmacies (Samitca et al. 2007, Lawrinson et al. 2008). In 2003, 81% of Swiss pharmacies in
the Canton of Vaud were providing OST (Samitca et al. 2007). However, only 10% of
Portuguese pharmacies were involved in OST in 2008 (Torre et al. 2010). There are also
differences in medications pharmacies are allowed to dispense. For example, in Australia
and the UK, both methadone and buprenorphine can be dispensed (Sheridan et al. 2007,
Lawrinson  et  al.  2008),  whereas  in  the  USA  only  buprenorphine  (mostly  BNX)  can  be
dispensed from community pharmacies (Gunderson & Fiellin 2008).
In Finland, dispensing of BNX from community pharmacies has been possible since
February 2008 (Ministry of Social Affairs and Health 2008). According to the Decree
33/2008, clients need to sign a contract which compels them to be prescribed by a single
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physician and for  all  OST medicines  to  be  dispensed from the same pharmacy.  Physician
can determine the time intervals between medication supplies and information on
treatment can be exchanged between physician and pharmacy. If problems occur, clients
can be reassigned to their treatment service units for supervised or unsupervised treatment.
Pharmacists  do  not  supervise  the  consumption  of  BNX.  In  August  2009,  OST  clients
collecting BNX from community pharmacies were entitled to receive a reimbursement by
the  Social  Insurance  Institution  of  Finland  (SII).  The  number  of  clients  entitled  to  this
reimbursement increased from 31 in 2009 to 135 in 2012 (Social Insurance Institute 2013).
Winstock and colleagues examined OST-related problems experienced by community
pharmacies in Australia (Winstock et al. 2010). During the previous month, 41% of
respondents had refused to dose a client for any reason and 14% had terminated a client’s
treatment. Most commonly reported reasons were inappropriate behaviour, missed doses
and non-payment of dispensing fees. In general, the most commonly mentioned problems
were difficulty contacting prescriber and giving take-away doses to unstable clients (21%
and 19%, respectively). Contrasting results regarding OST-related problems in community
pharmacies have been published. In the USA, 85% of pharmacists reported that BNX clients
had not caused problems in pharmacies (Raisch et al. 2005). Contrary to these findings, a
Swiss study reported that 83% of pharmacists had experienced some problems related to
methadone treatment supervision (Samitca et al. 2007). The most commonly mentioned
problems were lack of follow-up by physicians (50%), time needed for supervision (41%)
and  difficult  relationships  (32%).  In  the  study  by  Lawrinson  and  colleagues,  the  most
commonly mentioned problems related to OST were argumentative behaviour (50%),
disturbances by clients (46%), thefts (38%) and aggressive behaviour (38%) (Lawrinson et
al. 2008). Thirty percent of pharmacists had detected diversion of methadone or
buprenorphine.  In  the  study  by  Nielsen  and  colleagues,  the  most  commonly  mentioned
concern about OST was related to diversion (Nielsen et al. 2007a). The rate of suspected
diversion was 33 per 100 clients per month. The most commonly mentioned reason clients
gave for diversion was saving the dose for later use (60%). The number of OST clients
served by a pharmacy seems to be associated with the frequency of problems and diversion
(more clients, more problems) (Winstock et al. 2010, Lawrinson et al. 2008).
About 70% of pharmacists in Australia and Scotland have received OST training
(Matheson et al. 2007, Lawrinson et al. 2008). However, in other countries, pharmacists’
need for more training related to OST and/or other services for drug users has been
identified as a target for development (Samitca et al. 2007, Torre et al. 2010). A study
conducted in the USA revealed that 68% of pharmacists had received two hours or less of
addiction education during their studies (Lafferty et al. 2006). Their knowledge of addiction
and substance abuse was relatively poor but improved with more education. Training was
also  associated  with  the  frequency  of  counseling  individuals  with  substance  abuse
problems. In New Zealand, an online training program turned out to be a feasible method
for improving pharmacists’ knowledge about OST (Walters et al. 2012). Lack of training
may have a negative impact on pharmacies’ willingness to provide OST services (Chaar et
al. 2013).
Supervised methadone consumption was provided by 19% of pharmacies in Scotland in
1995 (Matheson et al. 1999). In 2005, the proportion had increased to 72% (Matheson et al.
2007). In 2005, 59% of community pharmacies in the UK were involved in supervising the
consumption of OST medicines (Sheridan et al. 2007). In addition, 82% of pharmacists
considered supervision as an appropriate task for pharmacists. Some respondents were also
supportive for newer roles, such as supervising medications for comorbidity or providing
hepatitis B vaccinations (48% and 25%, respectively). According to OST clients, pharmacists
usually  require  them to  stay at  the  pharmacy until  the  dose  is  absorbed but  do not  check
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their mouth before leaving (50%) (Lea et al. 2008). Pharmacists in a Swiss study perceived
that they have a central role in the supervision of OST, as well as the assessment of clients’
compliance, health and wellbeing (Samitca et al. 2007). However, pharmacists felt that they
were not fully integrated with the care providers and would like to contribute even more to
the treatment of drug users. Difficulties in contacting the prescriber and problems with
communication have been reported in both Switzerland and Australia (Samitca et al. 2007,
Winstock et al. 2010).
Pharmacists had generally positive attitude towards OST services and 64% of them were
willing to take new OST clients in an Australian study (Lawrinson et al. 2008). As the
provision of OST has expanded, pharmacists’ attitudes towards this service have improved
(Matheson et al. 2007, Sheridan et al. 2007). McCormick and colleagues have reported
similar  results  (McCormick  et  al.  2006).  In  addition,  those  pharmacists  providing  OST
services had significantly higher attitude scores compared with those not involved in OST
(p<0.05) (Matheson et al. 2007, Luty et al. 2010). The attitudes of treatment staff have been
shown to be associated with OST practices and clients’ outcomes in substance abuse
treatment centers (Gjersing et al. 2010). A Scottish study revealed that other pharmacy
customers have expressed generally supportive opinions on drug misuse services provided
by community pharmacies considering that there was a private area for drug consumption
(Lawrie et al. 2004). Clients of these services were also worried about privacy in the
pharmacy (Lea et al. 2008). Other commonly mentioned problems were the high cost of
treatment and not being treated the same as other pharmacy customers. Problems with
privacy and concerns about pharmacists’ knowledge were the main barriers OST clients
mentioned for accessing help from pharmacists (Sheridan et al. 2005).  Nevertheless, clients
were generally satisfied with OST services (mean score 8.1/10, 10=excellent) (Lea et al.
2008). Ezard and colleagues have reported similar results (Ezard et al. 1999). Pharmacy
dispensing fees may be an important barrier for OST clients accessing treatment (Chaar et
al. 2011). Winstock and colleagues examined the dispensing fees related to community
pharmacy-based OST and found that dispensing fees for methadone and buprenorphine
were similar, even though buprenorphine clients had a lower frequency of dosing
(Winstock et al. 2007). However, the length of time needed for consumption should also be
taken into consideration. Disintegration time of BNX tablet can take up to 20 minutes
(Tacke et al. 2009). Seventy percent of pharmacists responded that the time needed to
supervise dosing was a negative aspect of buprenorphine treatment (Nielsen et al. 2007a).
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2.4 Rationale of the study
The abuse potential of buprenorphine has been demonstrated in several studies. In
addition, the abuse of buprenorphine has been reported in many countries. However,
studies examining the characteristics of buprenorphine users have been small, cross-
sectional or had short follow-up periods. Several studies have concentrated on the abuse of
buprenorphine merely among patients receiving buprenorphine for the treatment of opioid
dependence. Previous internationally published studies examining buprenorphine abuse in
Finland are relatively scarce. Social, health and treatment-related characteristics of persons
who abuse buprenorphine are not well established. Characteristics of heroin users and PO
users have been examined extensively; however, there is evidence that different subgroups
of  users  exist,  even within the  group of  PO users.  Clinical  characteristics  of  persons  with
substance abuse problems may be associated with successful treatment outcome. Exploring
the changes in characteristics can provide information on drug use trends. Therefore,
examining  the  characteristics  of  buprenorphine  users  is  important  for  both  clinicians  and
policy makers.
The provision of OST carries the risk of abuse and diversion of OST medicines, especially
if unobserved doses are granted. On the other hand, providing the possibility for take-
home  dosing  is  an  important  part  of  OST  and  supports  the  social  and  occupational
reintegration of patients into society. The challenge is to provide take-home doses in a safe
and  monitored  manner.  The  feasibility  of  novel  methods  such  as  electronic  devices  in
resolving clinical challenges related to unobserved dosing should be examined.
Community  pharmacies  offer  a  possibility  for  less  restricted  provision  of  OST.  In  many
countries community pharmacies have major involvement in the treatment of opioid
dependence. Community pharmacy -based provision of OST has not been studied in
Finland.
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3 Aims of the Study
The general aim of this thesis was to explore and describe the abuse of buprenorphine in
Finland and possibilities for improving unobserved buprenorphine dosing in OST. This
thesis examined the characteristics of persons who sought treatment for buprenorphine
abuse. In addition, the thesis explored possibilities for improved unobserved dosing in OST
with  electronic  medicine  dispensers  and  the  provision  of  OST  from  Finnish  community
pharmacies.
The specific aims of the study were:
1. To explore the trend in proportions and characteristics of clients seeking treatment
for  buprenorphine  abuse  and  compare  them  to  those  seeking  treatment  for  heroin
and amphetamine abuse (I)
2. To examine the social, health and treatment-related factors associated with
buprenorphine compared to amphetamine abuse (II)
3. To investigate whether electronic medicine dispensers can reduce the diversion of
take-home buprenorphine-naloxone in OST patients in a medium-sized Finnish city
(III); and
4. To explore the buprenorphine-naloxone dispensing practices, service experiences,
problems encountered and opportunities for future development in Finnish
community pharmacies (IV)
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4 Methods
The thesis utilized a range of data collection methods (Table 4). Studies I and II were based
on the data collected at the Helsinki Deaconess Institute between January 31, 1997 and
August  31,  2008.  Study  III  was  an  open-label  clinical  study  with  a  four-month  follow-up
period. Study III also included a survey which was conducted in the local needle exchange
service during the two-week periods in August 2010 and December 2010. Information on
the drug screens taken at the Kuopio University Hospital was collected between July 2010
and April 2011. Study IV was a cross-sectional postal survey to Finnish community
pharmacies in August 2011.
Table 4. Summary of study designs, study participants, data collection methods and study
periods included in the thesis
Study Design Study period Study participants Data collection
method
I A descriptive
study over a
12-year
period
January 31, 1997 -
August 31, 2008
Clients seeking treatment
for buprenorphine
(n=780), amphetamine
(n=1249) or heroin
(n=598) abuse
Structured clinical
interviews (The Huuti
study)
II A cross-
sectional
study
January 1, 2001 - August
31, 2008
Clients seeking treatment
for buprenorphine
(n=670) or amphetamine
(n=557) abuse
Structured clinical
interviews (The Huuti
study)
III An open-
label clinical
studya
September 2010-January
2011 (intervention)
August and December
2010 (NEP survey)
July 1, 2010-April 30,
2011 (drug screen data
collection period)
BNX-treated OST
patients eligible for take-
home dosing (n=37)
Questionnaires
Drug screen data from
the Kuopio University
Hospital
IV A cross-
sectional
survey
August 2011 Finnish community
pharmacies that had
dispensed
buprenorphine-naloxone
to OST clients (n=54)
Questionnaire
BNX: buprenorphine-naloxone combination product, NEP: needle exchange program, OST: opioid substitution treatment
a In addition to the study intervention, data were collected from the needle exchange service and the Kuopio University
Hospital.
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4.1 HUUTI STUDY (I, II)
4.1.1 Description of the study
The Huuti study is a large consortium project examining drug abuse and addiction in
Finland. The epidemiological part of Huuti study utilizes data collected at the Helsinki
Deaconess Institute (HDI) between January 31, 1997 and August 31, 2008. It contains
information on all clients seeking treatment during this time period (n=4,817). Originally
data  were  collected  for  the  purposes  of  clinical  practice.  The  HDI  is  a  large  public  utility
foundation that provides inpatient and outpatient treatment services for persons with
alcohol  and  other  substance  abuse  disorders.  Services  are  provided  to  clients  from  the
greater Helsinki metropolitan area, including Espoo, Vantaa and eight other nearby
municipalities (Kerava, Kirkkonummi, Porvoo, Nurmijärvi, Järvenpää, Lohja, Hyvinkää,
and Tuusula). Overall population of this area is estimated to be 1.3 million. Clients of the
HDI were self-referred, referred by, or transferred from other treatment units. These data
were used in two publications (studies I and II).
4.1.2 Data collection
All clients were interviewed as part of routine clinical practice by specialist physicians and
nurses. Data were collected using a structured questionnaire at each client’s initial visit to
HDI.  The  Huuti  questionnaire  included  adapted  versions  of  the  European  Addiction
Severity Index (EuropASI) and Treatment Demand Indicator. The EuropASI is a European
version of Addiction Severity Index (McLellan et al. 1980, Blacken et al. 1994). The
Treatment  Demand  Indicator  is  used  by  the  European  Monitoring  Centre  for  Drugs  and
Drug  Addiction  (Simon  et  al.  1999,  European  Monitoring  Centre  for  Drugs  and  Drug
Addiction 2000). The Huuti questionnaire included questions regarding each client’s
demographics, substance abuse behaviour, social and health conditions and treatment-
related factors. If the questionnaire was not fully completed during a client’s initial visit,
missing  data  were  collected  during  a  client’s  subsequent  consultations  if  they  occurred
within the following three months of the initial consultation. Data pertaining to each
client’s  age,  current  substance  abuse  behaviour  and  health  and  social  state  were  only
recorded during the initial visit. Each client was included in the analyses only once even if
they had repeat consultations at the HDI.
4.1.3 Study population
Each client's primary drug of abuse was defined using the Treatment Demand Indicator
definition as the drug causing the client the most problems. This was defined by clients
themselves  or  by  diagnoses  based  on  ICD-10.  According  to  the  primary  drug  of  abuse,
clients were categorized as buprenorphine, amphetamine or heroin clients. These
substances  were  selected  because  they  caused  most  substance  abuse  problems  in  Finland
and formed the largest client groups in the data. The users of BUP and BNX could not be
separated from each other and, therefore, the group of buprenorphine clients encompassed
all buprenorphine users. Study I included clients seeking treatment for buprenorphine
(n=780), amphetamine (n=1249) or heroin (n=598) abuse between 1997 and 2008. For study
II, clients seeking treatment for buprenorphine (n=670) or amphetamine (n=557) abuse
between January 1, 2001 and August 31, 2008 were included. The study sample was
restricted to this time period because more comprehensive data collection was conducted
from 2001 onwards. In addition, the number of buprenorphine clients increased sharply in
2000. Amphetamine was the most commonly used illicit drug among Finnish problem drug
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users in 2005 (80% of all problem drug users) (Partanen et al. 2007) and, therefore,
amphetamine users  were  selected as  the  comparison group.  Comparisons  to  other  opioid
users were not possible due to low number of clients seeking treatment for abuse of other
opioids between 2001 and 2008 (heroin users n=95, other opioid users n=32).
4.1.4 Measures and definitions
For  the  purposes  of  this  thesis,  the  terms  abuse  and  harmful  use  were  considered  as
synonymous with each other. The WHO defines harmful use as a pattern of harmful
psychoactive substance use causing damage to health (World Health Organization 2012).
The detailed descriptions and categories of variables used in the analyses are shown in
Table 5. Clients were asked to report primary and secondary drugs of abuse at the time of
the interview as well as other concurrent substance abuse over the past month. Substance
categories were alcohol, opioids (heroin, opium, morphine, ethylmorphine, codeine,
oxycodone, methadone, buprenorphine, pethidine, tramadol, fentanyl,
dextropropoxyphene, pentazocine, other opioids), stimulants (cocaine, amphetamine,
metamphetamine, MDMA, other stimulants), cannabis and prescription medicines
(barbiturates, BZDs, neuroleptics, other hypnotics and sedatives). The source of substances
was not defined (e.g. legal prescription, street market). Psychiatric symptoms were assessed
according to clients’ self-report and clinical diagnosis by treatment staff. Validated scales
were not used consistently because data were collected as part of clinical practice. Medical
comorbidity was assessed according to clients’ self-report and staff evaluation based on
client’s blood pressure, pulse, weight, infections, temperature, and condition of skin. Based
on the information from the interviews, clients were referred to appropriate treatment
either in HDI’s treatment facilities (outpatient or inpatient care) or in alternative treatment
units.
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Table 5. The description of variables included in the Huuti questionnaire
Variables Descriptions
Demographics
Sex Male, female
Age Age at the time of interview
Nationality Finnish, other
Housing Being able to report address (yes vs. no)
Marital status Married (including those cohabiting) vs. non-married (single,
divorced, separated, widowed)
Children under 18 years Yes vs. no
Educational level Basic (elementary school or less) vs. higher (high school, vocational
training, university)
Vocational status Employed vs. not employed (unemployed, student,
housewife/husband, retired)
Main source of income Salary vs. social benefits (pension, income support, unemployment
benefit)
Substance abuse behaviour
Route of administrationa Intravenous vs. other (oral, intranasal, smoking)
Frequency of usea Daily vs. non-daily (2-6 times per week, once per week or less, no
use during the previous month)
Age when started drug abuse Age when started the primary drug of abuse, age when first used
drugs/medicines
Concurrent substance abuse Last month (yes vs. no), drugs used
Injecting Life-time, last month (yes vs. no)
Sharing needles/syringes Life-time (yes vs. no)
Number of drug free months During last year (0-12)
Duration of primary drug abuse The difference between the onset of primary drug abuse and the
initial visit to HDI (years)
Social and health conditions
Threat of violence Threatened by violence by anyone (yes vs. no)
Smoking Current status (yes vs. no)
Psychotic symptoms When using drugs, at other times presently or during the previous 3
months (yes vs. no)
Depressive symptoms Presently or during the previous 3 months (yes vs. no)
Suicidal thoughts Presently or during the previous 3 months (yes vs. no)
Suicide attempts Life-time (yes vs. no)
Medical comorbidity No vs. yes (i.e. having an acute or chronic disease)
Treatment-related factors
Guidance for treatment Self-referred vs. by family/friends vs. by authorities (health/social
care unit, police or employer)
Main reason for seeking
treatment
Substance abuse vs. other (physical, psychiatric, social)
In treatment currently elsewhere Yes vs. no
Referral to treatment Outpatient, inpatient vs. other (consulting, guided elsewhere)
HDI: Helsinki Deaconess Institute
a Separately for primary and secondary drug of abuse.
4.2 ELECTRONIC MEDICINE DISPENSERS IN OPIOID SUBSTITUTION
TREATMENT (III)
4.2.1 Study setting
The  study  was  conducted  in  Kuopio  which  is  a  city  of  90,000  inhabitants  situated  in  a
predominantly rural area in Eastern Finland. This study was a naturalistic, open-label trial
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examining the use of EMDs in OST. There were three treatment units providing OST in
Kuopio:  the  addiction  psychiatry  outpatient  clinic  of  the  Kuopio  University  Hospital,  the
Kuopio region addiction services trust, and the health center of the Kuopio municipality.
Besides these services, three local community pharmacies dispensed BNX to OST clients. In
addition to the trial, a survey was conducted at the local needle exchange service (NEP
survey) and drug screens data from the emergency department and the intensive care unit
of the Kuopio University Hospital were analysed. The Kuopio University Hospital was the
only local provider of acute and emergency services in the study region.
4.2.2 Study participants
All OST patients who were registered at the treatment-services and eligible for the study
were asked to participate. Inclusion criteria were the following: (1) diagnosis of opioid
dependence (F11.22) according to ICD-10 criteria; (2) a stable dose of BNX; (3) OST started
at least 1 month before the initiation of the study; and (4) one or more take-home
allowance(s) per week. All patients were asked to give a written informed consent. Patients
not meeting the inclusion criteria at the time of study initiation (August-September 2010)
were included in the study later, if they became eligible and were willing to participate.
4.2.3 Electronic medicine dispenser
The  EMD  used  in  the  study  was  the  Med-O-Wheel  Smart  by  Addoz  Ltd.  Detailed
information about the device can be found from company’s website (Addoz Ltd. 2013). The
device is made from hard plastic and includes a locking system to prevent tampering and
access to tablets outside the pre-set time window. BNX tablets were removed from blisters
and the daily doses were put into the compartments of the dosage cassettes. A maximum of
daily doses for one week was dispensed at once to ensure the stability of BNX tablets.
EMDs were loaded and programmed by treatment staff (nurses, pharmacists). These
procedures took approximately 5–10 minutes per device, depending on the dose of the
individual patient. The compartment with the appropriate daily dose could be moved into
the opening position by pressing the cover of the device, which was only possible during a
3-hour time window around the pre-set dosing time. Dispensers were programmed
according to patients' individual dosing times. After the time window, the device was
“closed” automatically and tablets were inaccessible until the next dosing time. Missed or
skipped doses remained locked within the EMD.
4.2.4 Procedures
A  diagram  of  study  procedures  is  shown  in  Figure  1.  In  August  and  September  2010  all
eligible patients were asked to participate in the study.  Few weeks later, dispensing of
BNX  take-home  doses  in  EMDs  was  started  and  continued  for  the  next  4  months.  Aside
from this, normal standard care was continued, including the possibility for an increase or
decrease in the number of take-home allowances. All study protocol violations such
skipped doses or tampering with the device were handled according to unit-specific
treatment guidelines. The most usual consequence was the reduction of take-home
allowances. In case of revocation of all take-home allowances, EMD dispensing was ceased
and reintroduced if take-home allowances were granted again. During the intervention
phase, EMDs were provided to all OST patients with BNX take-home doses in the
municipality  as  part  of  routine  clinical  care,  regardless  of  their  participation  in  the  study
per se. This way we ensured that during the intervention phase no unobserved BNX doses
were dispensed without EMDs in the city of Kuopio. At the end of intervention period in
January 2011, patients were asked to fill in a questionnaire to give their opinions on EMD
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use.  A slightly  modified questionnaire  was distributed among treatment  staff  involved in
the study (nurses and pharmacists).
The NEP survey was conducted in the only needle exchange service located in Kuopio.
Anonymous  questionnaires  were  handed  out  in  the  NEP  during  the  two  2-week  periods
before EMD use in August 2010 (pre-EMD phase) and during EMD use December 2010
(EMD phase). All clients visiting the service during these study periods were asked to fill in
the questionnaire. The questionnaire was developed according to questions used in a
previous Finnish study examining buprenorphine abuse among NEP clients (Alho et al.
2007). To ensure the content validity, the questionnaire was developed in close
collaboration with service-staff (nurses and physicians).
Information on the  drug screens  taken at  the  emergency department  and the  intensive
care unit of Kuopio University Hospital was collected from the time period of EMD use
(EMD phase 1.10.-31.12.2010) and control periods before and after the intervention (pre-
EMD phase 1.7.-31.8.2010, post- EMD phase 1.2.-30.4.2011). Positive drug screens were
regarded as indicators for hospital-treated drug-related health problems. This was based on
the assumption that any licit or illicit buprenorphine user in Kuopio with an acute,
presumably drug-related health problem requiring hospital treatment would be subjected
to a urine drug screen. Drug screens included buprenorphine (with and without naloxone),
other opioids (methadone, oxycodone, heroin, codeine, morphine), other illicit drugs
(amphetamine, methamphetamine, cannabis, MDMA) and BZDs. Urine-samples were
analysed with the Cobas 6000 clinical chemistry analyser (Roche/Hitachi) at the Eastern
Finland Laboratory Centre Joint Authority Enterprise. For buprenorphine-analysis CEDIA
Buprenorphine Drugs of Abuse Assay reagents (Thermo Scientific) and the kinetic
interaction of micro particles in a solution (KIMS) reagents (Roche Diagnostics) were used.
Figure 1. Diagram of the study III procedures
4.2.5 Measures
The variables included in the questionnaire for study participants are described in Table 6.
The questionnaire was completed anonymously but participants were asked to provide
certain background information about their treatment: duration of OST (less than 3 months,
3-11 months, 1-2 years, more than 2 years) and the number of take-home allowances at the
time of completing the questionnaire. The questionnaire for treatment staff requested their
opinions  on  the  same  issues  and  whether  they  thought  EMDs  could  be  used  as  part  of
routine OST (agree, no opinion, disagree).
The questionnaire used in the NEP survey requested information on the frequency of
buprenorphine use during the previous month (none, 1-3 times, once a week, many times
per  week,  daily)  and  products  used  during  the  previous  month  (BNX,  BUP,  low-dose
buprenorphine product Temgesic®). Respondents were asked to report which of these
Jul-10 Aug-10 Sep-10 Oct-10 Nov-10 Dec-10 Jan-11 Feb-11 Mar-11 Apr-11
Pre-EMD phase 1.7.-31.8.2010 EMD phase 1.10.-31.12.2010 Post-EMD phase 1.2.-30.4.2011
Drug screen
data collection
Study intervention
NEP survey I
August 2010
NEP survey II
Dec ember 2010
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products they used most frequently. They were also asked to estimate the amount of money
they  were  willing  to  pay  for  one  tablet  of  BUP  (8  mg)  or  BNX  (8/2  mg),  and  the  present
availability on the local illegal drug-market (good, moderate, poor) as well as origin of BNX
they used (OST vs. other). The questionnaire was anonymous and similar in both data
collection periods. Respondents were asked to report their gender and age (less than 20
years, 20-29 years, 30-39 years, more than 40 years) for demographic background
information.
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Table 6. The description of variables included in the questionnaire for OST patients
Variable Description
The use of EMD
The effect of EMD on OST Useful vs. no effect vs. harmful, detailsa
Has EMD prevented diversion No vs. yes (the number of occasions)
Has EMD prevented other people to get hold of take-
home doses
No vs. yes (the number of occasions)
Willingness to use EMD after study period Yes vs. no, details a
Technical properties
The suitability of 3-hour time window Too short vs. suitable vs. too long
The ease of use Yes vs. no, details a
Problems with EMD Yes vs. no, details a
Tampering with EMDb Easy vs. difficult vs. impossible
Opinions
My BNX intakes have been more regular during the
study.
My life has been more flexible during the study.
It feels safer to keep OST medicines in the EMD
compared to paper sachet.
I have been more involved in treatment during the study.
In general EMD can prevent diversion of OST medicines.
Reduced supervision may lead to increased abuse in
some patients.
EMD is difficult to use.
Answer options: strongly agree, agree,
neither agree nor disagree, disagree, strongly
disagree, don’t know
BNX: buprenorphine-naloxone combination product, EMD: electronic medicine dispenser, OST: opioid substitution
treatment
a Room for open responses and/or possibility to choose from multiple answer options.
b Getting access to tablets in the device outside the time window.
4.3 COMMUNITY PHARMACY SURVEY (IV)
4.3.1 Data collection
A cross-sectional postal survey was conducted in all community pharmacies dispensing
BNX  to  OST  clients  in  Finland.  A  list  of  all  Finnish  community  pharmacies  that  had
supplied buprenorphine-naloxone since August 2009 was received from the company
(Reckitt Benckiser) with the marketing authorization for BNX (n=71). Of these pharmacies,
69 were community pharmacies and they formed the study sample.
Data were collected using a questionnaire which was developed according to previous
studies examining community pharmacy based OST services in other countries (Sheridan et
al. 1997, Matheson et al. 1999, Raisch et al. 2005, Matheson et al. 2007, Nielsen et al. 2007a,
Lawrinson et al. 2008). The face-validity of the questionnaire was pilot-tested in four local
pharmacies dispensing BNX to OST clients. According to the feedback received from pilot
pharmacies, questionnaire was slightly modified. Pilot pharmacies received the final
questionnaire at the same time as other pharmacies. Their initial responses were used
merely for pilot testing and they were not recorded.
Prior to mailing the questionnaires, all pharmacies were contacted by phone. This was
done in order to inform them about the study objectives as well as to maximize the
response rate. In August 2011, questionnaires were mailed together with a cover letter and
a prepaid return envelope. The cover letter informed participants about study background
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and objectives, and instructed the staff member most familiar with the pharmacy’s BNX
dispensing practices to complete the questionnaire. Staff members were instructed to
discuss their experiences before completing the questionnaire. Responses were anonymous
and confidentiality was assured. Return envelopes were coded in order to identify non-
respondents, but codes were not connected to the filled questionnaires. In September 2011,
non-respondents were contacted again by phone and reminder questionnaires were sent a
month after the initial mailing.
4.3.2 Measures
The questionnaire included both closed and open-ended questions. It was divided into five
sections: (1) background information, (2) BNX clients and pharmacy resources, (3) problems
and co-operation with treatment staff, (4) future development, and (5) sale of injecting
equipment (Table 7). Clients who collected their buprenorphine-naloxone from community
pharmacies were regarded as BNX clients. If pharmacies did not separate the numbers of
current and all  BNX clients,  the total number of all  clients was interpreted as same as the
number of current clients. The number of current BNX clients was compared to the number
of all buprenorphine-naloxone treated OST patients in Finland. In 2010, there were
estimated to be 1,080 patients treated with BNX (Tanhua et al. 2011). The questionnaire
included also a section of attitudinal questions on the personal opinions of the staff member
filling the  questionnaire.  These  data  were  not  included in  this  thesis  because  the  focus  of
the study IV was on the implementation of the new service and attitudinal factors were
considered to be beyond the scope of the study.
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Table 7. The description of variables included in the pharmacy survey questionnaire
Variables Descriptions
(1) Background information
Location
Size
Geographical location within Finland (province)
Urban, suburban, outside a city but within a local shopping mall,
or rural
Small or large (the annual number of prescriptions dispensed
?80,000 or >80,000)a
(2) BNX clients and pharmacy
resources
BNX clients
Time needed to serve a BNX client
(handling the prescription,
dispensing, labeling, counseling)
Resources
The number of current and all BNX clients
More, less or the same as other clients
Dispensing fee for BNX clients (yes vs. no)
The payer of the medicines (client, social service, SII)
Staff received training on OST (yes vs. no)
A nominated staff member responsible for OST (yes vs. no)
Satisfaction with BNX dispensing (very well, well, poorly, very
poorly)
(3) Problems
Co-operation with treatment staff
(communication, availability,
support)
Has pharmacy experienced problems related to providing OST
(yes vs. no; detailsb)
Suspicions about diversion/abuse during the previous 6 months
(yes vs. no; the number of occasions; consequencesb)
Has/have any BNX client(s) discontinued having BNX dispensed at
the pharmacy (yes vs. no; reasonsb)
Contacts with treatment staff (yes vs. no; reasonsb)
Satisfaction with co-operation with treatment staff (well, fairly
well, fairly poorly, poorly; details about problemsb)
(4) Future development
Opportunities for future development
Willingness to take more BNX clients
Supervised dosingc
Importance of pharmacies’ roles in
different fields of treatment
Yes vs. no; detailsb
Yes vs. no; reasonsb
How well supervised dosing suits Finnish pharmacies (well, fairly
well, fairly poorly, poorly; reasonsb)
Paperwork, treatment follow-up, dispensing, health education,
medication counseling (scale from 1 ‘not important at all’ to 4
‘very important’)
(5) Sale of injecting equipment Do you sell injecting equipment (yes vs. no)
How often do you sell injecting equipment (once a week or less
often, several times/week, daily)
Problems with clients (yes vs. no; detailsb)
NEP available in the city (yes vs. no)
BNX: buprenorphine-naloxone combination product, NEP: needle exchange program, OST: opioid substitution
treatment, SII: Social Insurance Institute in Finland
a Classification  was  based  on  dividing  pharmacies  into  two  groups  of  similar  size  according  to  the  mean  number  of
annual prescriptions in Finland (Association of Finnish Pharmacies 2011).
b Room for open responses and/or possibility to choose from multiple answer options.
c Pharmacist supervises the consumption of BNX and checks that mouth is empty before a client can leave.
4.4 STATISTICAL ANALYSES
Descriptive statistics were presented as proportions, means, medians and standard
deviations (SD). Categorical and ordinal variables were analysed using Pearson chi-square
??2) test and Fischer’s exact test depending on the number of categories. Statistical
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differences  in  continuous  variables  were  analysed  using  Mann–Whitney  U  -test  and
Kruskal–Wallis test. The assumption of normality was assessed graphically and tested with
Kolmogorov-Smirnov test and Shapiro-Wilk test. Significance level of 0.05 was used for all
tests. The Statistical Package for the Social Sciences Version 19.0 for Windows (SPSS Inc,
Chicago, IL, USA) was used for all analyses.
Study I
Separate analyses were performed for the time periods 1997-2001 and 2002-2008 in order to
determine possible changes over time. Buprenorphine (n=197), amphetamine (n=808) and
heroin clients (n=577) were all included in the analyses for 1997-2001. Heroin clients were
excluded from the analyses in 2002-2008 because the low number of clients (n=21)
precluded statistical testing. Changes in the characteristics of buprenorphine clients over
time were examined for 1997-2008. Non-parametric tests were used in the analyses of
continuous variables because normality assumptions were not met.
Study II
Binomial logistic regression models were used to analyse factors associated with
buprenorphine abuse. Clients seeking treatment for amphetamine abuse were considered
as a comparison group. The dependent variable in each model was dichotomous
(buprenorphine client yes vs. no). Linearity of continuous variables (age, age when first
used drugs/medicines) was confirmed. Statistically significant variables (p-value <0.1) in
univariate models were included in the multivariate model. Only the clinically most
relevant variable of two or more highly correlated predictive variables was selected for
inclusion in the multivariate model to avoid multicollinearity. The results were presented
as unadjusted and adjusted odds ratios (ORs) with 95% confidence intervals (CIs).
Study III
The small sample size limited the opportunity for statistical testing. Results of patient and
staff questionnaires were presented descriptively. The data from NEP survey and drug
screens  were  analysed  with  ?2 test, Fischer’s exact test and Mann–Whitney U –test.
Continuous variables were not normally distributed and, therefore, nonparametric tests
were used.
Study IV
Characteristics of pharmacies that responded prior to and after the reminder were
compared to assess possible response bias. Binomial logistic regression models were used
to analyse factors associated with perceived problems related to OST clients and BNX
dispensing. Only pharmacies dispensing buprenorphine-naloxone directly to BNX clients
were included in the analyses. The outcome measure in each model was dichotomous
(experienced  problems  yes  vs.  no).  Explanatory  variables  were  chosen  on  the  basis  of
previous studies indicating that they may be associated with problems (Nielsen et al. 2007a,
Lawrinson et al. 2008, Winstock et al. 2010). The size and location of pharmacy were
assessed as potential confounders. The results were presented as ORs with 95% CIs.
Adjusting for the size and location of pharmacy did not affect results and, therefore, only
unadjusted ORs were reported.
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4.4.1 Missing data
The Huuti study had a considerable amount of missing data. Data pertaining clients’
primary drugs of abuse were 100% complete but variables assessing other characteristics of
clients contained missing information. Missing values were especially prevalent in the data
collected during 1997-2000, but from 2001 onwards data were more complete. Therefore,
study II was restricted to clients seeking treatment from 2001 to enable investigation of the
associations  with  a  greater  range  of  covariates.  Study  I  included  all  clients  seeking
treatment for buprenorphine, amphetamine or heroin abuse from 1997 to 2008. Complete
cases  analysis  was  used in  study I.  Clients  with  missing information were  excluded from
the analyses. Complete case analysis may cause bias and loss of power, especially if the
amount of missing data is large (Graham 2009). Therefore, only variables with a relatively
low amount of missing data (<20%) were included in the analyses. The amount of missing
data (range 0-19.5%) was presented as a proportion of all cases for each variable included in
the  analyses  in  order  to  warrant  the  transparency  of  analyses.  In  addition,  multivariate
analyses were not conducted and, therefore, possible bias and loss of power had minor
effect on the results.
Multiple imputation (MI) was used to replace missing values in study II. Therefore, all
clients were included in the analyses. Multiple imputation is considered superior to
complete case analyses when data are missing at random (MAR) (Baraldi & Enders 2010,
Janssen et al. 2010). MAR allows the probability of missingness to depend on the observed
data, but not on the missing data (Schafer & Graham 2002, He et al. 2010). Missing value
analysis was done to check the MAR assumption. The following variables were associated
with missing data for any of the variables of interest: buprenorphine user (p=0.020), daily
use of the primary drug of abuse (p< 0.001), IV use of the primary drug of abuse (p< 0.001),
method of treatment (p=0.023), sex (p=0.042) and concurrent use of cannabis (p=0.012).
These variables were included in the imputation model to make MAR assumption more
tenable (Graham 2009, Baraldi & Enders 2010, McPherson et al. 2012). The dependent
variable did not contain any missing values. Multiple imputation with five iterations was
used to replace missing values in predictive variables (range of missingness 0.2-21.7%).
Imputation was done based on the values of other variables of interest and auxiliary
variables (concurrent use of cannabis, alcohol or medicines during previous month).
4.5 ETHICAL CONSIDERATIONS
All ethical standards for protecting human participants were maintained in accordance
with standards of the appropriate ethics committees and the Helsinki Declaration of 1975.
All data analyses were performed anonymously and strict confidentiality was assured. The
Huuti study protocol (studies I and II) was approved by the Research Ethics Committee of
the North-Savo Hospital District and the Ethics Committee of the Helsinki Deaconess
Institute. Permissions to use the data were obtained from appropriate municipal authorities
of all communities that clients reported as their places of residence. The Ministry of Social
Affairs and Health and the National Data Protection Ombudsman also approved the study
protocol. The protocol of study III was approved by the Research Ethics Committee of the
North-Savo Hospital District. The Clinical Trials protocol registration number of this study
is NCT01182402 (www.clinicaltrials.gov). Written informed consent was obtained from the
study participants. Participation was voluntary and decision to participate had no effect on
the treatment provided at the treatment units. Ethics approval was not required for the
study  IV.  According  to  the  recommendations  made  by  the  Finnish  National  Advisory
Board on Research Ethics, local ethics committee approval is not required for postal surveys
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(National Advisory Board on Research Ethics in Finland 2009). The research was conducted
in accordance with these guidelines. All potential participants were provided with written
information about the study. Return of the completed questionnaire after reading the cover
letter was considered as consent to participate.
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5 Results
5.1 CHARACTERISTICS OF CLIENTS SEEKING TREATMENT FOR
BUPRENORPHINE ABUSE (HUUTI STUDY) (I, II)
There were a total of 780 clients who sought treatment for buprenorphine abuse from the
HDI between 1997 and 2008. Between 2001 and 2008, 670 clients sought treatment for
buprenorphine abuse. The main characteristics of these clients as well as heroin and
amphetamine clients used as comparison groups are shown in Table 8. Study I examined
changes  in  the  characteristics  of  buprenorphine clients  over  time.  In  terms of  gender,  age
and the mode and level of buprenorphine abuse, the characteristics remained stable during
the study period 1997-2008 (p>0.05). Poly-substance abuse behavior changed over the study
period. The proportion of buprenorphine clients with concurrent abuse of alcohol
??2[df=4]=27.0, p<0.001), prescription medicines (?2[df=4]=40.1, p<0.001) and stimulants
??2[df=4]=18.8, p=0.001) increased. The proportion of buprenorphine clients abusing heroin
concurrently decreased from 60.9% in 1997-2000 to 12.7% in 2007-2008 (?2[df=4]=98.1,
p<0.001). The duration of buprenorphine abuse before seeking treatment from the HDI
increased during the study period (Kruskal-Wallis ?2[df=4]=62.4, p<0.001).
The annual proportion of buprenorphine clients increased from 0% in 1997 to 37.6% in
2008 (Figure 2). Since 2002, buprenorphine clients have represented at least half of all
opioid users seeking treatment from the HDI (range: 49.3% in 2006, 60.3% in 2008). From
1997 to 2008, there were a total of 598 clients who sought treatment for heroin abuse and
1,249 clients who sought treatment for amphetamine abuse. Until 2000, heroin was the most
commonly abused opioid among all clients. The number of heroin clients declined sharply
to approximately 1% of all clients seeking treatment from 2000 to 2002 and remained on
that level until the end of the data collection period. The proportion of amphetamine clients
decreased during the study period (range from 34.2% of all clients in 1998 to 13.9% in 2007-
2008).
Table 8. Main characteristics of participants in studies I and II
Study I
(1997-2008)
Study II
(2001-2008)
Buprenorphine
clients
(n=780)
Heroin
clients
(n=598)
Amphetamine
clients
(n=1,249)
Buprenorphine
clients
(n=670)
Amphetamine
clients
(n=557)
Males, n (%) 560 (71.8) 450 (75.3) 826 (66.1) 475 (70.9) 347 (62.3)
Mean age (SD) 25.7 (6.6) 25.6 (7.4) 27.1 (8.1) 25.8 (6.6) 27.6 (8.9)
Finnish nationality, n
(%)
753 (96.5) 550 (92.0) 1234 (98.8) 646 (96.4) 552 (99.3)
Homeless, n (%) 212 (27.2) 133 (22.2) 388 (31.1) 183 (27.6) 167 (30.6)
Mean age at the onset
of abusea (SD)
21.8 (5.7) 19.9 (5.0) 19.0 (5.3) 21.7 (5.7) 19.0 (5.5)
Daily usea, n (%) 576 (73.8) 370 (61.9) 418 (33.5) 491 (76.5) 186 (34.2)
Injectinga, n (%) 629 (80.6) 421 (70.4) 883 (70.7) 538 (82.8) 409 (75.7)
a The primary drug of abuse.
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Figure 2. The proportions of clients seeking treatment for buprenorphine (n=780),
amphetamine (n=1,249) and heroin (n=598) abuse from all clients (n=4,817) seeking
treatment from HDI in 1997-2008
Comparisons between buprenorphine clients and heroin and amphetamine clients were
performed separately for 1997-2001 and 2002-2008 (Table 9). Compared to heroin and
amphetamine clients, buprenorphine clients were more frequently daily users of their
primary drug (?2[df=2]=164.9, p<0.001) as well as secondary drug of abuse (?2[df=2]=17.0,
p<0.001) in 1997-2001. Injecting the primary drug of abuse was more common among
buprenorphine clients (83.2%) than among heroin and amphetamine clients (70.0% and
68.4%, respectively) (?2[df=2]=13.7, p=0.001). Amphetamine clients were more likely to be
concurrent abusers of alcohol (?2[df=2]=120.5, p<0.010), while buprenorphine clients were
more  likely  to  abuse  prescription  medicines  (?2[df=2]=43.8, p<0.001). Prescription medicines
(28.9%) were the most common secondary drugs of abuse among buprenorphine clients
whereas cannabis was the most commonly abused secondary drug of abuse among heroin
and amphetamine clients (33.6% and 45.9%, respectively). The length of primary drug
abuse before seeking treatment from the HDI was longest for amphetamine clients
(Kruskal-Wallis ?2[df=2]=151.3, p<0.001). In 2002-2008, buprenorphine clients were compared
solely to amphetamine clients. Buprenorphine clients were more likely to be daily users of
their primary (p<0.001) and secondary drugs of abuse (p=0.007) compared to amphetamine
clients. Concurrent alcohol abuse was more common among amphetamine clients, while
buprenorphine clients were more likely to abuse prescription medicines (p<0.001). In 2002-
2008, 41.3% of buprenorphine clients reported prescription medicines as their secondary
drug of abuse. Cannabis was the most commonly reported secondary drug of abuse for
amphetamine clients (37.2%). Nevertheless, concurrent abuse of prescription medicines
increased also among amphetamine clients from 30.0% in 1997-2001 to 55.1% in 2002-2008.
Study  II  included  only  clients  seeking  treatment  for  buprenorphine  (n=670)  or
amphetamine abuse (n=557) in 2001-2008. A minority of buprenorphine clients were
employed (12.5%, n=82) and 77.4% (n=499) reported elementary school or lower level of
education. Social benefits were the main source of income for the majority of
buprenorphine clients (n=503, 83.0%). The majority of buprenorphine clients reported
64
depressive symptoms (n=447, 73.2%) and psychotic symptoms when using drugs (n=377,
59.5%). Almost all buprenorphine clients were smokers (n=599, 96.0%) and 245 (40.2%) had
a medical comorbidity (acute or chronic disease). IV drug use was common (lifetime use
reported by 92.1%) and 345 (56.5%) had ever shared needles/syringes. Most buprenorphine
clients self-referred to treatment (n=446, 67.8%) and nearly one-third received concurrent
treatment from another provider (n=183, 28.3%). Most buprenorphine clients were referred
to outpatient treatment services provided by the HDI or some other treatment provider
(n=467, 75.8%). In multivariate analyses, factors significantly associated with
buprenorphine abuse in comparison to amphetamine abuse were male gender (OR 1.57,
95% CI 1.17-2.09), daily abuse (OR 5.45, 95% CI 4.14-7.18), no drug free months during the
last year (OR 1.68, 95% CI 1.23-2.29), self-referral to treatment (OR 1.33, 95% CI 1.01-1.75)
and being referred to outpatient treatment (OR 1.40, 95% CI 1.00-1.93) (Table 10). Increasing
age (OR 0.95, 95% CI 0.93-0.97 per year) and psychotic symptoms when using drugs (OR
0.33, 95% CI 0.24-0.45) were inversely associated with buprenorphine abuse.
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Table 10. Univariate and multivariate analyses of factors associated with buprenorphine abuse
Variable Unadjusted odds
ratio (95% CI)a
p
valueb
Adjusted odds
ratio (95 % CI)c
p value
Male 1.47 (1.16-1.87) 0.001 1.57 (1.17-2.09) 0.002
Age 0.97 (0.96-0.99) <0.001 0.95 (0.93-0.97) <0.001
Married 1.26 (0.85-1.88) 0.246
Homeless 0.87 (0.68-1.11) 0.262
Children under 18 years 0.78 (0.60-1.00) 0.048 1.02 (0.73-1.42) 0.924
Elementary school or less education 1.24 (0.95-1.61) 0.112
Employed 1.00 (0.71-1.40) 0.990
Salary as main source of income 0.87 (0.64-1.18) 0.361
Thread of violence 0.68 (0.46-1.00) 0.051 0.72 (0.42-1.22) 0.211
Psychotic symptoms (when using drugs) 0.39 (0.30-0.50) <0.001 0.33 (0.24-0.45) <0.001
Psychotic symptoms (other times) 0.54 (0.40-0.72) <0.001
Depressive symptoms 0.97 (0.75-1.26) 0.824
Suicidal thoughts 0.70 (0.55-0.88) 0.003 1.02 (0.77-1.35) 0.900
Suicide attempts 0.73 (0.54-0.99) 0.041
Medical comorbidity 1.05 (0.82-1.35) 0.714
Daily use of primary drug of abuse 6.27 (4.87-8.07) <0.001 5.45 (4.14-7.18) <0.001
IV use of primary drug of abuse 1.55 (1.17-2.06) 0.002 1.23 (0.87-1.75) 0.242
No drug free months during last year 2.11 (1.63-2.73) <0.001 1.68 (1.23-2.29) 0.001
Age when first used drugs/medicines 0.94 (0.91-0.97) <0.001 0.97 (0.93-1.01) 0.098
Smoking 1.79 (1.05-3.06) 0.033 1.21 (0.62-2.36) 0.569
IV drug use ever 2.21 (1.53-3.19) <0.001
IV drug use last month 1.85 (1.38-2.47) <0.001
Shared needles/syringes 1.02 (0.80-1.31) 0.876
Self-referral to treatment 1.60 (1.26-2.01) <0.001 1.33 (1.01-1.75) 0.044
Referred to outpatient treatment 1.39 (1.06-1.82) 0.018 1.40 (1.00-1.93) 0.048
Treatment because of drug abuse 1.66 (0.48-5.71) 0.425
In treatment concurrently elsewhere 1.12 (0.87-1.45) 0.375
IV: intravenous
a Separate unadjusted logistic regression models for each variable (dependent variable buprenorphine client yes vs. no).
b Variables with P value < 0.1 were included in the multivariate analysis. In case of highly correlated variables the
clinically most relevant variable was chosen to the model. Cox and Snell R Square ranged between 0.239-0.247
according to the imputed dataset.
c Adjusted logistic regression model for the other variables in the model.
5.2 THE USE OF ELECTRONIC MEDICINE DISPENSERS IN OPIOID
SUBSTITUTION TREATMENT (III)
Study intervention
A total of 37 BNX-treated OST patients participated in the study (participation rate 88%).
Twenty-one of them (57%) were males, the mean age was 30.0 years (SD 5.1) and they were
all Finnish by ethnic background. The mean duration of OST was 3.0 years (SD 2.9) and the
mean daily dose of buprenorphine was 17.2 mg (SD 4.3). In addition to study participants,
five patients who refused to participate and three patients who were pregnant during the
study got their take-home doses of BNX (and BUP for pregnant women) in EMDs during
the study period. Thirty-one patients (84%) completed the questionnaire at the end of the
EMD phase. Five patients (16%) reported that the EMD had prevented them from diverting
their medicines and 18 patients (58%) thought that EMDs could generally prevent
diversion.  Seven patients  (23%) responded that  EMD had prevented others  to  get  hold of
their medicines. The majority of patients (n=21, 68%) regarded EMDs as a safer option for
the storage of take-home doses than paper sachets which had been used in the routine
dispensing  practice  before  the  trial.  Most  participants  thought  that  tampering  with  the
device was impossible (n=18, 58%) or difficult (n=6, 19%).
Treatment staff returned a total of 19 questionnaires (3 from pharmacies, 16 from
treatment units). Response rate was estimated to be 84% according to the number of
67
returned  questionnaires  and  staff  involved  in  the  study.  The  majority  of  respondents  did
not think that EMDs could prevent diversion (n=16, 84%). In spite of that, 58% of
respondents (n=11) preferred to dispense take-home doses of BNX in EMDs compared to
paper sachets and 74% (n=14) reported that EMDs could be used routinely as part of OST.
Needle exchange program survey
For the first survey (pre-EMD phase), 35 responses (response rate 46%) were received and
for the second survey (EMD phase) 27 responses (39%) were received. In the first survey,
three  respondents  were  not  buprenorphine  users  and  they  were  excluded  from  the
analyses. Respondents were mostly males (56% and 64%, respectively) and younger than 30
years old (56% and 74%, respectively) in both surveys. Almost all respondents abused BNX
in both surveys (100% and 96%, respectively), and about half used buprenorphine on a
daily basis (47% and 59%, respectively) (Table 11). In the pre-EMD phase, more
respondents reported that BNX was the buprenorphine product they used most commonly
(n=26, 87%) than in the EMD phase (n=16, 59%) (p=0.033). In the EMD phase, more
respondents used illegal BUP compared to the pre-EMD phase (67% vs. 47%, p=0.188) but
the difference was not statistically  significant. Respondents indicated that the availability
of illegal BNX (p=0.371) or its origin from OST (p=1.000) had not changed between the
surveys.
Drug screen data
A total of 198 positive drug screen results from 121 individuals were registered during the
data collection periods. Overall, there were no statistically significant differences in drug
screen results between the data collection phases (pre-EMD, EMD and post-EMD phases)
??2[df=6]=1.429, p=0.964). About 10% of the drug screens were buprenorphine-positive during
all data collection periods (range 8.8%-11.4%). Positive drug screens for other opioids
(range 20.0%-23.8%), BZDs (range 47.9%-53.8%) and other drugs (range 13.8%-18.8%) also
remained stable between the study phases.
Table 11. Results of the NEP surveys conducted before the study intervention (pre-EMD phase)
and during the intervention (EMD phase)
Variable Pre-EMD
phase (n=32)
EMD phase
(n=27)
p valuea
BNX user, n (%) 32 (100) 26 (96) 0.458
BUP user, n (%) 15 (47) 18 (67) 0.188
Daily buprenorphine user, n (%) 15 (47) 16 (59) 0.435
BNX most commonly used buprenorphine product, n (%) 26 (87)b 16 (59) 0.033
Availability of BNX is good, n (%) 6 (19) 8 (30) 0.371
BNX originated from OST, n (%) 6 (19) 5 (19)c 1.000
Mean price (€) of one BNX tablet (8/2 mg) (SD) 42.92 (11.67) 43.34 (7.09) 0.943
Mean price (€) of one BUP tablet (8 mg) (SD) 50.71 (14.45) 55.27 (10.23) 0.110
BNX: buprenorphine-naloxone, BUP: single-ingredient buprenorphine, EMD: electronic medicine dispenser, OST: opioid
substitution treatment
a Fischer´s exact test for categorical variables, Mann-Whitney U-test for continuous variables.
b The responses of two persons are missing.
c The response of one person is missing.
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5.3 BUPRENORPHINE-NALOXONE DISPENSING IN FINNISH
COMMUNITY PHARMACIES (IV)
The survey questionnaire was completed and returned by 64 pharmacies (response rate
93%). The characteristics of 12 pharmacies responding after the reminder did not differ
statistically significantly from the other respondents indicating no response bias. Of the 64
respondents, 54 pharmacies dispensed BNX directly to clients. The remaining 10
pharmacies  dispensed BNX to  health  care  units  without  having contact  with  BNX clients.
Therefore, these pharmacies were excluded from the analyses. Of the 54 pharmacies
included in the analyses, 30 pharmacies (56%) were located in Southern Finland and 32
pharmacies (59%) had the total annual prescription volume of more than 80,000
prescriptions. Twenty-five pharmacies were located in city centres (46%), 24 pharmacies in
suburbs or within a shopping mall (44%) and 5 pharmacies in rural areas (9%).
Pharmacies had a total of 155 current or previous BNX clients (range 1–16 per
pharmacy). Of the 54 pharmacies, 48 pharmacies had a total of 108 current clients (range 1–
13 per pharmacy). Current clients represented 10% of all BNX treated OST patients in
Finland. Thirty-six pharmacies (67%) charged a dispensing fee for BNX clients (Table 12).
The mean dispensing fee per week was €5.26 (SD 2.59, range €0.67– €11.50). Seventy-eight
clients (72%) got SII reimbursement of their BNX expenses. In 14 pharmacies (26%) staff
had received training on OST and in 21 pharmacies (39%) there was a nominated staff
member responsible for OST. Overall satisfaction with BNX dispensing was high, with all
respondents perceiving that dispensing had gone ‘very well’ (n=31, 57%) or ‘well’ (n=21,
39%). Similarly, all respondents perceived that co-operation with treatment staff had gone
‘well’ (n=43, 80%) or ‘fairly well’ (n=9, 17%). In 20 pharmacies (37%), one or more BNX
client(s)  had  discontinued  receiving  BNX  dispensed  from  that  particular  pharmacy.  Most
commonly reported reasons for this included returning to dispensing from an addiction
treatment unit (n=11), changing pharmacy (n=9) and completion of OST with successful
withdrawal from BNX (n=3).
Fourteen pharmacies (26%) had encountered some problems which were mostly dose
timing issues or non-collection of scheduled doses (n=7), confusion with financial
obligations (n=5), confusion with prescriptions (n=4) or client’s difficulty paying for the
medications (n=3). Diversion had been suspected in 6 pharmacies (11%) and abuse in 4
pharmacies (7%) during the previous 6 months (Table 12). Problems were more likely to
occur in pharmacies with more than one BNX client compared to pharmacies with only one
client (OR 1.39, 95% CI 1.05-1.86) and in pharmacies where one or more clients had
discontinued pharmacy dispensing compared to pharmacies where no clients had
discontinued (OR 6.53, 95% CI 1.70-25.03). Most pharmacies recognized opportunities for
future development (n=43, 80%), such as financial remuneration for pharmacies (n=32, 74%
of those pharmacies which recognized a need for improvements), more training for
pharmacists (n=30, 70%) and better co-operation with treatment staff (physicians) (n=15,
35%). Most respondents replied that providing supervised dosing does not suit Finnish
community pharmacies (n=43, 80%). Nevertheless, most pharmacies (n=46, 85%) were
willing to dispense BNX to more clients in the future.
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6 Discussion
6.1 MAIN FINDINGS
6.1.1 The abuse of buprenorphine (I, II)
The proportion of clients seeking treatment for buprenorphine abuse increased from 0% in
1997 to 38% in 2008 (study I). Treatment seeking for heroin abuse decreased to the level of
approximately 1% of all clients after 2001. This shift from heroin to buprenorphine abuse
has also been reported in official national reports (Forsell et al. 2010, Varjonen et al. 2012).
In Canada, similar opioid abuse trends have been reported (Fischer et al. 2006). Increasing
PO abuse has been acknowledged worldwide e.g., (Compton & Volkow 2006b, Degenhardt
et al. 2008, Mendelson et al. 2008, Fischer et al. 2013b). However, in other countries the
abuse has focused more on other opioids than buprenorphine, such as fentanyl in Estonia
(Talu et al. 2010) or oxycodone and hydrocodone in the USA (Cicero et al. 2005). In the
USA, buprenorphine is predominately used in OST and not all studies consider it as a PO.
The shortage of heroin in the Finnish drug markets since 2001 (Forsell et al. 2010) has
probably triggered the increase in buprenorphine abuse. Simultaneously, the access to OST
has improved which has led to increased availability of buprenorphine. Increased
therapeutic use of opioids seems to be associated with more opioid abuse in the society
(Cicero et al. 2007b). Therefore, a possible explanation for the increased abuse of
buprenorphine is the increased availability due to expansions in therapeutic use. Another
country where buprenorphine abuse has been reported to be high is France (almost 60% of
IDUs had injected buprenorphine in the previous 6 months) (Obadia et al. 2001). In France,
the availability of buprenorphine has been high since 1996 because all GPs have been able
to prescribe buprenorphine for people with opioid dependence. These findings support the
role of availability in determining the scale of abuse. However, international differences in
treatment practices, take-away policies as well as illegal drug markets shape this
association.
According to previous studies, self-medication of withdrawal symptoms and/or
dependence has been the most common reason for buprenorphine abuse (Alho et al. 2007,
Hakansson et al. 2007, Otiashvili et al. 2010, Schuman-Olivier et al. 2010, Moratti et al. 2010,
Larance et al. 2011b, Bazazi et al. 2011). A qualitative Finnish study revealed that study
participants regarded their buprenorphine use as self-medication, even though they mainly
injected buprenorphine (Malin et al. 2006). Reliance on self-medication indicates a shortage
of treatment resources, dissatisfaction with current treatment options or both. That
probably explains the increase in abuse in Finland in the early 2000s because OST was still
in the state of development. Malin and colleagues reported that their study participants
regarded the threshold to get into OST as too high, the number of treatment slots too low
and treatment in general too burdensome because of regular visits and drug screens.
However,  as  the  provision  of  OST  increased  in  Finland  throughout  the  2000s,  the  lack  of
treatment seems unlikely to be a major explanatory factor for constantly increasing abuse.
Nevertheless, increased provision of OST does not necessarily ensure a quick treatment
initiation everywhere. According to a report from 2007, waiting time for OST was more
than a year in some Finnish cities (Hermanson 2008). OST legislation has become more
liberal which should lower the threshold for seeking and getting into treatment. In previous
foreign studies, OST patients have valued the possibility for unobserved dosing and found
it to increase their treatment compliance (Stone & Fletcher 2003, Treloar et al. 2007, Madden
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et  al.  2008).  The possibility  for  community  pharmacy dispensing of  BNX was intended to
help to get more opioid users into treatment. However, this study was not able to take this
into account as pharmacy dispensing has been possible since February 2008 and the data
collection period of the Huuti study was terminated in August 2008. There is evidence that
some users start their IV drug abuse primarily with buprenorphine (Partanen et al. 2004,
Winslow et al. 2006, Otiashvili et al. 2010, Simojoki & Alho 2013). This suggests that
buprenorphine can also  be  abused due to  its  opioid agonist-like  effects  which may partly
explain the scale of the abuse.
The results of this study showed that clients seeking treatment for buprenorphine abuse
in Finland had risky abuse patterns. This was evidenced by the fact that the majority of
clients injected buprenorphine (81%) and used it on a daily basis (74%). These patterns were
constant during the study period from 1997 to 2008. Injecting and daily abuse of both
primary and secondary drugs of abuse were more common among buprenorphine clients
compared to amphetamine and heroin clients. Compared to users of buprenorphine and
POs  in  other  countries,  injecting  was  more  common  among  buprenorphine  clients  in  this
study (Cicero et al. 2007c, Degenhardt et al. 2009, Aich et al. 2010). Concurrent abuse of
alcohol, stimulants and especially prescription medicines increased among buprenorphine
clients during the study period indicating increasing poly-drug abuse. Frequent poly-drug
abuse among buprenorphine users, especially BZDs, has been acknowledged in previous
Finnish (Partanen et al. 2004, Tammi et al. 2011) and foreign studies as well (Winslow et al.
2006, Nielsen et al. 2007b, Otiashvili et al. 2010, Lofwall & Havens 2012). Concurrent
substance abuse complicates the treatment of opioid dependence (Kraus et al. 2011) and
increases health risks related to abuse. Concurrent use of BZDs and buprenorphine
increases the risk of fatal poisonings (Häkkinen et al. 2012).
Based on the findings of study I, we hypothesised that buprenorphine clients have more
social and health-related problems compared to amphetamine clients. However, findings
from study II revealed that buprenorphine and amphetamine clients shared similar social,
health and treatment-related characteristics, despite the fact that buprenorphine clients
reported more intense abuse patterns. As expected, amphetamine clients more commonly
reported psychotic symptoms which are a well-known complication of stimulant abuse
(Curran et al. 2004, Zweben et al. 2004, Darke et al. 2008, Wang et al. 2012). Otherwise, there
were no differences between these groups in social or health-related factors. The higher
frequency of psychotic symptoms may explain the finding that amphetamine clients were
more commonly referred to inpatient treatment. Another treatment-related difference was
the finding that buprenorphine clients were more commonly self-referred to treatment
compared to amphetamine clients (OR 1.33, 95% CI 1.01-1.75) or compared to users of
buprenorphine and POs in previous studies (Basu et al. 2000, Aich et al. 2010, Fischer et al.
2010). This may be explained by the intensity of abuse among buprenorphine clients. On
the other hand, the lack of established pharmacological treatment options for amphetamine
dependence may have affected amphetamine clients’ willingness to seek treatment. In
general, buprenorphine clients reported higher frequency of unemployment, lower
educational levels and higher reliance on society benefits compared to users of
buprenorphine and POs in other countries (Cicero et al. 2007c, Moore et al. 2007, Fischer et
al. 2010, Vicknasingam et al. 2010). Buprenorphine clients in this study seemed to resemble
more  the  characteristics  of  heroin  users  entering  treatment  in  terms  of  injecting,
employment status, income sources and poly-drug abuse (Ross et al. 2005). Therefore, our
results do not seem to support a perception that abuse of prescription drugs is less
dangerous compared to illicit substances (Mendelson et al. 2008, Ling et al. 2011). It has also
been hypothesized that PO abuse may offer public health benefits due to a lower
prevalence of risk behaviours (Fischer et al. 2009). Possible benefits do not appear to apply
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to clients seeking treatment for buprenorphine abuse in Finland. According to our results,
we hypothesize that the route of administration may be a stronger determinant of social,
health and treatment-related factors than the primary drug of abuse. Both buprenorphine
and amphetamine clients in study II were mainly IV-users (83% and 76%, respectively).
Similar  findings  have  been  reported  in  an  Australian  study  which  found  that  heroin  and
PO users with high rates of injecting shared similar socio-demographic and health-related
characteristics as compared to PO users not injecting (Nielsen et al. 2011).
6.1.2 Electronic devices as a method to prevent buprenorphine-naloxone diversion (III)
The  main  finding  of  the  study  III  was  that  we  were  not  able  to  clearly  detect  that  EMDs
could prevent the diversion of BNX. Five patients (16%) who took part in the study
intervention reported that EMDs had prevented them from diverting their medicines. This
represents about half of the proportion of BNX patients who reported diversion (30%) in an
Australian study (Larance et al. 2011b). However, these numbers may not be comparable
because the extent of unobserved dosing and other treatment practices also affect the
frequency of diversion (Bell 2010). Treatment staff also had suspicions about whether EMDs
could prevent diversion. This is most likely explained by the fact that treatment staff was
aware of some patients tampering with the device (getting BNX from the device outside the
dosing window without the possibility to later detect this through visual inspection).
However, we have a reason to assume that few patients actually tampered with the device
because most patients reported that tampering was difficult or impossible. However, there
is a possibility of tampering with monitoring devices when using them in clinical practice.
Both patients and treatment staff appreciated the safety of dosing and storage of BNX in
EMDs. It is possible that EMDs can reduce the pressure to sell or pass on medicines to other
users or dealers.
Changes in the number of hospital-treated buprenorphine-related health problems and
the availability of illicit buprenorphine were regarded as indicators of changes in
buprenorphine diversion. Despite comprehensive use of EMDs during the trial, there were
no reductions in hospital-treated drug-related health problems measured by drug screen
results. However, statistical power may have been insufficient, due to small sample size. In
addition, since the Kuopio University Hospital is the only emergency hospital for a large
catchment area, patients from outside Kuopio may have diluted our results. According to
NEP surveys,  the  availability,  price  or  source  of  illicit  buprenorphine did not  change as  a
consequence of the intervention. However, BNX was the most commonly abused product
more often in the pre-EMD phase than in the EMD phase (p=0.033) and BUP abuse
appeared more common in the EMD phase (p=0.188), even though the difference was not
statistically significant. Therefore, results indicated a slight shift from BNX to BUP abuse
among NEP clients during the intervention. This shift may be explained by decreased
availability of BNX as a consequence of the intervention or by better availability of BUP in
the EMD phase for reasons unrelated to the trial. It is believed that most illicit
buprenorphine is smuggled into Finland from other counties (Skretting & Rosenqvist 2010).
Changes in drug supply may not directly impact on the drug prices which can be seen as an
indicator of availability (Gibson et al. 2005, European Monitoring Centre for Drugs and
Drug Addiction 2010). Therefore, explanations remain speculative because multiple
interacting factors influence illegal drug markets (European Monitoring Centre for Drugs
and Drug Addiction 2010). Supply-based interventions may lead to a shift in the use of
another substance instead of reducing harms (Unick et al. 2013). Therefore, in order to
reduce opioid abuse related harms, focusing the prevention resources on treatment and
demand-side reduction may be more productive.
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6.1.3 Buprenorphine-naloxone dispensing in Finnish community pharmacies (IV)
The results of pharmacy survey indicated that community-pharmacy based dispensing of
BNX was still relatively small-scale in Finland but the first experiences have been positive.
Most pharmacies providing OST were located in Southern Finland. The geographical
distribution of OST pharmacies reflects probably the distribution of pharmacies rather than
the availability of OST, which has been acknowledged in previous studies as well (Nielsen
et al. 2007a). In addition, the majority of Finnish drug users live in large cities in Southern
Finland and, therefore, also treatment services are concentrated on this area (Partanen et al.
2007).  About  10%  of  BNX-treated  OST  clients  had  their  BNX  dispensed  from  community
pharmacy. The proportion of OST clients dispensed at pharmacies was relatively low
compared to Switzerland and Australia, where almost 70% of OST clients were treated in
community pharmacies (Samitca et al. 2007, Lawrinson et al. 2008). It is possible that the
fear  of  diversion  and  abuse  may  partly  explain  the  scale  of  BNX  dispensing  in  Finnish
community  pharmacies.  In  addition,  community  pharmacy  dispensing  of  BNX  was
relatively new possibility at the time of the study. Most pharmacies had small OST
programs (41% of pharmacies had only one OST client). The number of OST clients was
associated with the prevalence of problems (OR 1.39, 95% CI 1.05-1.86). Other studies have
reported similarly that more OST clients pharmacies served, more likely they had
experienced problems (Lawrinson et al. 2008, Winstock et al. 2010). According to our
survey, only 26% of pharmacies had experienced problems, which were mostly technical
issues related to dose timing or prescriptions/ financial obligations. Previous studies have
reported more serious problems such as argumentative behaviour, disturbances and thefts
(Lawrinson et al. 2008), as well as concerns about diversion (Nielsen et al. 2007a). In
addition, the prevalence of problems has been higher, e.g. in Switzerland 83% of
pharmacies had experienced problems (Samitca et al. 2007), and 41% of Australian
pharmacists had refused to dose an OST client during the past month (Winstock et al. 2010).
However, there were likely to be differences in how ‘problem’ has been defined and
understood  by  respondents  in  different  studies  (i.e.  problems  in  OST  provision  from
pharmacy in general or related to OST clients per se) (Raisch et al. 2005, Samitca et al. 2007).
It  is  possible  that  the  low  frequency  of  problems  in  Finnish  community  pharmacies  is
explained  by  the  treatment  practices  since  all  OST  clients  are  first  stabilized  in  addiction
treatment units and carefully selected for suitability for community pharmacy dispensing.
According to Australian experience, stabilization of OST clients in specialist clinics has been
associated with fewer problems in community pharmacy dispensing (Winstock et al. 2010).
Even though all respondents thought that pharmacy dispensing of BNX had gone well
or very well, 80% of them recognized opportunities for future development, most
commonly financial remuneration for pharmacies. Finnish community pharmacies do not
receive  any  Government  funding  to  provide  OST  services.  Financial  issues  should  be
examined more carefully in case of increasing demand of OST services from pharmacies
and, especially, if new responsibilities, such as supervised dosing, will be introduced in the
future. Needed improvements cited by the pharmacies were similar to the ones reported in
previous studies, such as more training for pharmacy staff (Fleming et al. 2001, Samitca et
al. 2007, Torre et al. 2010) and better co-operation and communication with physicians
(Samitca et al. 2007, Winstock et al. 2010). Most respondents stated that supervised dosing
is not a suitable service in Finnish pharmacies, even though it is a common procedure in
many other countries (Matheson et al. 2007, Nielsen et al. 2007a, Samitca et al. 2007).
However, these attitudes may reflect the fact that BNX dispensing was relatively novel and
unfamiliar to Finnish pharmacy staff at the time of the survey. In England, pharmacists’
acceptability of dose supervision has increased as the service has expanded (Sheridan et al.
2007). It is possible that the lack of private area to supervise dosing may have affected
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pharmacists’ attitudes. Both OST clients as well as other pharmacy customers have
expressed their concerns about ensuring the privacy of OST medicine dosing in the
community pharmacies (Lawrie et al. 2004, Lea et al. 2008). Despite having expressed a
negative attitude towards supervision, most respondents (85%) were willing to accept more
OST  clients  in  the  future,  which  was  a  higher  proportion  than  in  previous  studies
(Lawrinson et al. 2008).
6.2 METHODOLOGICAL CONSIDERATIONS
6.2.1 Study populations
The Huuti studies were based on data collected at the HDI which consists of information
about all clients seeking treatment during the data collection period from January 31, 1997
until August 31, 2008. Clients at the HDI were self-referred to the treatment or referred by
other clinicians/ treatment units due to their substance abuse problems. In case of later
client  group,  clients  may  have  had  more  severe  substance  abuse  problems  because  the
physician had regarded it necessary to refer the person to a specialized service. However,
the aim of this study was not to select a representative sample of general population with
substance abuse problems but to examine characteristics of those who seek treatment for
substance abuse. This minimizes the possibility of the presence of selection bias. Substance
abuse services of the HDI were relocated to another suburb of Helsinki in 2000 which may
have affected the client population. The new location was further from a residential area
with a high prevalence of amphetamine abuse. This may partly explain the decrease in the
number of amphetamine clients seeking treatment from the HDI during the study period.
Some clients had multiple visits to HDI but only the first visit was included in this study in
order to ensure the consistency of data. Detailed information on the number of clients
receiving OST was not available. These clients may differ from the clients entering
treatment for the first time.
The participation rate for the intervention of study III was high (88%) and the study
sample can be regarded as a representative sample of BNX treated OST patients in Kuopio.
Patients who refused to participate were mainly males (four out of five patients). However,
these patients were also obliged to use EMDs as part of their treatment. Therefore, the
number of patients not willing to participate in the trial had no effect on the control of BNX
take-home dosing or  diversion measurements.  All  clients  visiting the  NEP service  during
the data collection periods were asked to fill in the questionnaire. The response rates were
relatively low (46%, 39%) but satisfactory considering the target population and similar
compared to a response rate in another Finnish survey among NEP clients (30%) (Alho et
al. 2007). Nevertheless, the absolute numbers of participants and respondents were
relatively  low and this  limited statistical  testing.  Hence,  there  may not  have been enough
power to detect changes in outcome measures. However, in order to be able to create a
study  design  similar  to  our  study  (comprehensive  control  of  BNX  take-home  doses),  a
larger multicentre study with possible patients would have been very difficult to conduct.
The list of pharmacies who had supplied BNX was received from the company with the
marketing authorization for the BNX product but it is possible that the list has not been all-
inclusive.  However,  there  is  no  evident  reason  to  assume  that  the  amount  of  possibly
missing information was large or differential. The response rate was high (93%) and
respondents can be regarded as a representative sample of Finnish community pharmacies
with OST clients. Due to low number of non-respondents, the presence of selection bias is
unlikely.  The  characteristics  of  pharmacies  responding  after  the  reminder  were  similar  to
other pharmacies indicating no response bias. Similarly to study III, the absolute number of
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respondents was low and limited the possibility of statistical testing. Some of the logistic
regression models may have been underpowered.
6.2.2 Study designs
Study  I  was  a  descriptive  study  of  clients  seeking  treatment  during  the  12-year  study
period. Individual-level follow-up data were not available but characteristics of clients
seeking treatment in different years were compared to examine changes over time. This
provides  more  information  than  studies  with  merely  cross-sectional  study  designs  which
are commonly used in studies examining buprenorphine abuse (Table 2, Chapter 2.2.3.1).
Studies II  and IV were cross-sectional.  It  is not possible to determine causality with cross-
sectional study designs. Study III utilized an innovative study design. A clinical trial was
combined  with  NEP  surveys  and  the  review  of  drug  screen  data  from  a  large  university
hospital.  The  clinical  part  of  the  study  utilized  a  naturalistic  open-label  design  without  a
control group which challenges the reliability of results.  However, controlled studies may
not provide information about intervention’s performance in real-world settings and,
therefore, the naturalistic setting can be considered as strength of the study. The duration of
the  study  (four  months)  may  have  been  too  short  to  detect  the  impact  of  EMDs  on
diversion. It has to be remembered that EMDs could only detect whether tablets were
removed  from  the  device,  not  when  the  medicine  was  actually  taken  or  by  whom.
Stockpiling medicines and diverting little by little has been possible despite the use of
devices.
6.2.3 Data collection and measures
Huuti data were mainly based on clients’ self-reports which is a possible source of
information bias and response bias. Self-reported data may be prone to recall bias. Some
clients  may  have  been  under  the  influence  of  drugs  and/or  alcohol  during  their
consultation. Clients’ desire to receive specific treatments may have affected their self-
reporting. Data were not available from urine drug screens to confirm self-reported drug
use. However, the validity and reliability of self-reported data on substance use and related
behaviour have been established (Darke 1998, Napper et al. 2010, Smith et al. 2010), even
though contrasting results have also been published (Chermack et al. 2000). Clients may be
more likely to self-report drug abuse at intake into a drug abuse treatment program than at
follow-up visits (Wish et al. 1997, Chermack et al. 2000). In addition, the abuse of a drug
which is the main reason for treatment seeking may be self-reported more likely than other
concurrent  drug  abuse.  The  type  of  substance  and  the  severity  of  client’s  drug  abuse
problems may also influence clients’ willingness to report substance abuse. Nevertheless,
self-report is the most feasible method for measuring certain aspects of substance abuse
such as intensity and route of administration (Smith et al. 2010). Validated assessment tools
(e.g., EuropAsi and TDI) were used to ensure the quality of data collection. Psychiatric
symptoms and medical comorbidities were clinically diagnosed by specialist physicians in
accordance with established criteria. However, depressive and psychotic symptoms were
not consistently assessed using validated scales because data were collected as part of
clinical practice. Nevertheless, there is evidence that key informants (e.g., drug treatment
centre directors and councillors) can provide reliable assessments of their patients’ drug
abuse problems (Cicero et al. 2011a).
The characterization of clients as buprenorphine, heroin or amphetamine clients was
based on clients’ self-reported primary drug of abuse. Misclassification is possible because
poly-drug abuse is common (Darke & Hall 1995, Partanen et al. 2004, Winslow et al. 2006,
Otiashvili et al. 2010, Tammi et al. 2011, Lofwall & Havens 2012). The present availability
and price  of  substances  may have an impact  on clients’  choice  of  primary drug of  abuse.
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However, the categorization was performed using a validated assessment tool. In addition,
possible misclassification is likely to be non-systematic because there is no reason to assume
that clients would have reported another substance as their primary drug of abuse more
likely than another. Clients may have been prone to report opioids as their primary drug of
abuse if they want to get into OST. However, during the study period OST inclusion criteria
were strict and, therefore, this kind of behaviour has been less likely. Underreporting of
substance abuse is probably not as likely in treatment seeking drug user population than in
general population. Confounding by poly-drug use and uncertainty concerning the actual
content of used substances may have also affected clients’ self-reported drug abuse. In
study I, analyses were performed separately for time periods 1997-2001 and 2002-2008. No
further adjustsments were made because the purpose of the study was to describe the
characteristics of clients. In study II, the multivariate model was adjusted for factors
statistically significant in univariate models including basic demographic characteristics
(age,  gender)  possibly  confounding the  results.  However,  there  is  always a  possibility  for
residual confounding because unmeasured factors cannot be adjusted for.
Study III utilized different data collection procedures. All questionnaires (patients’ and
staff’s questionnaires, NEP surveys) were anonymous and, therefore, it is reasonable to
assume that reports were reliable. However, the psychometric properties of questionnaires
were not validated. To our knowledge, there were no validated questionnaires suitable for
our study and, therefore, we had to develop questionnaires for the purposes of this study.
The questionnaire to OST patients was modified from the one used in a previous study
(Tacke et al. 2009). However, the questionnaire was not pilot-tested in this previous study.
The questionnaire used in the NEP survey was developed in co-operation with service-staff
to  ensure  content-validity.  However,  NEP  survey  responses  as  well  as  buprenorphine-
positive drug screens served as surrogate outcomes for diversion. The results of surrogate
outcome measures should be interpreted with caution. The use of drug screen data was
based on the assumption that any licit or illicit buprenorphine user in Kuopio with an acute
health problem requiring hospital treatment would be subjected to a urine drug screen, if
his/ her condition was suspected to be drug-related. It is possible that this assumption was
not fully tenable which means results of drug screen data may be underestimations.
However, the purpose of the study was to compare the proportions of positive drug screens
between trial periods, and not to explore the absolute numbers per se. Therefore, it is
unlikely  that  this  had  a  major  impact  on  the  results.  Even  though  several  different
indicators were used to measure diversion, qualitative measurements could have been used
as well.
The questionnaire used in the study IV was developed according to the aims of the
study. It was pilot-tested for face-validity and content-validity before the study. However,
it is possible that respondents may have misunderstood some questions, because the
questionnaire was not formally validated. Staff members were encouraged to discuss their
experiences before completing the questionnaire. Despite these instructions, it is possible
that responses reflect predominantly the experiences of the individual pharmacist
completing the questionnaire. In this case, the presence of problems and the numbers of
diversion/ abuse suspicions may have been underestimated. The location and size of
pharmacy were assessed as potential confounders. Adjusted models provided similar
results compared to unadjusted ones and, therefore, these results were not reported. In
addition, the 95% CIs for adjusted ORs were relatively wide, indicating dispersion of values
and possible inaccuracy in the parameter estimates.
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6.2.3.1 Missing data
The Huuti studies had a considerable amount of missing data, especially for the first four
years  of  data  collection.  In  2001,  data  collection  process  was  changed  and  more
comprehensive data were available from then on. Nevertheless, missing data exist
throughout the data collection period. There can be various possible explanations for
missing data. Data were collected for the purposes of clinical practice. Clinically irrelevant
questions may have been skipped, e.g., absence of certain symptoms or clinical findings. It
is possible that the data files of clients with more severe abuse problems and/ or those
intoxicated during the consultation included more missing information which may have
caused information bias. However, the bias caused by missing data was minimized in this
study by including only variables with a relatively low level of missing information (<20%)
into the analyses of study I and by multiple imputation and restricting analyses to years
2001-2008 in the study II.
6.2.4 Generalizability of findings
Results  of  the  Huuti  study  can  be  generalized  to  those  seeking  treatment  in  the  Helsinki
metropolitan area. It is likely that buprenorphine users in other parts of Finland resemble
those from the Helsinki area but generalizing the results should be done with caution.
However, as discussed previously people abusing buprenorphine in other countries are
different from buprenorphine users in Finland. Buprenorphine is not regarded as a PO in
all studies, especially, in those conducted in North America. This means that caution is
required when making comparisons to other studies examining PO users. Results may not
be generalizable to people not seeking treatment. The data collection period of the Huuti
study was in 1997-2008. Availability of different illicit substances changed over time.
Single-ingredient buprenorphine was withdrawn from the market in December 2007 and
replaced  by  BNX  which  may  have  had  impact  on  abuse  patterns  among  opioid  users.  In
addition, treatment practices have changed over time. The availability of OST has markedly
increased in Finland during the previous decade which has probably had an impact on
users’ willingness to seek treatment.
Results of study III can be generalized to medium-sized Finnish cities with OST practices
similar to those in Kuopio. All eligible OST patients were asked to participate in the clinical
part of the study and participation rate was high (88%). Therefore, study participants can
be regarded as a representative sample of BNX-treated OST patients in Kuopio. In addition,
all patients not willing to participate in the trial used EMDs as part of their routine
treatment in order to ensure a comprehensive control of BNX take-home dosing. Results
cannot be generalized to different treatment settings or other devices than the one used in
this trial.
For study IV, sampling was not performed because all community pharmacies that had
supplied BNX were contacted. The response rate was high (93%) and therefore respondents
can be regarded as a comprehensive sample of community pharmacies providing OST
services in Finland. The study took place in August 2011 and presently, two years after the
survey, there may be more pharmacies dispensing BNX. The results of this study may have
limited generalizability to the present situation. There are substantial differences in
pharmacy-based OST services, including medicines dispensed (BNX, BUP, and/or
methadone) and the provision of supervised dosing, as well as in pharmacy practices and
legislations between countries and, therefore, results may not be generalizable to other
countries.
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7 Conclusions
Based on the findings of the four studies included in the thesis, the following conclusions
were made:
1. The proportion of clients seeking treatment for buprenorphine abuse increased in
Finland between 1997 and 2008. Most buprenorphine clients were injecting
buprenorphine and using it on a daily basis. Intravenous administration and daily
abuse were more common among buprenorphine compared to heroin and
amphetamine clients. Concurrent substance abuse, especially the abuse of
prescription medicines, increased during the study period.
2. Despite more intense abuse patterns, buprenorphine clients had similar social, health
and treatment-related characteristics compared to amphetamine clients.
Unemployment, low educational levels and reliance on social benefits were common
among buprenorphine clients.
3. The use of electronic medicine dispensers provided a feasible method for improving
the safe storage of take-home doses of buprenorphine-naloxone. However, the
ability of this method to prevent the diversion of buprenorphine-naloxone could not
be demonstrated.
4. Buprenorphine-naloxone dispensing from Finnish community pharmacies has
remained small-scale. About 10% of all BNX-treated clients in Finland collected their
medicines  from  a  community  pharmacy.  The  first  experiences  have  been  positive
and only every fourth pharmacy had experienced one or more problems related to
OST services.
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8 Implications for the Future
8.1 PRACTICE IMPLICATIONS
This study showed a constant increasing trend in treatment seeking for buprenorphine
abuse in Finland. Treatment providers and policy makers should take into account that
treatment services (e.g. OST) for opioid users in Finland should be targeted specifically for
buprenorphine users. Buprenorphine users were commonly IV-users and the frequency of
daily use was high. Concurrent substance abuse, social problems such as unemployment
and reliance on society benefits, as well as health problems such as depressive symptoms
were  common.  These  factors  should  be  taken  into  account  in  a  comprehensive  treatment
approach. In addition, this study reported that clients seeking treatment for buprenorphine
and amphetamine abuse were relatively similar in terms of social, health and treatment-
related factors. These results may imply that the route of administration is a stronger
determinant of these characteristics than the primary drug of abuse. It seems that PO abuse
does  not  offer  public  health  benefits,  if  drugs  are  injected.  It  has  been  suggested  that  PO
abuse can offer public health benefits because PO abuse is associated with a lower
prevalence of risk behaviours relevant for morbidity and mortality (e.g., injecting)
compared to heroin abuse (Fischer et al. 2009).
The  results  of  this  thesis  show  that  new  technology  such  as  electronic  medicine
dispensers can be used as part of OST in a ‘real-life’ setting. EMDs can improve the safety
of take-home dosing from the perspectives of both patients and staff. If EMDs can relieve
the  external  pressure  to  sell  or  pass  on  OST  medicines,  they  can  provide  clinically
significant benefits to OST. However, whether this method can be used in the prevention of
diversion in general is unclear. The possibility for tampering with devices should be taken
into consideration when using them in clinical practice. Based on the experiences from our
trial, the manufacturer of the device made technical changes to make the device more
tamper-proof. However, it may not be possible to design a totally tamper-proof device
without any pitfalls. Therefore, it should be carefully considered whether attempting to
prevent diversion via technical, restrictive methods is reasonable or efficient. It might be
more powerful to concentrate on the reasons behind diversion, such as patients’
dissatisfaction with treatment, financial problems and offering OST to patients with low
treatment motivation.
This thesis includes the first study on OST medicine dispensing by Finnish community
pharmacies. The service provision has remained small-scale but first experiences have been
positive  and  problems  were  rare  even  though  only  in  one  fourth  of  pharmacies,  the  staff
had  received  training  on  OST.  The  stabilization  of  OST  in  treatment  units  and  careful
selection of suitable OST clients may be contributing to this success. Therefore, current
treatment practices in Finland appear to be functioning well, even though improvements in
pharmacy staff’s training levels and possible financial remunerations should be considered
when developing OST services. The possibility of expanding pharmacy-based OST services
without compromising current functionality could be considered in the future. Expanding
community pharmacy-based BNX dispensing can release both financial and staff resources
in treatment units and assist the rehabilitation of OST clients.
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8.2 FUTURE RESEARCH DIRECTIONS
More longitudinal studies on buprenorphine abuse are needed, because most existing
studies have been cross-sectional. Reasons behind buprenorphine abuse, whether it is self-
medication, euphoria-seeking or other reasons, should be explored in different settings.
More studies are needed in order to understand different abuse patterns among opioid
users, especially among the evolving group of PO users. Best treatment practices designed
specifically for people who abuse buprenorphine should be examined and evaluated.
Results from study II implied that the route of administration is a stronger determinant of
social, health and treatment-related characteristics than the primary drug of abuse. The
validity of this hypothesis could be tested.
Larger controlled studies with more patients and longer follow-up periods are needed to
examine the effect of electronic devices on the diversion of OST medicines. Studies should
utilize different devices in different treatment settings. The possibility to use other
outcomes measures, especially non-surrogate measures, should be considered. Other uses
of  EMDs could be  explored,  such as  in  the  treatment  of  chronic  non-malignant  pain with
opioid-analgesics or as part of BZD detoxification.
Further studies are needed to reflect the current situation with OST provision from
Finnish  community  pharmacies.  The  number  of  OST  patients  has  increased  in  Finland  in
recent years (Social Insurance Institute 2013, Simojoki 2013) and, therefore, it is likely that
the pharmacy dispensing of BNX has grown as well. Studies examining the experiences and
opinions of service users,  i.e.  OST clients collecting their BNX from pharmacies,  would be
important for the development of community pharmacy-based OST provision. The
possibility  of  providing  supervised  OST  medicine  dosing  from  the  Finnish  community
pharmacies and should be explored.
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